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1.1 Migraine as a disease
Migraine is a common brain disorder characterized by episodic attacks of severe throbbing unilateral 
headache that is accompanied by nausea, vomiting, photophobia and phonophobia. Attacks can last 
from 4 to 72 hr (ICHD 2004). Migraine is clinically divided into two main types, migraine with aura 
(MA) and migraine without aura (MO); one-third of patients suffer from MA. The aura that can 
accompany the migraine headache in patients with MA consists of focal disturbances that almost 
always include visual symptoms but may also include sensory, aphasic, and motor symptoms. In 
western countries migraine affects about 15% of the general population (Lipton & Stewart 1998, 
Goadsby et al 2002). Migraine is most prevalent in the age range 25 to 55 and is three times more 
common in women than men (Lipton et al 2001). Attack frequency varies widely from a few attacks 
per year to several attacks per month; at least 10% of patients report weekly attacks (Goadsby et al 
2002). Because of its severity and high prevalence the World Health Organization has rated migraine 
among the most common chronic disabling disorders of central nervous system (Vos et al 2013). 
Understanding the pathophysiology of migraine is important to identify new drug targets, which is 
dearly needed as many patients receive inadequate treatment despite the effectiveness of standard 
pain killers and serotonin agonists (so-called triptans) (Goadsby et al 2002). 
1.2 Migraine pathophysiology
1.2.1 Migraine aura
Visual auras present as flashing jagged lights with fortification figures that spread from the center of the 
visual field to the periphery. In the beginning of the aura there is a short transient period of hyperemia 
with an increase in neuronal activity and cerebral blood flow (CBF) that is followed by oligemia or 
hypoperfusion that lasts much longer and is probably due to silencing of neuronal activity, which 
extends into the headache phase (Olesen et al 1981). Already early on, it was proposed that the aura 
was caused by cortical spreading depression (CSD) (Lauritzen 1994). The CSD phenomenon was 
initially discovered by Aristides Leaõ in 1944 (Leao 1944). While trying to record pin prick-induced 
seizures in the cortex of rabbits, Leaõ noticed that instead of inducing seizure activity he observed a 
temporary silencing of cortical electrical activity (presented as a flattening of the electrocorticogram 
trace) that propagated over the cortex. We now know that CSD is a wave of depolarization of neurons 
and glia cells, followed by suppression of neuronal activity, that spreads at a rate of 3-5 mm/min 
through the cortex via grey matter continuity and is associated with a massive disruption of ionic 
balance (Somjen 2001). 
Evidence that CSD is relevant to migraine pathophysiology mainly comes from studies in animals. 
Regardless, using imaging techniques it was convincingly demonstrated that the observed temporal 
and spatial characteristics of cortical blood flow changes as they occur during CSD nicely correlated 
with patients descriptions of the spread of their aura symptoms (Hadjikhani et al 2001). Observations 
like these led to the now widely accepted notion that CSD is the electrophysiological correlate of 
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migraine aura. There is an active debate though whether CSD events also occur in migraine without 
aura attacks, in so-called “silent” brain areas (i.e., other than visual cortex), whereby CSD events 
would remain unidentifiable to the patient. Except for an isolated case with characteristic spreading 
blood flow changes reminiscent of a CSD in a patient with migraine without aura attacks (Woods 
et al 1994), it is mere speculation whether CSD indeed occurs in MO. Nonetheless, unraveling the 
neurobiological mechanisms underlying CSD is important for understanding not only the diseased 
brain but also normal brain functioning (Somjen 2004).
1.2.2 Migraine headache
How migraine pain is generated is not fully understood. The current view is that the headache is 
generated by activation of the trigeminovascular system (TGVS). The TGVS consists of meningeal 
and superficial cortical blood vessels that are innervated by the trigeminal nerve. Release of vasoactive 
peptides from perivascular afferents are able to trigger a series of events during which sensory (i.e., 
nociceptive) input is transmitted to trigeminal ganglion (TG) neurons and further to neurons in the 
brainstem trigeminal nucleus caudalis (TNC). Sensory signals from these nuclei are sent rostrally to 
thalamus and from there to higher brain centers to produce the sensation of pain (Goadsby et al 2002). 
1.2.3. Can CSD/aura initiate headache mechanisms?
What the initial triggers are for activation of the TGVS remains to be determined. It is debated whether 
CSD events can trigger migraine headaches (Ayata 2010, Charles 2010). Although there is quite 
compelling evidence from studies in experimental animals suggesting that this is the case, evidence 
in humans is lacking. Already in 1993 it was shown by Moskowitz and colleagues (Moskowitz et al 
1993) that experimentally induced CSD in rat brain can activate neurons in the ipsilateral TNC, as 
shown by increased expression of neuronal activation marker c-fos. The fact that the increased c-fos 
signal could be blocked by transection of trigeminal meningeal afferents innervating the dura, as well 
as by administration of 5-HT
1B/1D
 receptor agonist sumatriptan, an effective migraine drug, suggested 
that CSD is important in generating migraine headache. Second, it was shown that CSD induction, in 
addition to increasing c-fos immunoreactivity in TNC, also caused an increase in middle meningeal 
artery diameter and protein extravasation from trigeminal meningeal afferents (Bolay et al 2002). 
Third, CSD can activate both peripheral and central components of the trigeminovascular pathway 
as CSD induction has been shown to cause increased firing of (i) peripheral meningeal nociceptors 
that in some trials showed a time-delay reminiscent of aura-headache events seen in patients (Zhang 
et al 2010) and (ii) central trigeminovascular neurons in the C1-2 spinal trigeminal nucleus (Zhang et 
al 2011a). Sensitization of first-order neurons that project from trigeminal ganglia and innervate the 
meninges are believed to be responsible for the throbbing nature of migraine headache (Strassman et 
al 1996). Sensitization of higher-order trigeminovascular neurons of the medullary dorsal horn, which 
project to thalamus and receive convergent sensory information from the dura and extracranially from 
the skin of face and limbs, is thought to control the development of cutaneous allodynia, the perceived 
painful response to non-noxious stimuli such as combing one’s hair that many patients experience 
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during attacks (Burstein et al 2000). Figure 1 summarizes the role of pain pathway activation, and the 
possible relationship with CSD, in migraine headache.
1.3 Genetics of migraine
Migraine has a strong genetic component, which is already exemplified by the fact that migraine runs in 
families. Family-and population-based epidemiological studies revealed an increased risk for migraine 
in first-degree relatives of individuals with migraine (Russell & Olesen 1995, Stewart et al 1997). In 
addition, twin studies showed that the concordance rate was significantly higher in monozygotic 
than in dizygotic twins (Gervil et al 1999, Ulrich et al 1999), which is also regarded as a proof that 
migraine has a genetic component. The heritability (i.e., the proportion of the phenotypic variance 
explained by genetic factors) is approximately 50%; the other half is explained by environmental 
factors (Mulder et al 2003). 
1.3.1 Genetic findings in common forms of migraine
The identification of genes that confer migraine risk for common forms of migraine has been challenging 
for a long time. Multiple gene variants, each with only a small contribution to disease risk, together with 
environmental factors, are expected to render an individual susceptible to common forms of migraine 
(de Vries et al 2009). The advent of unbiased genome-wide association studies (GWAS) in recent years 
has made it possible to identify migraine susceptibility genes. So-called “associated variants” show a 
difference in allele frequency between cases and controls for a specific single-nucleotide polymorphism 
(SNP) with a level of significance that survives correction for the many performed statistical tests. 
GWAS produce statistically robust findings, but the associated variants almost without exception have 
a small effect size indicating that an individual genetic factor increases disease risk by only a little. The 
genes that were assigned to associated loci seem to affect neurons (i.e., glutamatergic neurotransmission 
and the development of neurons and synapses), brain vasculature, and pain sensation (Anttila et al 2010, 
Chasman et al 2011, Freilinger et al 2012, Anttila et al 2013). Future research will hopefully give insight 
in how these genes contribute to causing migraine. 
1.3.2 Genetic findings in monogenic familial hemiplegic migraine
Initial success in gene identification in migraine came from investigating familial hemiplegic migraine 
(FHM), a rare monogenic subtype of migraine with aura (ICHD 2004). FHM is characterized by at 
least some degree of body weakness (hemiparesis) during the aura that may last from min to several hr 
or days. Apart from the hemiparesis, the headache and aura features of an FHM attack are identical to 
those of attacks of common forms of migraine; the majority of FHM patients also experience attacks 
of “normal” migraine with or without aura that are not associated with hemiparesis (Thomsen et al 
2002). Thus, from a clinical point of view, FHM seems part of the migraine spectrum, and a valid 
model to study the common forms of migraine. Genetic research in FHM led to the discovery of three 
genes (van den Maagdenberg et al 2007). FHM1 is caused by mutations in the CACNA1A gene, which 
encodes the α
1
 pore-forming subunit of Ca
V
2.1 calcium channels (Ophoff et al 1996). These channels 
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are involved in presynaptic release of neurotransmitters (Mintz et al 1995, Wu et al 1999). CACNA1A 
mutations are associated with various clinical phenotypes, e.g., FHM and episodic ataxia type 2 (van 
den Maagdenberg et al 2007). Clinical presentations with FHM1 mutations can range from pure FHM 
(e.g., with missense mutation R192Q) (Ophoff et al 1996) to a complex severe phenotype of FHM 
with cerebellar ataxia, susceptibility to seizures and sometimes lethal cerebral edema after trivial 
head trauma (with missense mutation S218L) (Kors et al 2001, Stam et al 2009).
Figure 1. Schematic overview of brain anatomy and mechanisms involved in migraine aura and headache. 
Cortical spreading depression (CSD) is a slowly propagating wave of neuronal and glial depolarization that starts in the 
visual cortex and is accompanied by the release of neurotransmitters, ions and vasoactive neuropeptides such as SP, CGRP 
and NKA (indicated by colored circles around dural vessels) into the extracellular space. These molecules may reach 
pial, arachnoid (not shown) and dural surfaces and activate the perivascular trigeminovascular sensory afferents from 
the trigeminal ganglion (TG) neurons. Signals of activated meningeal nociceptors are relayed via the TG to trigeminal 
nucleus caudalis (TNC) neurons and from there, further to thalamic and cortical areas involved in the processing of pain. 
From the trigeminal nucleus caudalis, collaterals are also send to dural vessels via the sphenopalatine ganglion (SPG). 
Adapted from Goadsby et al 2002.
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The FHM2 gene, ATP1A2, encodes the α
2
 subunit of the Na+/K+-ATPase (De Fusco et al 2003) that 
in adulthood is expressed in glial cells (McGrail et al 1991). This catalytic subunit binds Na+, K+, and 
ATP, and utilizes ATP hydrolysis to exchange Na+ ions out of the cell for K+ ions into the cell. Thus, 
the ATPase is able to modulate the re-uptake of K+ and glutamate from the synaptic cleft into the glial 
cell. FHM2 mutations have been associated with pure FHM (De Fusco et al 2003, Riant et al 2005, 
Vanmolkot et al 2006), FHM with cerebellar ataxia (Spadaro et al 2004), and also permanent mental 





1.1 sodium channels (Dichgans et al 2005). These channels are mainly expressed 
in inhibitory interneurons (Ogiwara et al 2007) where they play a crucial role in the generation and 
propagation of action potentials (Catterall et al 2005). 
Cellular studies of FHM mutations have suggested a single common consequence, i.e., increased 
excitatory neurotransmission (Figure 2); either by gain-of-function effects on Ca
V
2.1 channels by 
FHM1 mutations in excitatory neurons, loss-of-function effects on ATPases by FHM2 mutations in 
glial cells, or loss-of-function effects by FHM3 mutations on inhibitory interneurons. 
1.4 Modulators of migraine
1.4.1 Gender
The idea that gender is an important modulator of migraine comes from the observation that migraine 
is three times more common in women compared to men (Lipton et al 2001). Female hormones 
estrogen and progesterone have been implicated in the initiation and worsening of migraine attacks 
(Brandes 2006). Estrogen increases cortical excitability in humans (Smith et al 2002) and sudden 
changes in estrogen levels, such as estrogen withdrawal (Somerville 1972) may bring about migraine 
attacks. Notably, acute exposure of rat neocortical slices to estrogen and progesterone increases CSD 
frequency in a dose-dependent manner (Sachs et al 2007). Testosterone seems to counteract effects 
of estrogen as it was shown that testosterone down-regulates the expression of estrogen receptors in 
mouse cortex (Thakur & Sharma 2007); although it was not shown that testosterone directly inhibits 
neuronal excitability. Of note, danazol, a synthetic testosterone derivative, was shown effective in 
reducing migraine attack frequency and severity of headache in migraineurs (Lichten et al 1991).
1.4.2. Circadian rhythm 
Acute shifts in daily sleeping patterns (i.e., sleeping too much or too little) have been reported to 
precipitate migraine attacks suggesting that circadian factors can influence attack onset (Solomon 
1992). Attack occurrence has been reported to have a circadian component: migraine attacks occur 
more often between 4 am to 9 am, probably as a consequence of the changes that occur to prepare the 
body for the upcoming active period (Fox and Davis 1998). However, a prospective study in female 
patients pointed to a peak in attacks around the middle of the day (Alstadhaug et al 2008). The release 
of important hormones such as cortisol, melatonin and adenosine varies according to circadian rhythm. 
Presumably, particular hormonal and related neuronal activity changes occur during the transition 
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from the light to the dark period. It can be envisaged that the inability of an organism to adequately 
adapt to these abrupt changes might turn on a modulator of migraine attack onset. 
1.4.3 Stress 
The experience of stress and especially the recovery after a stressful period has been reported by 
patients as precipitating factor of their migraine attacks (Robbins 1994, Fanciullacci et al 1998, 
Hauge et al 2011). However, it is not known how stress would bring about migraine attacks. Of 
note, no significant link was observed between objective (i.e., saliva cortisol, heart rate and heart 
rate variability) and subjective (e.g., perception of stress) stress-related parameters and the onset of a 
migraine attack (Schoonman et al 2007). A recent study proposed a relationship between changes in 
perceived stress and migraine attacks (Lipton et al 2014) which could involve changes in perception 
rather than actual changes in stress levels (Goadsby 2014). Studies in rodents indicate that stress and 
in particular stress hormone corticosterone (i.e., the equivalent of cortisol in human) can increase 
neuronal excitability (Yuen et al 2009, Popoli et al 2011), which would link to migraine via the 
concept that cortical hyperexcitability is believed to underlie the sensitivity to migraine attacks 
(Aurora & Wilkinson 2007). Perhaps stress, with its associated changes in stress hormones, can act 
as a modulatory (i.e., additive) factor adding to the already heightened brain excitability in migraine 
sufferers, thus increasing the propensity for a migraine attack.
1.4.4 Migraine triggers and migraine?
Migraine is a heterogeneous disease. Not surprisingly most patients report more than one triggering 
factor as modulator of their migraine attacks (Hauge et al 2011, Pavlovic et al 2014). In addition to the 
modulators already mentioned, alcohol consumption (especially red wine), consuming certain food 
items, intense physical exercise, and smoking, are also often reported as migraine triggers (Hauge et 
al 2011). Still there is no solid scientific evidence that, and if proven, in which combination and how, 
the different modulatory factors, may bring about migraine attacks.   
1.5 Pathways associated with cortical spreading depression
CSD, the mechanism underlying aura, can be triggered in the brain experimentally by a variety 
of stimuli such as pinprick, application of electrical current, application of K+ or glutamate, and 
compounds such as endothelin (Somjen 2001, Dreier et al 2002). CSD can be more readily triggered 
in “smooth” non-convoluted brains of rodents than in convoluted brains of cats, monkeys and humans 
(Bures et al 1974). CSD events are associated with neuronal, glial and vascular changes in the brain, 
as well as inflammatory and biomolecular changes that are briefly discussed below.
1.5.1 Neuronal and glial changes associated with CSD
CSD consists of a large negative shift of extracellular potential due to a massive depolarization of 
neurons and glial cells which is associated with a massive redistribution of ions (Somjen 2001). The 
massive efflux of K+ from neurons during CSD is accompanied by a concomitant neuronal release of 
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glutamate and organic anions (Szerb 1991, Fabricius et al 1993). At the same time there is an influx 
of Na+, Cl- and Ca2+ into neurons (Hansen & Zeuthen 1981, Somjen & Aitken 1984). The excess of 
extracellular K+ is taken up by glial cells mainly via passive flow through ohmic conductances and by 
activation of the Na+/ K+  ATPase (Somjen 2004). On the other hand, the excess of glutamate in the 
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Figure 2. Functional effects of FHM mutations on neuronal excitability.
The illustration shows a glutamatergic tripartite synapse of the brain of a WT mouse (A) compared to a situation with an 
FHM1 (B), FHM2 (C) or FHM3 (D) mutation, respectively (red circles). (B) FHM1 mutations in the CACNA1A gene 




2.1 calcium channels. Due to the gain-of-function effect of FHM1 
mutations the influx of calcium through voltage-gated Ca
V
2.1 channels in the presynaptic neuron terminal is enhanced 
causing neurotransmitter vesicles to fuse and release the neurotransmitter glutamate. Note that the gain-of-function effect 
is found only in the excitatory glutamatergic neurons and not in inhibitory GABAergic interneurons. (C) FHM2 mutations 
in the ATP1A2 gene which encodes the α
2
 isoform of the Na+/K+-ATPase. FHM2 mutations lead to loss-of-function effects 
which abate the ability of glial cells to remove K + and glutamate from the synaptic cleft and terminate the action of the 
excitatory neuron. (D) FHM3 mutations in the SCN1A gene which encodes the Na
V
1.1 voltage-gated sodium channels. 
FHM3 mutations lead also to loss-of-function effects inhibiting the generation and propagation of action potentials in 
inhibitory interneuron which regulate the activity of excitatory neurons. The net effect of each gene mutations will lead 
to an increase in neuronal excitability.
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cells, e.g., EAAT1 and 2 (Danbolt 2001). Of the large voltage changes in neurons that occur during 
CSD, most notable are changes in inward and outward currents in dendrites and somata, respectively. 
Other notable changes are an increase in extraneuronal electrical impedance following CSD, and 
the increase in neuronal membrane potential that reaches almost zero during CSD (Collewijn & 
Harreveld 1966, Ferreira-Filho & Martins-Ferreira 1982). The glial cells follow the action of neurons 
during CSD. Glial cells also depolarize, mainly because of the neuronally-induced rise in extracellular 
K+ that enters glial cells via their their K+-permeable membrane (Muller & Somjen 2000), while the 
input resistance of glial cells drops slightly. The observation that CSD is preceded by an increase 
in neuronal excitability, which is a phase-locked activity of groups of neurons, led to the idea that 
CSD is an all-or-non phenomenon that, once started, becomes independent of the triggering stimulus 
(Rosenblueth & Garcia Ramos 1966, Herreras & Somjen 1993). 
1.5.2 Vascular changes associated with CSD
As mentioned above, CSD is associated with a marked CBF response. The response is typically 
triphasic in character with an initial hypoperfusion that is followed by transient hyperemia and 
subsequently a pronounced oligemia that can last for an hr (Piper et al 1991, Eikermann-Haerter 
& Ayata 2010). Whereas the vascular response to CSD is comparable among most species, mice 
present a unique variability. Mice differ from for instance rats, in the sense that in mice the CSD-
induced initial hypoperfusion is much more pronounced and the following hyperemia is reduced, 
suggesting species-specific differences in vascular sensitivity to elevated extracellular K+ (Ayata et 
al 2004). Brennan and colleagues (Brennan et al 2007) studied arterial diameter in mice during CSD 
and reported an initial dilation which is followed by a profound constriction and subsequently an even 
larger dilation. 
1.5.3 Neuroinflammation associated with CSD
Recently, experimental evidence emerged that provided a convincing link between CSD, inflammation 
and headache. Karatas and colleagues (Karatas et al 2013) provided evidence how CSD may lead 
to sustained activation/sensitization of trigeminovascular afferents in mice. They showed that CSD 
induction causes the opening of Pannexin 1 megachannels (Panx1) in neurons. Opening of Pannexin 
channels activates Caspase-1, which initiates a parenchymal inflammatory cascade by releasing high-
mobility group box 1 (HMGB1) and interleukin-1β (IL-1β). In glial cells the increased levels of 
HMGB1 and IL-1β can trigger the translocation to the nucleus of astrocytes of nuclear factor κB 
(NF-κB) and induction of cyclooxygenase-2 (COX2) and iNOS. The activation of this inflammatory 
cascade provides the necessary sustained activation for the sensitization of trigeminal afferents and 
initiation of headache as shown by headache-like behavior in mice. As second piece of evidence that 
inflammation is important in migraine comes from the fact that administration of tumor necrosis 
factor-α (TNF-α) in rat trigeminal ganglia induced mechanical sensitization of meningeal nociceptors 
via a COX-dependent mechanism, as shown by an increased firing rate of the trigeminal neurons 
(Zhang et al 2011b). 
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1.5.4 Biochemical changes associated with CSD
CSD is associated with profound changes in concentrations of various neurotransmitters, (neuro) 
peptides and metabolites. Elevated extracellular levels of glutamate have been detected during a CSD 
wave in animals (Fabricius et al 1993; Iijima et al 1998). In agreement with changes during CSD, 
Martinez and colleagues (Martinez et al 1993) found increased levels of glutamate in cerebrospinal 
fluid (CSF) in both MA and MO patients during an attack compared to controls, while glutamate 
levels in plasma were lower in both MA and MO compared to controls. Other studies though found 
increased levels of glutamate in the plasma for both MA and MO patients during migraine attacks 
compared to controls (Ferrari et al 1990). 
During CSD in experimental animals there are also increased levels of neuropeptides such as calcitonin 
gene related peptide (CGRP), neurokinin-α (NKA) and substance P (SP) (Colonna et al 1994, Tozzi et 
al 2012).  Changes in these compounds have also been observed in patients during migraine attacks. 
For example, during migraine attacks but not in headache-free periods, CGRP levels in plasma were 
higher in MA compared to MO young patients whereas the NKA levels were similarly increased 
in MA and MO compared to controls (Gallai et al 1995). In another study, MA and MO patients 
interictally had similarly elevated plasma levels of CGRP and SP (Fusayasu et al 2007).
In addition to neurotransmitters and neuropeptides, CSD induction causes changes in the levels 
also of metabolites in animals. CSD induction triggers an increase in levels of cyclic guanosine 
monophosphate (cGMP) in rats and nitric oxide (NO) in cats (Read et al 2001, Wahl et al 1994). 
Similar to experiments in animals, levels of cGMP and NO are increased in MA and MO patients 
during migraine attacks (Shimomura et al 1999, Stepien and Chalimoniuk 1998). Not surprisingly, 
levels of adenosine triphosphate (ATP) decrease during CSD in rats (Selman et al 2004) due to the 
high energy demand required to restore homeostasis following CSD. In addition, CSD triggers the 
release of arachidonic acid (Lauritzen et al 1990) and lactate in rats and human patients with acute 
brain injury (Cruz et al 1999, Feuerstein et al 2010).
From the above it is clear that CSD causes major changes in brain biochemical status which can be of 
relevance to migraine. Studying those changes in transgenic mice with migraine relevant mutations 
will potentially provide insights on the role of CSD in migraine pathophysiology.
1.6 Transgenic mouse models of migraine 
1.6.1 Transgenic knock-in mice that harbor FHM1 mutations
The use of disease mouse models offers great opportunities for understanding disease pathophysiology 
and developing novel therapeutics. To this end knock-in (KI) mouse models were generated that 
carry CACNA1A missense mutations R192Q or S218L that both cause gain-of-function effects on 
Ca
V
2.1 channels that were previously identified in FHM patients. The mutations were introduced 
in the mouse orthologous Cacna1a gene by homologous recombination (van den Maagdenberg et 
al 2004, van den Maagdenberg et al 2010). Whereas homozygous mice of the R192Q strain did 
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not show an overt phenotype, S218L mice showed cerebellar ataxia, a greater tendency for seizures 
and brain edema after a mild head trauma (van den Maagdenberg et al 2004, van den Maagdenberg 
et al 2010). Electrophysiological studies revealed that the mechanism underlying these phenotypes 
was an increased neuronal calcium influx through Ca
V
2.1 channels with concomitant increased 
neurotransmitter release at peripheral and central synapses of mutant mice that was more pronounced 
in the severer S218L strain (van den Maagdenberg et al 2004, Eikermann-Haerter et al 2009, Tottene 
et al 2009, van den Maagdenberg et al 2010). Both strains of KI mice showed a marked increased 
propensity for CSD with a gene-dosage effect and a more pronounced phenotype in S218L mice. 
Furthermore, female mutant mice showed a greater CSD susceptibility compared to male mice. 
1.6.2 Other transgenic mouse models of migraine
Three additional transgenic mouse models of migraine have been generated. First of all, a transgenic 
KI mouse FHM2 model with the W887R missense mutation in the α
2
-subunit of Na+, K+-ATPase 
was generated (Leo et al 2011). Heterozygous KI mice had a reduced threshold for CSD and an 
increased CSD propagation rate similar to effects observed with the FHM1 KI mice. Second, a “CGRP 
transgenic mouse model” was generated to investigate the in vivo role of increased CGRP levels by 
overexpressing the wild-type receptor activity-modifying protein-1 (RAMP1) protein under control 
of the Nestin promotor gene (Zhang et al 2007). RAMP1 codes for a transmembrane protein that is 
necessary for the functioning of CGRP receptor (McLatchie et al 1998). Overexpression of human 
RAMP1 sensitizes the mice to the action of CGRP as a result of which mutant mice have increased 
CGRP-induced plasma extravasation in trigeminal ganglia which was interpreted as evidence for 
increased central sensitization after induction of mechanical allodynia (Marquez de Prado et al 2009). 
Nestin/hRAMP1 mice showed a migraine-relevant phenotype of increased light-aversive behavior 
that was worsened by administration of CGRP and abrogated by a CGRP blocker (Recober et al 2009, 
Recober et al 2010). Third, transgenic overexpressor mice were generated that carry a mutation in 
casein kinase Iδ (CKIδ), a protein kinase that plays a role in circadian rhythm, which was identified 
in patients with familial advanced sleep phase syndrome (FASP) and migraine with aura (Brennan et 
al 2013). Patients with FASP go to sleep unusually early in the evening and get-up very early in the 
morning. Transgenic CKIδ mice exhibited various migraine-relevant features including a reduced 
threshold for CSD and hyperalgesia after nitroglycerine administration (Brennan et al 2013).  
1.7 Scope and outline of the thesis
The aim of the studies performed for this thesis was to investigate and delineate modulatory factors for 
and consequences of CSD in transgenic mice with the human pathogenic R192Q missense mutation 
in the α
1
 subunit of voltage-gated Ca
V
2.1 calcium channels that causes familial hemiplegic migraine 
in patients.  
The physiological condition of an organism, especially blood pressure and levels of blood gases, 
influences the outcome of experiments that aim to determine CSD susceptibility. In Chapter 2 we 
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investigated to what extent controlling and maintaining critical physiological parameters within a 
range, or allowing these parameters to vary freely during a course of an experiment, affects CSD 
frequency and threshold measurements in male and female FHM1 R192Q and WT mice.
Chapter 3 addressed the question whether the enhanced CSD susceptibility in FHM1 R192Q mice 
is related to changes in cortical excitability as measured by EEG and multi-unit recordings in freely 
behaving mice. Observed alterations in EEG activity and occurrence of CSD events in the visual and 
motor cortex from the long-term recordings in freely behaving mice were paralleled by studies in 
anesthetized and physiologically-controlled FHM1 R192Q mice in which CSD frequency and CSD 
threshold were compared for different times of the day and different regions of the cortex.
In Chapter 4 the role of stress and its main hormone corticosterone on CSD susceptibility were 
investigated in FHM1 R192Q and WT mice. Restraint stress was used as a physiological stressor 
whereas corticosterone administration was used to selectively mimic the rise in stress hormone in the 
experiments. 
In Chapters 5 and 6 we tested the applicability of matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI - MS) imaging to reveal changes in biomolecular distribution of proteins, 
peptides and metabolites in different brain regions. In Chapter 5 we addressed the question whether 
CSD causes changes in composition of these compound classes after CSD in the brains of WT mice. 
In Chapter 6 we assessed which molecular changes occur following CSD events in the mouse brain, 
but with high spatial resolution. To this end, we subjected mice to a fixed number of CSD events (or a 
sham procedure) after which changes in metabolite, peptide and protein distribution in the brain were 
measured and compared between FHM1 R192Q and WT mice.
In Chapter 7 we addressed the question whether changes in metabolite profiles, assessed by capillary 
electrophoresis mass spectrometry (CE-MS) technology, could also be captured in blood after 
inducing CSD events in the brains of FHM1 R192Q and WT mice. 
A general discussion on the experimental findings from this thesis is presented in Chapter 8 along 
with suggestions for future research. 
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Changes in physiology and anesthesia modulate susceptibility to cortical spreading depression (CSD), 
the neurobiological correlate of migraine aura. Here we investigated to what extent CSD susceptibility 




 pH and 
blood pressure) were: i) not monitored at all, ii) only monitored (i.e., measured in blood from a femoral 
artery catheter; physiological monitoring), or iii) monitored and controlled (i.e., adjusted during the 
experiment by subtle changes in mechanical ventilation using tracheotomy; physiological control). In 
addition, we investigated to what extent the anesthesia gas mixture affects these CSD parameters. We 
studied effects of the methodologies in both wild-type (WT) mice and familial hemiplegic migraine 
type 1 (FHM1) transgenic mice that express the human pathogenic R192Q missense mutation in 
voltage-gated Ca
V
2.1 Ca2+ channels (R192Q mice). A previous study revealed an enhanced CSD 
frequency in the visual cortex of mutant mice, an effect that was most pronounced in females, when 




 anesthesia and physiological control. In the 
present study, however, using isoflurane-air anesthesia without physiological monitoring and without 
physiological control, we observed that visual cortex CSD frequency was equally enhanced in mutant 
mice of both genders. In contrast, a gender difference was observed for CSD threshold which was 
decreased in R192Q mice compared to WT to a larger extent in males than in females. The absence 





but to the presence of mechanical ventilation and possible subtle changes in pH, pCO
2
 or 
blood pressure when physiological parameters were not controlled. Genotypic effects of enhanced 
CSD susceptibility in R192Q compared to WT mice were identified irrespective of the tested 
methodologies. Comparison of CSD susceptibility in visual cortex vs motor cortex revealed a regional 
difference in CSD susceptibility that was influenced by gender in the absence of physiological control. 
Physiological control can either unmask or mask a gender effect on specific CSD parameters. This 
sensitivity of CSD susceptibility to methodology has important implications when comparing data 
from different studies. Moreover, it suggests that there is a drawback of controlling physiological 
status of an animal as one may miss specific characteristics of CSD susceptibility when these depend 
on differences in physiological parameters between R192Q mutant and WT mice. 
031
INTRODUCTION  
One-third of migraine patients experience auras in addition to headaches, characterized by 
neurological sensory dysfunctions that in most cases consist of visual symptoms (Goadsby et al 
2002, ICHD 2004). Cortical spreading depression (CSD) is the likely cause of the migraine aura, and 
it is characterized by a slowly propagating wave of neuronal and glial depolarization followed by a 
transient suppression of neuronal activity (Lauritzen 1994). 




 and blood pressure have been shown to 
influence CSD susceptibility measurements in animals under anesthesia as they can change neuronal 
excitability and vascular function (Holland et al 2012, Kudo et al 2008, Pietrobon & Moskowitz 
2014, Ruusuvuori & Kaila 2014, Sukhotinsky et al 2010). For this reason, physiological parameters 
are in most studies monitored via femoral artery catheterization (physiological monitoring) and 
controlled using mechanical ventilation by changing the ventilation settings to adjust physiological 
parameters as needed (physiological control). In addition to the presence or absence of physiological 
monitoring and control, CSD experiments also vary with respect to choice of anesthesia gas mixture, 
which can also affect the outcome of CSD susceptibility measurements. For instance, N
2
O (instead 
of pressurized air) in the anesthesia gas mixture has a suppressive effect on CSD parameters (Kudo 
et al 2008). Consequently, the experimental design of CSD experiments under anesthesia that may 
include physiological monitoring or physiological control, or neither, is expected to result in different 
outcomes of CSD frequency and threshold. 
The importance of understanding the consequences of methodologies for assessing CSD parameters 
is especially relevant when comparing results from different studies. Here we show the relevance of 
different methodologies for CSD assessment with respect to the investigation of transgenic knock-
in mice that carry the R192Q missense mutation in the α
1
 subunit of Ca
V
2.1 Ca2+ channels (van den 
Maagdenberg et al 2004). In humans, this mutation causes familial hemiplegic migraine 1 (FHM1; 
(Ophoff et al 1996). FHM1 R192Q mice have been used in different laboratories to unravel migraine-
relevant mechanisms (Ferrari et al 2015).  
Different methodologies and read-out measures have been used in different laboratories to assess the 
susceptibility of CSD in R192Q mice. A decreased threshold for the induction of CSD, assessed with 
increasing electrical stimulus intensity, was reported for the visual cortex of mutant mice that were 
kept under urethane anesthesia (van den Maagdenberg et al 2004, van den Maagdenberg et al 2010). 
Physiological parameters were not monitored during these experiments, and a gender difference was 
not reported. In another study, an increased frequency of CSD, assessed with a 30-min application of 





(70%/30%) anesthesia and physiological monitoring and control 
(Eikermann-Haerter et al 2009a, Eikermann-Haerter et al 2009b). In those studies, female mutant 
mice showed a higher CSD frequency than male mutants; ovariectomy normalized CSD frequency in 
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mutant females to males levels. WT mice showed no gender difference and no effect of ovariectomy in 
females. Notably, a gender difference had been observed when CSD threshold was studied in the cortex 
of C57BL/6 WT mice that were kept under isoflurane-air anesthesia and physiologically monitored 
(Brennan et al 2007). Apparently, a gender difference is revealed when using one methodology but 
not another methodology. This leads to the question whether certain aspects of CSD susceptibility 
may only be observed when a specific combination of methodology and anesthetics is used, and 
whether results between laboratories can be compared.  
We here assessed cortical CSD frequency in male and female R192Q and WT mice using various 
methologies. Namely, i) without monitoring and control using  isoflurane-air anesthesia, ii) monitoring 









anesthesia. In addition, we 
compared CSD frequency and threshold in visual and motor cortex, in both male and female mice, in 
the absence of physiological monitoring and physiological control. 
MATERIALS AND METHODS
Animals
Male and female homozygous Cacna1a FHM1 R192Q knock-in (“R192Q”) and wild-type (“WT”) 
mice of 2-4 months were used. The R192Q mice were generated by introduction of the human FHM1 
pathogenic R192Q missense mutation in the mouse Cacna1a gene using a gene targeting approach 
(van den Maagdenberg et al 2004). All experiments were approved by the Animal Experiment Ethics 
Committee of Leiden University Medical Center. 
CSD threshold and frequency recordings without physiological monitoring  
or physiological control
All experiments were performed during daytime between 10.00 am–13.00 pm. Mice were anesthetized 




) and were breathing spontaneously. Core 
body temperature was maintained at 37 ºC using a heating pad (Stoelting, Wood Dale, IL, USA). Mice 
were mounted into a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). Subsequently, 
a midline incision of ~2.5 cm was made over the top of the head, the skin was retracted to expose the 
skull, and the periosteum was removed with cotton-tipped applicator sticks. Two craniotomy windows 
were drilled at the following coordinates in the right hemisphere (in mm with respect to Bregma): 
3.5 posterior/2.0 lateral (visual cortex) and 1.5 anterior/2.0 lateral (motor cortex) (Figure 1A). Care 
was taken to keep the dura intact to minimize trauma to the underlying brain tissue. At the recording 
site a sharp glass capillary electrode (FHC Inc., Bowdoin, ME, USA) filled with 150 mM NaCl was 
advanced through the dura to a depth of 300 µm. After insertion of the electrode, a drop of mineral oil 
(~5 µL) was applied to the recording site to prevent drying of cortical tissue. The surgical procedure 
was completed within 20 min after the start of the anesthesia. DC-potential signals were measured 
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with respect to an Ag/AgCl reference electrode placed subcutaneously at the neck and amplified 10x 
(Molecular Devices, Sunnyvale, CA, USA). The DC signal was low-pass filtered at 4 Hz and digitized 
at 100–200 Hz using PowerLab 16/30 hardware (AD Instruments, Inc., Colorado Springs, CO, USA). 
Data were recorded and analyzed off-line using LabChart Pro (AD Instruments). In each mouse, first 
the CSD threshold was measured either in the visual or motor cortical window. To this end a cotton 
pellet (Interguide Dental Supply, Burlingame, CA, USA) soaked in a solution of KCl with a specific 
concentration (initially 5 mM) was placed on the dura overlaying either the visual or motor cortex for 3 
min. In case no CSD was induced during this time window, the cotton pellet was replaced with another 
pellet that contained a higher K+ concentration. Solutions contained increasing K+ concentrations with 
7.5-mM increments (with total osmolarity kept at 300 mOsmol by addition of NaCl to the solution). The 
measurements continued until a CSD event was observed, so the CSD threshold could be determined. 
After the CSD threshold measurement, the induction site was rinsed with 150 mM NaCl. Subsequently, 
CSD frequency was determined at the same location. The location used (visual vs motor cortex) is 
mentioned for the respective CSD frequency result in the legend. For CSD frequency measurements, 
CSD events were induced by placement of a cotton pellet soaked in 1 M KCl on the dura overlaying 
the visual or motor cortex for 30 min, with refreshment of the pellet after 15 min. The total number of 
CSD events that occurred within 30 min was used to calculate the frequency per hr. For both the CSD 
threshold and frequency measurements, only reversible DC deflections with amplitudes larger than 5 
mV were considered CSD events and included for further analysis. 
CSD frequency recordings with physiological monitoring 




 and allowed to breathe 
spontaneously. Blood gas and mean arterial blood pressure values were monitored by placing a 
catheter in the left femoral artery. The surgical procedures were completed within 30 min after the 
start of the anesthesia. Blood pressure was measured continuously via a blood pressure transducer 





; Table 2), 40-µL blood samples were collected before the start and at the 
end of the 30 min CSD frequency measurement and used for blood-gas analysis. Accepted ranges 




=30-40 mmHg; and 
blood pressure=70-110 mmHg. Visual cortex CSD frequency measurements were performed upon 
induction of CSD by 1 M KCl application on the dura overlaying the visual cortex, as described 





CSD frequency recordings with physiological control 
In contrast to experiments with physiological monitoring, described in the previous section, mice were 
now mechanically ventilated and physiological parameters adjusted when necessary. Measurement 
of CSD frequency with physiological control was performed as described in (Eikermann-Haerter et 
al 2009b), with slight modifications. In brief, mice were maintained under 1.5% isoflurane anesthesia 
in a gas mixture of 70-80% N
2
O and 20-30% O
2
. Blood gas and mean arterial blood pressure values 
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were monitored via a catheter in the left femoral artery, as described above. After insertion of the 
catheter in the femoral artery, an endotracheal tube was inserted in the trachea that allowed artificial 
ventilation of the mouse. The mouse received an i.p injection of 0.04 mg/kg pancuronium for muscle 
paralysis to suppress spontaneous breathing and was connected to a mouse ventilator (SAR-830, 
CWE Inc, Ardmore, PA, USA). The surgical procedures were completed within 45 min after the start 
of the anesthesia. Visual cortex CSD frequency was measured upon induction of CSD by 1 M KCl 
application on the dura overlaying the visual cortex (Figure 1A), as described in the previous section, 




 and blood pressure) were now monitored 
(Table 2) and, if necessary, controlled by adjustments in ventilation. Blood pressure was measured 
continuously, as described above. For the other parameters, 40 µL blood samples were collected before 
the start and at the end of the 30 min CSD frequency measurement and used for blood-gas analysis; 





mmHg; and blood pressure=70-110 mmHg. When pH and pCO
2
 values were outside the accepted 




were outside the accepted ranges,
 
adjustments were made to the administered O
2
 concentration. In this way physiological parameters 
were controlled during the experiment. The effect of the ventilator adjustments on physiological 
parameters was determined by taking a blood sample, immediately after the adjustment. 
Ovariectomy







). A 1 cm incision was made in the skin of the flank followed by an incision in 
the muscle wall. Ovaries were separated from the surrounding tissue with ligatures, and carefully 
removed, after which the skin was closed with sutures. The mouse was given a subcutaneous injection 
of 1 mL 0.9% NaCl to maintain physiological hydration. The mouse also received an intramuscular 
injection of 0.1 mg/kg temgesic for post-operative analgesia. After a 2-week recovery period, CSD 
threshold and frequency recordings were performed using isoflurane-air anesthesia in the absence of 
physiological monitoring or control, as described above.
Statistical analysis
For statistical analysis of CSD threshold, which is skewed, the Mann-Whitney U-test was used. For 
CSD frequency values, one-way ANOVA followed by Bonferroni correction or Student’s t-test was 






































































Figure 1. In the absence of physiological monitoring and control under isoflurane-air anesthesia, visual cortex CSD 
frequency is enhanced in R192Q mice compared with WT, with no difference between genders.
(A) Schematic representation of visual cortex CSD frequency measurements in anesthetized mice. CSD is induced by 
placement of a cotton pellet containing 1 M KCl on the dura overlaying the visual cortex for a period of 30 min, while CSD 
events are measured by DC-recording via a glass-electrode placed in the motor cortex. In experiments without physiological 
monitoring or control, CSD frequency measurements followed CSD threshold measurements (see Methods) (B) Example CSD 
frequency traces illustrating enhanced visual cortex CSD frequency in male R192Q compared with WT mice in the absence 
of physiological control using isoflurane-air aesthesia (C) Bar diagram depicting enhanced CSD frequency in the visual 
cortex in both male and female R192Q compared with WT mice (†p=0.0001 and ‡ p=0.0001; one-way ANOVA Bonferroni 
correction). No CSD frequency difference was observed for male compared with female R192Q mice in experiments without 
physiological control using isoflurane-air anesthesia. 
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RESULTS 
CSD frequency in the visual cortex is enhanced in R192Q mice without revealing 
a gender difference, when assessed in the absence of physiological monitoring or 
physiological control
We determined visual cortex CSD frequency (Figure 1A, B) of male and female R192Q and WT mice 
using isoflurane-air anesthesia in the absence of physiological monitoring or physiological control. 
Both female and male R192Q mice showed an enhanced visual cortex CSD frequency compared with 
WT (female R192Q, 16.4±3.3 CSD/hr, vs female WT, 8.5±3.6 CSD/hr, N=9, p=0.0001; male R192Q, 
17.0±2.1 CSD/hr, N=10, vs male WT, 8.9±2.8 CSD/hr, N=14, p=0.0001). For both R192Q and WT mice 
no gender difference was observed (female R192Q vs male p=0.6; female WT vs male p=0.7) (Figure 
1C). Table 1 summarizes CSD amplitude and duration characteristics for the different groups. Except 
for CSD duration, which was longer for female WT compared with female R192Q mice, no statistical 
differences were observed. Not finding a gender difference in R192Q mice contrasts with published data 





used and physiological parameters were controlled (Eikermann-Haerter et al 2009b).
CSD threshold in the visual cortex is reduced in R192Q mice, and more so in male 
mutants, when assessed in the absence of physiological monitoring and physiological 
control
A study by Brennan et al. (Brennan et al 2007) showed that CSD threshold in the visual cortex was 
reduced in female compared with WT mice in experiments in which physiological parameters were 
monitored, and not controlled. We here assessed visual cortex CSD threshold of R192Q and WT 
mice of both genders, using isoflurane-air anesthesia, without monitoring or controlling physiological 
parameters. CSD threshold, as assessed by the KCl concentration required to elicit a CSD (Figure 2A), 
was reduced in both female and male R192Q mice compared with WT mice of the same gender (female 
R192Q, median=51.8 mM KCl, N=14 vs female WT, median=68.7 mM KCl, N=9; p=0.01; male 
R192Q, median=38.7 mM KCl, N=11 vs female WT, median=58.7 mM KCl, N=14; p=0.001) (Figure 
2B). Rather unexpectedly, male R192Q mice showed a lower CSD threshold (p=0.02) compared with 
female R192Q mice. CSD threshold did not statistically differ between female and male WT mice, 
although male WT mice showed a trend towards a lower threshold (p=0.08). There were no statistical 
differences in CSD amplitude or duration between female and male mice, or between genotypes for 













































































Figure 2. Visual cortex CSD threshold is reduced in R192Q mice compared to WT in the absence of physiological 
control under isoflurane-air anesthesia, with strongest effect in males.
(A) Specimen recordings of CSD threshold assessments illustrating the lower KCl concentration that is required to induce 
a CSD in the visual cortex of a male R192Q compared with a WT mouse (B) Box plots depicting lower visual cortex CSD 
threshold in male R192Q compared with female mice (*p=0.02 male R192Q vs female R192Q, Mann-Whitney U-test) and 
in R192Q male and female mice compared with WT (#p=0.001 male R192Q vs WT; §p=0.01 female R192Q vs WT, Mann-
Whitney  U-test). 
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Table 1. CSD amplitude and duration characteristics of CSD frequency and threshold recordings 
from visual and motor cortex in R192Q and WT mice for experiments performed in the absence 
of physiological monitoring or control, using isoflurane-air  
Male Female








R192Q visual 10 18.9±3.3 32.4±11.9 14 20.4±2.6‡ 25.4±5.0
WT visual 14 20.9±3.0 34.4±18.0 9 23.4±2.6* 46.3±25.1*
R192Q motor 7 14.9±6.2 20.8±7.4 12 15.4±3.9 30.4±11.2
WT motor 10 21.1±4.1† 33.3±8.1 7 10.7±3.4 27.2±10.9
CSD Threshold
R192Q visual 11 21.9±1.9 71.1±35.2 14 22.2±3.5 63.5±22.8
WT visual 14 25.0±4.3 71.2±39.0 9 25.7±3.1* 72.4±19.5
R192Q motor 8 17.9±5.0 56.2±26.4 12 19.4±2.8 72.3±27.6
WT motor 11 22.7±2.7† 45.8±10.6 10 15.9±3.0 46.8±19.2
CSD susceptibility is not affected by gender when assessed in the motor cortex in the 
absence of physiological monitoring and physiological control 
Given reports on visual cortex hyperexcitability in migraine patients (Aurora & Wilkinson 2007), 
and the suggestion of CSD to initiate preferably in the visual cortex (Hadjikhani et al 2001), we next 
assessed whether effects of genotype and gender on measures of CSD susceptibility frequency and 
Table 1. Values are shown as mean ± SD. CSD duration was measured at half-maximal amplitude. CSD frequency data: 
comparison of CSD characteristics in CSD frequency recordings revealed a lower CSD amplitude in female WT mice for 
the motor cortex compared with female WT mice for the visual cortex (*p=0.0001), and compared with male WT mice in 
the motor cortex (†p=0.038, one-way ANOVA, Bonferroni correction). CSD amplitude was also reduced in female R192Q 
mice for the motor cortex compared to the visual cortex (‡p=0.049, one-way ANOVA, Bonferroni correction). There were 
no differences in CSD duration except for a shorter duration in female R192Q mice for the visual cortex compared with 
female WT mice visual cortex (*p=0.016, one-way ANOVA, Bonferroni correction). CSD threshold data: CSD amplitude 
was reduced in female WT mice for the motor compared to the visual cortex (*p=0.0001) and compared to motor cortex in 
male WT mice (†p=0.0001, one-way ANOVA, Bonferroni correction). There were no differences between groups in CSD 
duration for CSD threshold measurements.
039
threshold are specific to the visual cortex. Therefore, we investigated these CSD measurements also in 
the motor cortex. Experiments were carried out using isoflurane-air anesthesia without physiological 
monitoring or physiological control. Regarding a possible effect of genotype, for the motor cortex 
both male and female R192Q mice exhibited higher CSD frequencies compared with WT mice of the 
same gender (male R192Q, 14.0±3.6 CSD/hr, N=7 vs male WT, 7.6±1.3 CSD/hr, N=10, p=0.0001; 
female R192Q, 13.0±3.9 CSD/hr, N=12 vs female WT, 5.5±1.7 CSD/hr, N=7, p=0.0001) (Figure 3A). 
For CSD threshold however, both male and female R192Q mice showed comparable CSD thresholds 
as WT mice of the same gender (male R192Q, median=56.8 mM KCl, N=9 vs male WT, median=57.5 
mM KCl, N=11, p=0.8; female R192Q, median=59.3 mM KCl, N=12 vs female WT, median=63.1 
mM KCl, N=10, p=0.60 (Figure 3B). With respect to gender, for motor cortex CSD frequency, similar 
as observed for the visual cortex, no difference was observed between male and female mice for both 
R192Q (p=0.5) and WT mice (p=0.3) (Figure 3A). For CSD threshold measurements in the motor 
cortex, in contrast to the visual cortex, no difference was observed between genders in R192Q mice 
(p=0.7). In WT mice, as seen for the visual cortex, no gender effect was observed for motor cortex 





















































































































Figure 3. In the absence of physiological control, CSD susceptibility in the motor cortex is not influenced by gender. 
Experiments were performed in the absence of physiological control under isoflurane-air anesthesia (A) Bar diagrams 
showing an increased motor cortex CSD frequency for both male (†p=0.0001) and female R192Q mice (‡p=0.0001; one-
way ANOVA, Bonferroni correction) compared with WT, with no differences between genders among mice of the same 
genotype (B) CSD threshold values in the motor cortex were comparable between R192Q and WT mice of both genders in 
experiments without monitoring or control.
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Given these observations, we next assessed whether CSD susceptibility measurements of frequency 
and threshold may differ between the visual and motor cortex, with possible effects of genotype 
and gender. Between cortical regions, male R192Q mice exhibited comparable CSD frequencies for 
visual and motor cortex, although a trend towards higher CSD frequency was observed for the visual 
compared with motor cortex (p=0.05). Female R192Q mice displayed a significantly higher CSD 
frequency in the visual compared with motor cortex (p=0.02). CSD frequency was not different for 
the visual compared with motor cortex in male WT (p=0.2) and female WT mice (p=0.07) (Figures 
1C and 3A). CSD threshold was lower in the visual compared with the motor cortex (p=0.009) in 
male R192Q mice. Female R192Q mice however showed comparable CSD thresholds for both visual 
and motor cortex (p=0.1). In WT mice, CSD threshold was not different between motor and visual 
cortex in both male (p=0.6) and female mice (p=0.7) (Figures 2B and 3B). Table 1 summarizes CSD 
characteristics amplitude and duration for the different groups. For CSD frequency measurements, 
some differences were observed regarding CSD amplitude. In particular, for female R192Q mice, 
lower CSD amplitude was observed in motor compared with visual cortex. Furthermore, female WT 
mice showed lower CSD amplitude in the motor compared with the visual cortex, and compared with 
male WT mice in the motor cortex. For CSD threshold measurements, no differences were observed 
except for lower CSD amplitude in female WT mice in the motor compared with the visual cortex.
Ovariectomy has no strong influence on visual cortex CSD susceptibility in 
experiments without physiological monitoring and physiological control  
Although visual cortex CSD frequency was comparable between male and female R192Q mice in 
physiologically uncontrolled experiments, the enhanced CSD frequency that was observed for female, 
but not male, R192Q mice in the visual compared with the motor cortex suggests some effect of 
gender on CSD characteristics in the absence of physiological control. Hence we next determined, in 
experiments performed in the absence of physiological monitoring and control, whether ovariectomy 
in female R192Q mice may reduce visual cortex CSD frequency values to those observed for 
motor cortex. After ovariectomy in female R192Q mice, visual cortex CSD frequency did not show 
a difference anymore with motor cortex CSD frequency from intact female R192Q mice (p=0.2). 
Nevertheless, visual cortex CSD frequency itself was not significantly reduced by ovariectomy in 
female R192Q or WT mice (R192Q ovariectomized (Ovx), 15.2±4.0 CSD/hr, N=8 vs R192Q intact, 
16.4±3.3 CSD/hr, N=14, p=0.8; WT Ovx, 7.9±2.0 CSD/hr, N=5 vs WT intact, 8.5±3.6 CSD/hr, N=9, 
p=0.7). Similar as for intact female R192Q compared with WT mice, ovariectomized female R192Q 
mice showed higher visual cortex CSD frequency compared with ovariectomized WT mice (p=0.003). 
Given the observed, unexpected, higher visual cortex CSD threshold observed for female compared 
with male R192Q mice, we next determined whether this effect may be influenced by ovariectomy. 
Similar as for CSD frequency, visual cortex CSD threshold was not influenced by ovariectomy for both 
female R192Q and WT mice (R192Q Ovx, median=57.5 mM KCl, N=7 vs R192Q intact, median=51.8 
mM KCl, N=14, p=0.3; WT Ovx, median=72.5 mM KCl, N=5 vs WT intact, median=68.7 mM KCl, 
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N=9, p=0.4). As a consequence, ovariectomized female R192Q mice still showed a higher visual 
cortex CSD threshold compared with male R192Q mice (p=0.01). The genotype effect on visual 
cortex CSD threshold was also not influenced by ovariectomy. Ovariectomized R192Q mice showed 
reduced CSD threshold compared with ovariectomized WT (p=0.04). CSD amplitude and duration 
were not influenced by ovariectomy for both CSD frequency and threshold experiments.
CSD frequency in the visual cortex is enhanced in R192Q mice, and more so in female 
mutants, when assessed in the presence of physiological monitoring and physiological 
control
Although our experiments performed without physiological monitoring or physiological control show 
the reported genotypic effect of the R192Q mutation on CSD susceptibility, the absence of a gender 
effect on visual cortex CSD frequency is not in line with earlier experiments in R192Q mice from 
Eikermann-Haerter et al. that were performed in the presence of physiological control (Eikermann-
Haerter et al 2009b). For CSD threshold in WT mice, in contrast to studies from Brennan et al. 
(Brennan et al 2007) we did not observe an effect of gender, and for male R192Q mice we observed 
an unexpected lower CSD threshold compared with female R192Q mice. Given the variable duration 
of a CSD threshold paradigm that may have an impact on the studies in mice without physiological 
control, in our next experiments we choose to use only visual cortex CSD frequency assessment. We 





 anesthesia was used, and in which mice were kept under physiological control, 





 pH and blood pressure) are shown in Table 2. Both female 
(p=0.0002) and male R192Q mice (p=0.004) exhibited a higher CSD frequency compared with WT 
of the respective gender. In line with published data, CSD frequency was higher in female than in 
male R192Q mice (female R192Q, 22.8±4.5 CSD/hr, N=7 vs male R192Q, 16.32±1.9 CSD/hr, N=6; 
p=0.007), while no gender difference was observed for WT mice (female WT, 10.42±1.8 CSD/hr, 
N=5 vs male WT, 12.0±1.7 CSD/hr, N=5; p=0.1) (Figure 4). No statistical differences were observed 
for CSD amplitude and duration among the different groups, except for a longer CSD duration for 
female WT compared with female R192Q mice and compared with male WT mice (Table 2).
The absence of a gender effect on CSD frequency in experiments that are not 
physiologically controlled is related to the absence of mechanical ventilation and 
slight differences in physiology
The observation of a gender effect on visual cortex CSD frequency in R192Q mice in physiologically 
monitored and controlled experiments raises the question whether this gender effect may also be 
observed for experiments that are only physiologically monitored, provided that physiological 
parameters are within ranges. CSD threshold was not considered as a readout measure, given the 






























































controlled-isoflurane-N2O/O2 Figure 4. In physiologically controlled





 anesthesia, visual cortex CSD frequency 
is enhanced in female R192Q mice compared 
with males. In agreement with previous findings 
in which physiological parameters were controlled 





anesthesia (Eikermann-Haerter et al 2009b), female 
R192Q mice exhibited increased visual cortex CSD 
frequency compared with male R192Q mice (*p=0.007 
female vs male R192Q; Student’s t-test). Genotypic 
comparisons revealed a higher CSD frequency for both 
male and female R192Q mice in comparison with WT 
(§p=0.004 male R192Q vs male WT; †p=0.0002 female 
R192Q vs female WT, one-way ANOVA, Bonferroni 
correction).
Table 2. CSD amplitude and duration and physiological parameters of R192Q and WT mice 
for CSD frequency experiments performed with physiological monitoring-only, or with 















6 7.45±0.02‡ 97.8±4.0 25.5±2.7 74.2±1.1$ 21.1±1.1* 27.1±5.1
Female R192Q 
monitored-air




































5 7.38±0.01 128.7±3.5 31.5±2.4$ 99.5±9.0‡ 21.6±6.9 45.2±14.0
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in male and female R192Q mice that were physiologically monitored (by femoral artery catheterization) 
but not controlled (i.e., animals were breathing freely and were not mechanically ventilated). Under 
these conditions, we compared CSD frequency characteristics between male and female R192Q 
mice for experiments performed with air (as in our unmonitored and uncontrolled experiments) with 









 in the gas anesthesia mixture, physiologically monitored male and female R192Q mice 
showed comparable CSD frequencies (isoflurane-air: male R192Q, 17.8±2.0 CSD/hr, N=6 vs female 




: male R192Q, 16.1±3.0 CSD/hr, N=5 vs 
female R192Q, 15.4±2.9 CSD/hr, N=6, p=0.7) (Figure 5A, B). For these monitored experiments, 
all physiological parameters were within accepted ranges (Table 2). No consistent relationship was 
apparent between higher or lower CSD frequency values and levels of physiological parameters, with 
physiological values showing changes in both positive and negative directions. 
Table 2. Values are shown as mean ± SD. CSD duration was measured at half-maximal amplitude. In monitored 
experiments, physiological parameters were only monitored (via femoral artery catheterization) but not controlled by 










 anesthesia. In physiologically controlled experiments physiological parameters were maintained within physiological 
range by adjusting ventilation guided by femoral artery blood measurements. For some of the experimental groups, 
differences in CSD amplitude, duration or physiological parameters were observed. For female R192Q and WT mice, 
CSD amplitude and duration were not different among groups. There were some differences in physiological parameters: 
pH was higher (*p=0.044) whereas pCO
2














group exhibited higher pO
2
 values (‡p=0.031) and higher MABP (§p=0.0001, one-way ANOVA, 
Bonferroni correction) compared to the female R192Q monitored-air group. For male R192Q mice, CSD duration was 




 group showed a lower CSD 





 group (†p=0.021, one-way ANOVA, Bonferroni correction). For the male R192Q monitored-air group compared 




 group, pH was slightly higher (‡p= 0.042) and pCO
2
 was lower (§p=0.013, one-way 




 group compared to both male 




 groups (#p=0.010, one-way ANOVA, Bonferroni 




group showed higher CSD amplitude compared to 






(†p=0.007, Student’s t-test). In addition, the male R192Q monitored-air group 





groups, some differences were observed in CSD characteristics and physiological parameter 
values between WT and R192Q mice, for both males and females. Although CSD amplitude for these experiments was 
comparable among groups, CSD duration was longer for female R192Q compared with female WT mice (*p=0.0001) 







female WT mice exhibited higher MABP values compared with female R192Q (‡p=0.002) 
and compared with male WT mice (§p=0.005, one-way ANOVA, Bonferroni correction). Lastly, pCO
2 







of female R192Q mice compared to female WT ($p=0.038) and compared with male R192Q 




































































































































































































































Next, we carried out a direct comparison of the visual cortex CSD frequency data from male and 
female R192Q mice from the 4 different experimental methodologies used in the present study, i.e., 









. This comparison revealed that for male R192Q mice, CSD frequency was comparable for all 
4 conditions. For female R192Q mice however, CSD frequency was significantly higher for the 




















O p=0.005; one-way ANOVA, 
Bonferroni correction) (Figure 5C). Comparison of CSD duration revealed no differences among 











 group. In 




 group showed higher CSD amplitude compared to 




 group (Table 2). 
Finally, we assessed whether the absence of higher CSD frequency in R192Q female mice that 





 and blood pressure) in comparison to experiments under physiological control. 











 values were slightly higher (p=0.02) and pH was slightly lower 








 group (controlled vs monitoring-only-air 




 p=0.01) (Table 2). Physiological parameters were 









except for a lower blood 











Figure 5. Increased visual cortex CSD frequency in female R192Q mice in experiments with physiological control is 
not related to the anesthesia gas mixture but to the use of mechanical ventilation.
(A, B) Bar diagrams depicting the lack of a gender effect on visual cortex CSD frequency between male and female R192Q 
mice for experiments carried out in the presence of physiological monitoring (via the femoral artery), but in the absence of 
mechanical ventilation (i.e., animals were allowed to breathe spontaneously and were not physiologically controlled), using 
isoflurane-air anesthesia (A) (p=0.1, male vs female R192Q, Student’s t-test) and (B) isoflurane-N2O/O2 anesthesia (p=0.7, 
male vs female R192Q Student’s t-test) (C) Bar diagrams depicting the comparison of the visual cortex CSD frequency data 
from male and female R192Q mice tested among the different experimental conditions. Grey colour indicates that these data 
were presented in earlier figures. Male R192Q mice displayed no differences in visual cortex CSD frequency across the 4 
different experimental conditions. Female R192Q mice however displayed a significantly increased CSD frequency (indicated 





 anesthesia) in comparison to female R192Q mice that were: i) uncontrolled with isoflurane-air (p=0.001); 





 (p=0.005 one-way ANOVA, Bonferroni correction). 
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DISCUSSION 
Using CSD frequency as readout for CSD susceptibility, we here showed that in the absence of 
physiological monitoring and control, R192Q mice exhibit an increased visual cortex CSD frequency 
compared to WT. In contrast to earlier studies, performed in the presence of physiological control 
(Eikermann-Haerter et al 2009b), the effect was not more pronounced in females. The absence of a 
gender effect was not explained by the CSD readout parameter: also with threshold measurements 
visual cortex CSD susceptibility was not enhanced, and was even increased, for female compared 
to male R192Q mice. In addition, comparison between visual and motor cortex as sites of CSD 
induction revealed that also for the motor cortex, CSD frequency was specifically enhanced in 
R192Q compared with WT mice.  CSD threshold however was not different for R192Q compared 
with WT mice in the motor cortex. Gender had no influence on CSD frequency or threshold in the 
motor cortex. When comparing the two cortical regions, CSD susceptibility was enhanced in visual 
compared to motor cortex for CSD threshold in male R192Q mice, and for CSD frequency in female 
R192Q mice, indicating an effect of gender. Ovariectomy however had no effect on either visual 
cortex CSD frequency or threshold in female WT and R192Q mice in the absence of physiological 
control. Experiments performed with physiological monitoring, but without physiological control, 
revealed that the lack of a gender effect on visual cortex CSD frequency in the absence of control was 




but to the absence of mechanical ventilation. In these 
monitored experiments, slight differences in pH, pCO
2
 and blood pressure were observed that may 
contribute to the lack of enhanced CSD frequency in female compared to male R192Q mice when 
physiological parameters are not controlled. 
Our data indicate that parameters of CSD susceptibility can be masked or unmasked depending on the 
experimental paradigm used. This has important implications for the interpretation and comparison 
of experimental CSD studies across laboratories, since it is plausible that certain effects on CSD 
characteristics are related to the used methodology. Below, we discuss possible implications of certain 
methodologies with respect to specific CSD characteristics. 
The effect of enhanced visual cortex CSD frequency in R192Q mice in the present study for 
experiments performed using isoflurane-air anesthesia, is in line with findings from earlier work 





Haerter et al 2009a, Eikermann-Haerter et al 2009b). This indicates that the genotypic effect on CSD 
frequency is not influenced by the presence or absence of physiological monitoring or control, or by 
the used anesthesia gas mixture. Our data extend the genotypic effect on CSD frequency also to the 
motor cortex. The reduced visual cortex CSD threshold in R192Q mice which we observed for both 
genders in the absence of physiological control is for male mice in line with earlier uncontrolled 
CSD studies. In those studies urethane was used instead of isoflurane anesthesia, and for threshold 
assessment electrical stimulation was used (van den Maagdenberg et al 2004, van den Maagdenberg 
et al 2010) instead of topical KCl application. Gender effects were not studied before in FHM1 
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mice for CSD threshold. We observed an opposite gender effect in the absence of physiological 
control, with visual cortex CSD threshold being lower in male compared to female R192Q mice. In 
addition, contradictory effects were observed for possible regional differences in CSD susceptibility 
among genders. Furthermore, ovariectomy had no effect on visual cortex CSD frequency or threshold 
in R192Q mice for physiologically uncontrolled experiments. For CSD frequency this contrasts 
reported effects of ovariectomy for experiments performed under physiological control (Eikermann-
Haerter et al 2009b). It is plausible that in the absence of physiological control, variations occur in 
physiological parameters that influence CSD susceptibility characteristics, in particular during CSD 
threshold paradigms with variable durations. 
Apart from CSD threshold and frequency, amplitude and duration of CSD events may also be 
influenced by alterations in physiology. A longer CSD duration for example has been associated 
with impaired tissue perfusion and recovery in rats (Sukhotinsky et al 2010). In previous studies 
under physiologically controlled conditions, CSD duration and amplitude were not different for 
visual cortex CSD frequency recordings between male and female mice for both WT and R192Q 
mutants (Eikermann-Haerter et al 2009b). In our study, no differences in CSD duration were observed 
that could contribute to the enhanced CSD frequency for female R192Q mice in the physiologically 
controlled group. CSD amplitude differences that were observed among some of the experimental 
groups were not related to differences in CSD frequency. In general, it should be noted that CSD 
amplitude may not be considered a reliable readout for CSD susceptibility given its dependence on 
recorded cortical depth. 
Enhanced CSD susceptibility of female FHM1 mice is clinically relevant in the context of the 
higher propensity of women for migraine (Fettes 1999). Underlying mechanisms could involve 
enhancement of glutamatergic neuronal excitability by estradiol (Kelly et al 2003, Sato et al 2003, 
Smith 1989, Woolley et al 1997). A direct effect of estradiol on glutamatergic neurotransmission fits 
the observation of a gender effect only in FHM1 and not in WT mice. The finding that a gender effect in 
physiologically controlled experiments was observed regardless of estrous cycle, as the phase was not 
determined, suggests that intrinsic brain differences between males and females (Borsook et al 2014) 
may contribute to enhanced CSD susceptibility in female FHM1 mice. Interestingly, expression of the 
subunit of P/Q-type Ca2+ channels was shown to be enhanced in the pituitary of female compared to 
male rodents, and fluctuate during the estrous cycle (Fiordelisio et al. 2007), suggesting a modulation 
of CSD frequency by female hormones at the level of the mutant Ca2+ channels. The observation that 
a gender effect on CSD frequency was not observed in physiologically uncontrolled experiments 
suggests that mechanisms underlying the gender effect are influenced by changes in physiology. 
Although in all monitored experiments physiological parameters were within normal ranges for 
anesthetized rodents, monitored-only female R192Q mice displayed slightly higher pCO
2
 and lower 
blood pressure values compared to female R192Q mice from the physiologically controlled group. 
Changes in pCO
2
 and related changes in brain pH can modulate neuronal excitability by affecting ion 
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channels and transporters (Ruusuvuori & Kaila 2014), whereby high pCO
2
 and low pH are expected 
to lower CSD susceptibility (Holland et al 2012). It is thus possible that the absence of a gender effect 
in monitored-only female R192Q mice relates to the slightly higher pCO
2 
for this group. Changes in 
blood pressure can also affect CSD characteristics (Sukhotinsky et al 2010). Lower blood pressure 
of monitored-only female R192Q mice, compared to physiologically controlled mice, may thereby 
have contributed to a lower CSD frequency, thus masking a gender effect in the absence of control. 
Alternatively, it is possible that the use of mechanical ventilation for physiological control causes 
certain changes in physiology that are not monitored, but which may influence CSD characteristics. It 
has been described that mechanical ventilation can affect cerebral blood flow (Milan et al 2009), which 
has a bi-directional relationship with CSD initiation and propagation (Ayata 2013). Since estradiol 
can alter the brain’s vascular responses to CGRP (Gupta et al 2007), it is possible that vascular effects 
of mechanical ventilation influence modulation of CSD susceptibility by estradiol. 
Our CSD experiments performed in the absence of physiological control suggested that the visual 
cortex may be more susceptible to CSD than the motor cortex in R192Q, but not in WT mice. If 
true, this would be in line with neurophysiological studies reporting visual cortex hyperexcitability 
in migraine patients (Aurora et al 1998, Aurora et al 2003, Aurora & Wilkinson 2007). Further 
clinical relevance comes from imaging studies in migraine patients suggesting CSD initiation to 
occur preferably in the visual cortex (Hadjikhani et al 2001). Our data however showed that an 
effect of cortical region on CSD susceptibility was evident for CSD threshold only in male, and 
not in female R192Q mice. For CSD frequency, a regional difference was observed only in female, 
and not in male R192Q mice. Since these observations were made in the absence of physiological 
monitoring and control it is difficult to assess whether these findings may be confounded by possible 
changes in physiology during recordings. Studies in WT mice under halothane anesthesia, in the 
absence of physiological monitoring or control, showed no difference in CSD susceptibility between 
the occipital and frontal cortex (Godukhin & Obrenovitch 2001), similar to our observations in WT 
mice. For insight in a putative effect of cortical region on CSD susceptibility, additional experiments 
with physiological monitoring, and possibly mechanical ventilation for control, would be useful, as 
well as CSD studies in freely behaving mice that allow for exclusion of possible effects of anesthesia, 
catheterization or ventilation.
In conclusion, we showed that in experimental CSD studies in mice, control of physiological parameters 
can influence CSD susceptibility characteristics. Although the mechanisms remain to be unraveled, the 
occurrence of a gender effect on visual cortex CSD frequency in R192Q mice appeared sensitive to the 
use of mechanical ventilation and to possible changes in systemic pH, pCO
2
 or blood pressure levels. 
Effects of other factors on CSD susceptibility, such as a putative effect of cortical region, may become 
apparent in the absence of control if such effects are sensitive to changes in physiology that are influenced 
by mechanical ventilation. Comparison among CSD studies need to take into account influences of the 
used methodologies and, ideally, should include studies in awake, unanesthetized animals. 
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Migraine is an episodic brain disorder for which cortical hyperexcitability has been proposed as 
one of the key disease mechanisms. Two main subtypes of migraine are distinguished based on the 
presence of an aura that can accompany headaches in many patients. The aura is likely caused by 
cortical spreading depression (CSD), a slowly spreading wave of neuronal and glial depolarization. 
Familial hemiplegic migraine type 1 (FHM1) mutant mice that carry a R192Q missense mutation in 
the Cacna1a gene, which had been previously identified in patients, display enhanced (glutamatergic) 
neuronal excitability and increased CSD susceptibility. Here we performed continuous day-night DC-
EEG and multi-unit activity recordings in visual and motor cortex from freely behaving FHM1 R192Q 
and wild-type (WT) mice to investigate whether cortical network properties differ between genotypes 
and whether these can lead to spontaneous CSD events. Parallel experiments under anesthesia were 
aimed to investigate whether CSD susceptibility differs between the light and dark period and/or 
between visual and motor cortex. Under freely behaving conditions, FHM1 mice displayed enhanced 
gamma (30-45 Hz) EEG power in both visual and motor cortex throughout vigilance states (i.e., active 
waking, REM sleep and non-REM sleep); delta (0.75-5 Hz) power was reduced in motor cortex during 
REM and non-REM sleep. In 4 out of 10 FHM1 mice, in total 13 spontaneous CSD events occurred 
that were never observed in WT mice. CSD events occurred both during light and dark periods. For 
9 events, the start of CSD was observed first in the visual cortex while for the remaining events the 
CSD event appeared nearly simultaneously in the visual and motor cortex. Under anesthesia, CSD 
frequency did not show a correlation with the time-of-day, and was enhanced in both visual and motor 
cortex for FHM1 mice compared with WT. Taken together, the changes in EEG power and occurrence 
of spontaneous CSD events in FHM1 mutants are in line with increased cortical network excitability 
in mutants. Cortical network changes and occurrence of spontaneous CSD events in FHM1 mice 
provide a unique opportunity to study the episodic nature of migraine attacks.
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INTRODUCTION     
Migraine is a common episodic brain disorder characterized by recurrent attacks of headache and 
associated autonomic and neurological symptoms (ICHD 2004, Goadsby et al 2002). In one-third 
of patients migraine attacks are accompanied, in most cases preceded, by an aura, which typically 
consists of visual symptoms. Cortical spreading depression (CSD) is the most likely mechanism of 
migraine aura (Lauritzen 1994, Hadjikhani et al 2001), and a potential trigger of the headache, as 
suggested by studies in rodents (Bolay et al 2002, Zhang et al 2010, Zhang et al 2011). CSD is defined 
as a slowly spreading cortical wave of neuronal and glial depolarization that is followed by a temporary 
suppression of activity (Lauritzen 1994). Clinical and animal data indicate that migraine attacks may 
be caused by neuronal hyperexcitability (Welch et al 1990, Aurora & Wilkinson 2007, Badawy & 
Jackson 2012). The visual nature of migraine auras (Eriksen et al 2004), reports of photophobia 
(Maniyar et al 2015) and structural (Granziera et al 2006) and functional alterations (Aurora et al 
1999) in the visual cortex of patients suggest that in the migraine susceptible brain, hyperexcitability 
may prominently manifest itself in the visual cortex. Moreover, circadian changes in physiology may 
contribute to the enhanced neuronal excitability (Herzog 2007, Cho 2012) that can explain apparent 
circadian rhythmicity in the timing of attacks with the majority of the attacks occurring during the 
active/light period in humans (Fox & Davis 1998, Alstadhaug et al 2008).
To investigate the link between neuronal hyperexcitability and migraine susceptibility, transgenic 
knock-in mice have been generated that carry the missense mutation R192Q in the Cacna1a gene 
that encodes the α
1
 subunit of Ca
V
2.1 (P/Q-type) Ca2+ channels (van den Maagdenberg et al 2004). 
In patients, this mutation causes familial hemiplegic migraine type 1 (FHM1) (Ophoff et al 1996). 
FHM1 R192Q knock-in mice display increased propensity to experimentally induced CSD under 
anesthesia (van den Maagdenberg et al 2004, Eikermann-Haerter et al 2009, van den Maagdenberg 
et al 2010), and enhanced glutamatergic neuronal transmission in cortical brain slices (Tottene et al 
2009, Vecchia et al 2014). 
The well-controlled conditions in which neuronal excitability was studied in brain slices and 
anesthetized mice exclude studying effects of sleep-wake patterns or interactions of external and 
internal stimuli with brain physiology. Enhanced neuronal network excitability resulting from such 
interactions may sporadically create a window of opportunity for the initiation of spontaneous 
attacks in patients (Stankewitz & May 2009) that can only be identified in freely behaving mice. To 
assess in what way FHM1 mutations affect ongoing neuronal network activity patterns in the intact 
awake brain, we performed longitudinal day-night recordings of full-band (DC) EEG and multi-unit 
activity (MUA) in freely behaving FHM1 R192Q and WT mice. Findings were related to the time-
of-day and cortical location (i.e., visual vs motor cortex). In parallel, we compared susceptibility to 
experimentally induced CSD (i.e., by cortical application of KCl to the exposed dura) performed at 
the start of the light vs the dark period, as well as between visual and motor cortex, in anesthetized 
mice under physiological monitoring and control. Our data reveal that freely behaving FHM1 R192Q 
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mice can display spontaneous CSD events. Observed changes in EEG power are suggestive of overall 
enhanced cortical excitability. When taking into account also experiments in anesthetized mice, it 
seems that CSD susceptibility is enhanced independent of the time-of-day in both visual and motor 
cortex.
MATERIALS AND METHODS  
Animals 
Male wild-type (‘WT’) and homozygous Cacna1a FHM1 R192Q knock-in (‘R192Q’) (van den 
Maagdenberg et al 2004) were used that were backcrossed for at least 6 generations with C57BL/6J 
mice. Prior to experiments, animals were maintained under a 12-hr light/12-hr dark regime unless 
specifically mentioned. Standard mouse chow and water were available ad libitum. All experiments 
were approved by the Animal Experiments Committee of Leiden University Medical Center and 
Massachusetts General Hospital Subcommittee on Research Animal Care. 
EEG recordings in freely behaving mice
The weight of mice at surgery was 31.2±2.7 gr and 28.4±2.3 gr (p=0.43, Student’s t-test, N=10; 
WT and R192Q mice, respectively); the age was 145±19 days and 161±75 days, (p=0.51, Student’s 
t-test, N=10; WT and R192Q mice, respectively). Under isoflurane anesthesia (1.5%), 7 electrodes 
were stereotactically implanted at the following coordinates (in mm relative to bregma): a pair of 
Platinum (Pt) electrodes 3.5 posterior/2.0 lateral/0.8 ventral from dura (right visual cortex); a pair of 
Pt electrodes 1.5 anterior/1.5 lateral/0.8 ventral from dura (right motor cortex); a Silver (Ag) ball-
tip electrode 3.5 posterior/2.0 lateral on the dura (left visual cortex); an Ag ball-tip electrode and 
an Ag-AgCl ball-tip electrode were placed above cerebellum that served as reference and ground 
electrodes, respectively (Figure 1A). Electrodes were attached to the skull using dental cement 
(Optibond FL, Kerr, Orange, CA, USA). After a recovery period of 7 days, animals were placed in 
a shielded recording cage and connected to the recording hardware through a counterbalanced, low-
torque custom-built electrical commutator. Epidural and intracortical EEG signals were pre-amplified 
3x and were fed into separate amplifiers for DC-EEG and AC-EEG. For DC-EEG, signals were low-
pass filtered (500 Hz) and amplified 10x. For AC-EEG, signals were band-pass filtered (0.05 Hz to 
500 Hz) and amplified 1200x. Signals were digitized (Power 1401, CED, Cambridge, UK) at a rate 
of 1000 Hz for DC-EEG and 5000 Hz for AC-EEG. In addition, signals from paired intracortical Pt 
electrodes were used for detection of multi-unit activity (MUA) by amplifying them differentially 
(36000x), band-pass filtering them (500 Hz to 5000 Hz) and digitizing them at 25000 Hz. Alongside 
the EEG and MUA recordings, locomotor activity was recorded using a passive infrared custom-built 
motion detection sensor and drinking activity was recorded with a custom-built beam-break sensor in 
front of the drinking bottle.
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CSD induction with intracortical KCl infusion
To assess whether our recording technique is able to accurately detect cortical spreading depression, 
we performed a set of experiments in which we induced CSD using reverse microdialysis with 500 mM 
KCl. For these experiments, surgery was performed as described above, with two modifications: 1) the 
posterior pair of intracortical Pt electrodes in the right hemisphere was placed in the somatosensory 
cortex (1.5 posterior/1.5 lateral/0.8 ventral from dura) and 2) a guide cannula (Brainlink, Groningen, 
the Netherlands) was placed in a cranial window over the visual cortex (3.5 posterior/2.0 lateral/
terminating on dura) (Figure 2D). After the recovery period, recordings were started as described 
above. On day two of the recording, a microdialysis probe (Brainlink, Groningen, the Netherlands) 
was placed in the guide cannula with the 1 mm membrane extending from dura to a depth of 1 
mm below dura. Microdialysis perfusion with minimal perfusion fluid (140.3 mM Na+, 2.7 mM K+, 
1.2 mM Ca2+, 1.0 mM Mg2+, and 147.7 mM Cl-) was started at a flow rate of 1 µL/min using a 
microperfusion syringe pump (Harvard Apparatus Inc, South Natick, MA, USA). On day 4 of the 
recording, the perfusion fluid was changed to modified minimal perfusion fluid containing 500 mM 
of KCl (500 mM K+, 1.2 mM Ca2, 1.0 mM Mg2+, 504.4 mM Cl- in MilliQ water) during a 30-min time 
window to induce CSD events.
EEG data analysis, scoring of vigilance states and spontaneous CSD detection
For spectral analysis of EEG data, 24 hr of recorded EEG was used that was obtained after at least 
24 hr of habituation of the animal to the recording cage. Data were obtained from the second (N=3 
WT mice and N=2 R192Q) or third day of recording (N=7 WT and N=8 R192Q). Comparison of 
power spectra from the first 4 recording days for N=3 WT and N=3 R192Q mice indicated stable EEG 
power spectra with little variability across recording days for both WT and R192Q mice: Intraclass 
Correlation Coefficient (Bartko 1966) was higher than 0.9 for visual cortex and motor cortex vigilance 
state-specific power spectra, for all animals over the first 4 recording days. For the 4 R192Q mice in 
which spontaneous CSD were observed, EEG analysis was performed on a 24-hr slot during which 
no CSD was observed, which was the second recording day for two R192Q mice (21 hr after first and 
only CSD; 27 hr after first CSD, 7 hr before second CSD) and third recording day for the other two 
R192Q mice (before occurrence of first CSD for both animals).
Signals from the visual and motor cortex were low-pass filtered at 100 Hz and down-sampled to 
200 Hz (Spike2 V7, CED, Cambridge, UK). Power spectra were computed using a Fast Fourier 
Transform (FFT) routine (Hanning window, 0.25 Hz resolution) for each 4-sec epoch of the 24 hr of 
recording. Epochs containing movement or technical artifacts (typified e.g., by large irregular and 
often high-frequency waveforms associated with movement in case of movement artifacts, or by 
irregular clipping of signals or 50 Hz or high-frequency noise) were excluded from further analysis. 
The overall spectral composition of network activity in the motor and visual cortex was quantified 
by averaging the power spectral density per cortical region over the entire recording for each animal. 
For the comparison across genotypes, the total power was calculated for 5 defined spectral bands: 
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delta (δ, 0.75-5Hz), theta (θ, 5-10Hz), alpha (α, 10-15Hz), beta (β, 15-30Hz), and gamma (γ, 30-45 
Hz). As the spectral composition of mouse cortical network activity varies across vigilance states, 
we also performed a vigilance-state-specific comparison of EEG power spectral composition. For 
this analysis, only spectra were selected from epochs with clearly defined vigilance states (i.e., active 
waking, REM sleep and non-REM sleep) that were determined by applying an automated algorithm 
for defining vigilance state per 4-sec epoch on the basis of the recorded behavioral activity and the 
spectral composition of the visual cortex EEG signal. In the algorithm, epochs with locomotor or 
drinking activity were classified as active waking (19.6 ± 4.8% for WT, 15.8 ± 6.8% for R192Q; 
Student’s t-test, p=0.17). The first 10 epochs following cessation of behavioral activity were classified 
as passive waking (15.1 ± 2.9% for WT, 16.3 ± 3.4% for R192Q; Student’s t-test, p=0.40) (Fisher et al 
2012). Remaining epochs were classified as sleeping (64.6 ± 6.5% for WT, 67.1 ± 8.8% for R192Q; 
Student’s t-test, p=0.49) and further subdivided into non-REM sleep or REM sleep on the basis of the 
visual cortex EEG power spectrum: epochs with strong delta activity (>2x average delta power) were 
classified as non-REM sleep (30.9 ± 3.8% for WT, 28.5 ± 4.2% for R192Q; Student’s t-test, p=0.20). 
Epochs with high theta (>average theta power) and low delta (< average delta power) activity were 
classified as REM sleep (12.3 ± 2.7% for WT, 13.0 ± 4.3% for R192Q; Student’s t-test, p=0.69). Sleep 
epochs not fulfilling the above criteria were left unclassified. 
The occurrence of spontaneous CSD events was detected on the basis of the following criteria: 1) the 
presence of a transient negative DC-shift in the DC-EEG signal with an amplitude of 5 mV or more 
that was detected on multiple recording sites within 60 sec from the first occurrence, 2) a depression 
of AC-EEG amplitude coinciding with the start of the DC-shift and, if MUA signal was available, 
3) multi-unit activity silencing coinciding with the start of the DC-shift. Events were scored as CSD 
when criterion 1 was met together with either criterion 2 or 3, or all 3 criteria together.
Effect of time-of-day on CSD susceptibility 
WT and R192Q mice were randomly assigned to a ‘light’ or a ‘dark’ group and acclimatized to the 
following shifted light/dark regimes for at least 2 weeks before follow-up procedures. Mice in the 
‘light’ group were kept with ‘lights on’ from 08.30 am until 20.30 pm; mice in the dark group were 
kept with lights on from 20.30 pm until 08.30 am All experiments started around 08.15 am, so that 
mice from the light group just started the light (resting) period at the start of experiment, while mice 
from the dark group just started the dark (active) period. At least 4 days before the CSD experiment a 
blood sample (~20 µL) was collected by a small tail cut to determine baseline corticosterone plasma 
levels. Plasma was obtained after centrifugation for 10 min at 4000 rpm at 4oC, temporarily placed on 
dry ice and stored until used at -80oC. Corticosterone plasma levels were determined using a RIA kit 
according to manufacturer guidelines (MP Biomedicals Inc., Santa Ana, CA, USA) (Sarabdjitsingh 
et al 2010).
CSD frequency recordings were carried out under full physiological control as previously described 
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(Shyti et al 2015). Physiological parameters were maintained within the following ranges; blood 
pressure: 70-120 mmHg, pCO
2
: 30-40 mmHg, pO
2
: 80-140 mmHg and pH: 7.30-7.40. The weight 
of mice at surgery was 25.9±1.2 gr; N=5 for WT and 25.1±1.2 gr; N=5 for R192Q of the ‘light’ 
group (Student’s t-test, p=0.3) and 25.8±1.3 gr; N=7 for WT and 24.4±1.9 gr; N=5 for R192Q mice 
of the ‘dark ‘group (Student’s t-test, p=0.2). The age of the mice at surgery was 122.8±13.0 days; 
N=5 for WT and 123.0±14.0 days; N=5 for R192Q mice of the ‘light’ group (Student’s t-test, p=0.1) 
and 106.6±13.6 days; N=7 for WT and 106.0±7.9 days; N=5 for R192Q mice of the ‘dark ‘group 
(Student’s t-test, p=0.4). 
For CSD measurements, mice were intubated, muscle paralyzed with an i.p. injection of 0.04 mg/kg 
body weight pancuronium and mechanically ventilated (SAR-830, CWE Inc, Ardmore, PA, USA). 
Mice were maintained under 1% isoflurane anesthesia in 20-30% O
2
 and 70% N
2
O. Blood gas values 
and mean arterial blood pressure were measured via a catheter in the femoral artery and a blood 
gas analyser (RapidLab248, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). During 
the experiment, ventilation parameters were adjusted when necessary to maintain physiological 
parameters within normal range. Experiments were only included for analysis when physiological 
parameters were within normal range. Core body temperature was maintained at 37oC using a heating 
pad (Stoelting, Wood Dale, IL, USA). The mouse was fixed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA. USA) and a midline incision of ~2.5 cm was made over the top of the 
head, the skin was retracted to expose the skull, and the periosteum was removed with cotton-tipped 
applicator sticks. Two craniotomy windows were prepared at the following coordinates (in mm with 
respect to Bregma): 3.5 mm posterior/2.0 mm lateral (visual cortex) and 1.5 mm anterior/1.5 mm 
lateral (motor cortex). Care was taken to keep the dura intact to minimize trauma to the underlying 
brain tissue. At the recording site a sharp glass capillary electrode (FHC Inc., Bowdoin, ME, USA) 
filled with 150 mM NaCl was advanced through the dura to a depth of 300 µm. After insertion of the 
electrode, a drop of mineral oil (~ 5 µL) was applied to the recording site to prevent drying of the 
cortical tissue. DC-potential signals were measured with respect to an Ag/AgCl reference electrode 
placed subcutaneously at the neck and amplified 10x (Molecular Devices, Sunnyvale, CA, USA). The 
DC signal was low-pass filtered at 4 Hz and digitized at 100–200 Hz using PowerLab 16/30 hardware 
(AD Instruments, Inc., Colorado Springs, CO, USA). Data were recorded and analyzed off-line using 
LabChart Pro (AD Instruments). Due to the time needed for surgical preparation, CSD frequency 
measurements started around 09.00 am. 
Regional differences in CSD susceptibility 
The surgery with full physiological monitoring and control for determining regional differences in 
CSD susceptibility was performed as described above. The weight of mice at surgery was 26.0±1.3 
gr; N=13 and 24.7±1.9 gr; N=16 for WT and R192Q mice (Student’s t-test, p=0.1), respectively. The 
age of mice at surgery was 77.1±20.4 days; N=13 and 88.6±18.7 days; N=16 for WT and R192Q 
mice (Student’s t-test, p=0.1), respectively. To determine the CSD induction threshold, a cotton 
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pellet (Interguide Dental Supply, Burlingame, CA, USA) soaked in solution with an increasing K+ 
concentration was placed on the dura for 3 min to measure either motor (from bregma: 1.5 mm 
anterior/1.5 mm lateral or visual (from bregma: 3.5 mm posterior/2 mm lateral) cortex CSD threshold. 
K+ concentrations were prepared with 7.5 mM increments, starting at 5 mM, with total osmolarity 
kept at 300 mOsmol with NaCl. Upon successful induction of a CSD event, the induction site was 
rinsed thoroughly with 150 mM NaCl. 
Subsequently, two additional cranial windows were prepared in the opposite hemisphere in the same 
mouse at the same motor and visual cortex locations as described above to measure CSD threshold 
in the opposite direction: e.g., motor cortex CSD threshold was measured on the contralateral side 
in case the visual cortex threshold had been measured first in the other hemisphere or vice versa 
(Figure 4C). After CSD threshold assessments in both hemispheres, CSD frequency was measured 
in the same hemisphere and location as used for the last CSD threshold measurement by continuous 
application of a cotton pellet soaked in 1 M KCl on the dura for 30 min (with refreshment of the pellet 
after 15 min). Only reversible DC deflections with amplitudes larger than 5 mV were considered a 
CSD event and included in the CSD characteristics analysis.
Nissl and GFAP staining
At the end of the longitudinal EEG/MUA recordings, brains were histologically processed for 
verification of electrode location and possible inflammatory reaction. Mice were transcardially perfused 
with 1x PBS and 4% paraformaldehyde (PFA), the brain removed and post-fixated in 4% PFA for at 
least 2 hr. Subsequently, brains were cryoprotected in consecutive steps of 10.5% (overnight), 10.5% 
(overnight) and 30% (overnight) sucrose and embedded in 11% gelatin/10% sucrose. Brains were 
sectioned sagittally at 40 µm using a cryotome (Leica microsystems, Wetzlar, Germany). Sections 
were washed for 2 hr in 10% fetal calf serum (FCS) to block endogenous peroxidase activity followed 
by incubation for 72 hr in primary rabbit polyclonal anti-GFAP antibody (DAKO Cytomation, 
Copenhagen, Denmark) diluted 1:30000 in 2% FCS and 0.5% TX100. Sections were next treated for 
2 hr in the avidin-biotin peroxidase complex (Vectastain ABC peroxidase kit, Vector Laboratories 
Inc., Burlingame, CA, USA), washed once in 0.1 M Tris-HCl and allowed to react in a solution of 




for 10 min. Sections were 
washed in MilliQ, dehydrated in graded alcohol, cleared in xylene, and coverslipped using permount 
mounting medium (Thermo Fisher Scientific, Waltham, MA, USA). For Nissl staining, sections were 
immersed into cresyl violet solution for 3 min followed by consecutive dehydration steps in MilliQ, 
50% EtOH, 96% EtOH, 100% EtOH and xylene.
Statistical analysis
For skewed parameters corresponding non-parametric tests were used. For comparison of EEG power 
in the different spectral bands between genotypes, cortical areas and vigilances states, we used Mann-
Whitney U-test with false discovery rate correction (FDR; Benjamini-Hochberg method) to control 
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for multiple testing. To test whether EEG characteristics varied between different recording days, 
we calculated the Intraclass Correlation Coefficient (Bartko 1966). Mann-Whitney U-test was also 
used for comparison of CSD threshold between genotypes and comparison of corticosterone plasma 
levels between light and dark phases, and Wilcoxon signed ranked test for regional CSD threshold 
comparisons among mice of the same genotype. CSD frequency data were compared using one-
way ANOVA followed by Bonferroni correction. Data are presented as median (CSD threshold, 
corticosterone plasma values and power spectra) or mean±SD (CSD frequency).  
RESULTS   
EEG spectra of freely behaving R192Q mice display increased gamma power in both 
visual and motor cortex
To assess effects of the R192Q mutation on neuronal network activity, we recorded longitudinal intra-
cortical EEG from the Pt electrodes in the right hemisphere in 10 freely behaving male R192Q and 
10 WT mice (Figure 1A-C). Comparison of 24-hr EEG power spectra from the first 4 recording days 
of N=3 WT and N=3 R192Q mice revealed that EEG power spectra were stable across recording 
days with little variability for both R192Q and WT mice (Intraclass Correlation Coefficient > 0.9 for 
vigilance state specific power spectra, for all animals over the first 4 recording days, for both visual 
and motor cortex), allowing us to combine data from different days across mice. For comparison 
between R192Q and WT mice, EEG spectral composition was analyzed from 24 hr EEG recorded 
on either the second or third day of the recording session (see Materials and Methods), both for the 
total 24-hr window as well as for separate vigilance states such as active waking, REM and non-REM 
sleep. The approximate distribution of vigilance states during the 24 hr periods, as determined from 
the movement sensor and EEG power (see Materials and Methods), is shown in Table 2. No significant 
differences were observed between R192Q and WT mice regarding the times spent across vigilance 
states. The total 24-hr EEG power of all frequency bands (0.75-45Hz) did not differ between genotypes 
in visual or motor cortex (p>0.05). In the motor cortex, but not in the visual cortex, we observed that 
both for the 24-hr average as well as during REM sleep and non-REM sleep, power in the delta band 
(δ, 0.75-5 Hz) was significantly lower in R192Q than in WT mice (Figure 1E). In the visual cortex and 
the motor cortex, power in the gamma band (γ, 30-45 Hz) was significantly higher in R192Q than in 
WT mice, both for the 24-hr average and for the separate vigilance states (Figure 1F).  
Power in the theta band was not different in the visual cortex but was significantly reduced in the 
motor cortex in the 24-hr average during REM sleep and during non-REM sleep. Power in the alpha 
band was significantly higher in the visual cortex in the 24-hr average and during REM sleep but 
significantly lower in R192Q mice in motor cortex during non-REM sleep. Power in the beta band 
was significantly higher in the visual cortex of R192Q mice in the 24-hr average and during REM 
sleep, non-REM sleep and waking. Beta power was also significantly higher in motor cortex in R192Q 
mice during waking.
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To control for variation in absolute power among individual mice, which can be due to differences in 
the depth of intracortical EEG electrodes, we next determined the contribution of relative EEG power 
for the different frequency bands in relation to total EEG power for the overall 24-hr average as well 
as per vigilance state. For visual cortex recordings of R192Q mice, the relative contribution of delta 
band activity to the total EEG power was decreased during REM and non-REM sleep, whereas the 
Figure 1. EEG spectral composition shows enhanced power in higher frequency bands in R192Q mutant mice. 
(A) Schematic depicting electrode locations used for simultaneous recording of intracortical DC-EEG and multi-unit 
activity from the visual and motor cortex in freely behaving FHM1 R192Q and WT mice. (B) Photomicrograph of sagittal 
section (Nissl counterstaining) showing histological verification of electrode tracks in middle to deep layers of the motor 
and visual cortex. (C) Example traces of visual cortex EEG during active waking, REM and non-REM sleep stages in WT 
and R192Q mice. (D) Averaged 24-hr EEG power spectra from the right hemisphere reveal an overall increased gamma 
band activity in the visual cortex and motor cortex of R192Q mice (N=10) compared with WT (N=10); δ:0.75-5 Hz, θ:5-
10 Hz, α:10-15 Hz, β:15-30 Hz, γ:30-45 Hz. (E) Analysis of delta band activity across specific vigilance states reveal 
reduced delta power in the motor cortex of R192Q mice during REM and non-REM sleep. (F) In contrast, gamma band 
activity shows significantly higher power in R192Q mice for all vigilance states in both visual cortex and motor cortex. 
*corrected p-value <0.05, **corrected p-value <0.01; Mann-Whitney U-test followed by false discovery rate correction 
(FDR), Benjamini-Hochberg method.
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contribution of beta and gamma band was increased in R192Q compared with WT for all vigilance 
states. The relative contribution of theta and alpha band activity to total EEG power for the visual 
cortex was comparable between genotypes during active waking and REM sleep, but enhanced for 
the alpha band activity in R192Q animals during non-REM sleep. For the motor cortex, during active 
waking and REM sleep, the relative contribution of delta band activity to total EEG power in the 
motor cortex was decreased in R192Q compared with WT mice. Similar as for the visual cortex, the 
contribution of beta and gamma band activity to total EEG power was increased for the motor cortex 
in R192Q compared with WT animals for all vigilance states (Table 1).  
Table 1. Relative EEG power from visual and motor cortex in freely behaving R192Q and WT mice
Visual cortex
δ (0.75-5) Ηz θ (5-10) Hz α (10-15) Hz β (15-30) Hz γ (30-45) Hz
R192Q WT R192Q WT R192Q WT R192Q WT R192Q WT













































































δ (0.75-5) Ηz θ (5-10) Hz α (10-15) Hz β (15-30) Hz γ (30-45) Hz
R192Q WT R192Q WT R192Q WT R192Q WT R192Q WT












































































Table 1. Data are presented as medians with [min, max values]. Power/frequency band was quantified as percentage of 
the total power across bands for N=10 R192Q and N=10 WT mice. R192Q mice had a significantly reduced relative delta 
power compared with WT. This was the case in the visual cortex for the 24-hr average as well as the separate vigilance 
states, and in the motor cortex for active waking and REM sleep. In contrast, R192Q mice had a significantly increased 
relative power  in the theta and alpha power in the visual cortex for the 24-hr average and non-REM sleep state, and for 
beta and gamma power for the 24-hr average and for all the separate vigilant states. Beta and gamma power in motor cortex 
were enhanced in R192Q mice for the 24-hr average as well as for all separate vigilant states. Comparable changes in 
gamma and delta power described for other transgenic mouse models have been linked to enhanced neuronal excitability 






Figure 2. Detection of spontaneous and induced CSD in freely behaving mice using a novel combination of 
intracortical DC-EEG and Multi-Unit Activity (MUA) recording. (A) Experimental setup with example recordings 
showing spontaneous CSD events in 2 homozygous R192Q mice. Pre-amplified signals from bipolar Pt electrode pairs in 
the right cortex are split into multiple channels that are individually amplified and filtered to obtain a DC-EEG (0-500 Hz) 
channel, an AC-EEG (0.1-500 Hz) channel and a multi-unit activity (MUA, 500-5000 Hz) channel for the right motor 
cortex and right visual cortex. A single epidural ball-tip electrode placed on the left visual cortex that yields a DC-EEG 
and an AC-EEG channel but no MUA. During 7 days of recording we detected spreading depolarization coinciding with 
AC-EEG and MUA suppression in 4 out of 11 homozygous R192Q mice and 0 out of 10 WT mice. In the panel example, 
the CSD wave appears first in the right visual cortex, then spreads to the right motor cortex and then appears in the left 
visual cortex. In the example of the bottom panel, the CSD wave first appears in the left visual cortex and then spreads 
to the right visual cortex and reaches the right motor cortex last. (B) Time course of the observed CSD events in the 4 
R192Q animals. In animal 1, 5 CSD events were detected, 3 of which were bilateral (including the example depicted 
in A). In all events in this animal, the CSD wave first appeared in the right visual cortex. In animal 2 (panel example in 
A), the CSD wave first appeared in the left visual cortex. In animal 3, the start of the negative DC-shift and MUA/EEG 
silencing was observed within 10 sec from each other in all 3 locations. In animal 4, the start of the negative DC-shift 
and MUA/EEG silencing was observed within 10 sec from each other in all 3 locations in the first two events. For the 
3rd and 4th event, the CSD wave started in the left visual cortex and subsequently appeared in the right visual cortex and 
right motor cortex. (C) Distribution of CSD events over the 24 hr light-dark cycle. Seven out of 13 CSD events occurred 
during the light phase (between 6 am and 6 pm) whereas 6 out of 13 events happened during the dark phase. (D) To 
confirm the accuracy of our CSD detection methodology, we performed a separate experiment in which we induced 
CSD in the visual cortex of freely behaving WT mice by performing reverse microdialysis with a 500 mM KCl solution 
through a microdialysis probe placed in the V1 visual cortex. Using the same intra-cortical bipolar electrodes as in A, we 
recorded DC-EEG, AC-EEG and MUA at two locations ipsilateral to the microdialysis probe. Shortly after starting the 
microdialysis with 500 mM KCl, A transient negative DC-shift coinciding with EEG silencing and MUA suppression 
appeared first in the somatosensory S1 cortex and then spread to the M1 motor cortex.
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R192Q mice exhibit spontaneous CSD events
Notably, during the longitudinal EEG recordings in freely moving mice, we observed a total of 13 
spontaneous events resembling CSD in 4 of the 10 recorded R192Q mice (Figure 2A), while no such 
events were observed in the 10 recorded WT mice. In addition to the intracortical electrodes in the 
right visual and motor cortex that were used for EEG analysis, an epidural Ag electrode placed on 
the left visual cortex was used for CSD detection. The events were characterized as CSD on the basis 
of the occurrence of a transient negative DC-shift exceeding 5 mV, accompanied by a suppression of 
neuronal multi-unit activity (MUA), and dampening of EEG amplitude, that spread throughout the 
cortex across the different electrode locations (Figure 2A). Figure 2B shows the order of appearance 
of the CSD events at the different cortical locations. For 9 events from 3 mice, CSD events were 
observed first in the visual cortex. Of those, 5 events (from 1 R192Q mouse) were first detected 
in the right visual cortex before reaching the right motor cortex, followed by the left visual cortex. 
Three CSD events (from 2 different R192Q mice) were first observed in the left visual cortex before 
being detected at the right visual cortex and, subsequently, right motor cortex. For 4 events in 2 mice, 
CSD events were observed in all 3 recording locations near simultaneously (2- to 13-sec time delay). 
The spontaneous CSD events occurred at different times of the day. Specifically, 5 out of the 13 
spontaneous CSD events occurred during the dark (active) period whereas 7 events occurred during 
the light (resting) period and 1 event occurred during the transition from light to dark (Figure 2C). 
The amplitude of the CSD events was 12.2 ± 4.6 mV, with duration of 32.1 ± 7.3 sec for the right 
visual cortex (N=9), and 19.9 ± 8.8 mV with a duration of 30.7 ± 6.9 sec for the right motor cortex 
(N=13). We validated our methodology for CSD detection in freely behaving mice by experimentally 
inducing CSD in the visual cortex using micro-infusion of 500 mM KCl solution. Electrophysiological 
characteristics of evoked CSD events were comparable to spontaneous CSD events with a transient 
spreading negative DC-shift exceeding 5 mV accompanied by neuronal silencing (evidenced from 
suppression of MUA) and dampening of EEG amplitude (Figure 2D). 
Relation of spontaneous CSD occurrence with EEG spectral changes and vigilance state 
Following the spreading transient DC-shift of about 30-sec duration as indicated above, we observed 
a secondary, longer-lasting negative DC-shift in all animals (Figure 3A). The secondary negative DC-
shift had comparable or even larger amplitude as the first shift (17.3 +/- 5.4 mV for right visual cortex; 
23.1 +/- 8.0 mV for right motor cortex) and duration of 20 to 40 min. During the secondary DC-shift, 
animals were inactive as determined from the movement sensor, and EEG was characterized by 
high amplitude delta activity (Figure 3B; 140 +/- 28% power in the delta band in the visual cortex 
between 10 and 30 min after CSD onset compared to the 24-hr average delta power during non REM 
sleep; paired samples t-test, p=0.008). In contrast, power in higher EEG frequency bands and MUA 
was reduced compared to baseline for up to 60 min after the CSD (Figure 3A and B). Outside the 
60-min time window after CSD, the EEG spectra of the R192Q mice with CSD events (N=4) did 
not show overt differences with the EEG spectra of the N=6 R192Q mice in which no CSD events 
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were observed. Vigilance state analysis revealed that the occurrence of CSD events was not limited 
to a specific vigilance state prior to the CSD. CSD was preceded by waking for 4 events, by non-
REM sleep for 5 events and by REM sleep for 4 events. During a CSD event however, in all cases 
(9 out of 13) where an animal was sleeping prior to the CSD, the animal woke up and displayed 
locomotor activity. All animals displayed locomotor activity for a period of 1 to 10 min after the start 
Figure 3. Impact of CSD on cortical network activity and vigilance state. (A) Representative time course of MUA 
and EEG spectral composition in relation to bi-phasic DC-EEG shift. In line with previous reports on induced CSD under 
anaesthesia (Chang et al 2010), DC-EEG (top trace, red) in freely behaving R192Q mice showed a biphasic negative 
DC shift during spontaneous CSD in which the spreading negative depolarization wave (lasting  32.1 +/- 7.3 sec) is 
followed by secondary negative DC shift lasting 20 to 40 min. Following a short MUA burst when the front of the CSD 
wave reaches the recording electrode, neuronal activity is rapidly suppressed after which it gradually recovers to baseline 
levels over the course of 30 to 60 min. The time-frequency plot shows the frequency-dependent impact of CSD on EEG 
power. Red indicates high power and dark blue indicates low power. Note the prominent delta activity from 5 to 30 min 
after CSD. (B) Averaged time course (averaged from all CSD events in the 4 animals with spontaneous CSD, weighted so 
each animal has an equal contribution to the overall average) of vigilance state, visual cortex EEG power in the different 
frequency bands and MUA from 60 min before until 60 min after the start of CSD (time 0, vertical dashed line). Note 
that post-CSD, delta activity (0.75-5Hz) rapidly recovers to baseline levels (indicated by horizontal dashed lines) and 
increases to 140 +/- 28% of 24 hr average delta power during non-REM sleep between 10 and 30 min after CSD onset. In 
contrast, power in higher EEG frequency bands is not elevated post-CSD but instead recovers gradually to baseline in a 
comparable time frame as MUA. (C) Staining for GFAP revealed comparable levels of astrocyte activation surrounding 
the electrode in WT animals and in R192Q with and without spontaneous CSD events.
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of CSD, after which they went into a non-REM like sleep state characterized by high amplitude delta 
oscillations for a period of 20 to 40 min. 
To investigate whether the observed spontaneous CSD events in R192Q mice may relate to a genotype-
specific tissue inflammatory response, we compared Nissl and glial fibrillary acidic protein (GFAP) 
stained sections from N=4 R192Q mice in which CSD events were observed with those of N=4 WT 
and N=4 R192Q mice without CSD events (Figure 3C). Around electrode tracks, enhanced GFAP 
staining was observed for all animals, with no overt differences between groups. For none of the 
recorded animals, including the R192Q mice that displayed spontaneous CSD events, signs of tissue 
damage or bleeding were observed that could relate to inflammatory responses or an infarct.
Table 2. Distribution of vigilance states over 24-hr of EEG recording in freely behaving WT and 
R192Q mice.  






% active waking 19.1 ± 4.3 15.2 ± 7.5 0.17
% NREM 31.3 ± 3.4 29.9 ± 4.1 0.20
% REM 12.3 ± 2.9 12.7 ± 4.0 0.69
% passive waking 15.1 ± 2.5 15.5 ± 3.2 0.40
% sleeping 65.0 ± 5.7 68.7 ± 9.9 0.49
% unclassified sleeping epochs 21.5 ± 6.0 26.1 ± 8.2 0.20
% drinking 0.9 ± 0.4 0.7 ± 0.6 0.87
% artefacts 0.8 ± 0.8 0.3 ± 0.5 0.09
Anesthetized R192Q mice kept under full physiological control display enhanced visual 
cortex CSD frequency compared with WT, both at the start of the light and the start of 
the dark period
In freely behaving R192Q mice, CSD events occurred both during the dark and during the light 
period, with a slight majority (7 out of 13) events occurring during the light period. To specifically 
address whether CSD susceptibility may differ in relation to the light compared with the dark period, 
we compared the frequency of KCl-induced CSD at the beginning of the light and dark periods. 
Experiments were performed under isoflurane anesthesia, under continuous physiological monitoring 
Table 2. Data are presented as mean±SD. R192Q (Ν=10) and WT (Ν=10) mice spent a comparable fraction of time 
across different vigilance states for the analyzed 24-hr EEG windows. Numbers indicate the % of total time spent in a 
specific vigilance state, determined from 4 sec bins from the analyzed 24-hr window. See Materials and Methods for 
details and definitions of vigilance states.
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Figure 4. FHM1 R192Q mice display enhanced CSD susceptibility in both visual and motor cortex, independent of 
the time-of-day. (A left) In R192Q (light; N=5; *p=0.0001, dark; N=5; *p=0.002) mice, visual cortex CSD frequency is 
increased compared with WT (light; N=5, dark; N=7) with no difference between the start of the light and start of the dark 
period within the same genotype. (A right) CSD frequency is increased in both the visual (*p=0.005) and motor cortex 
(*p=0.01) of R192Q (visual; N=6, motor; N=8) mice compared with WT (visual; N=6, motor; N=6). (B) Representative 
DC-potential traces from CSD frequency recordings from WT and R1912Q mice in the visual and motor cortices. (C left) 
Schematic depicts the KCl application sites and electrode locations for the visual and motor cortex CSD susceptibility 
assessments. (C right) CSD threshold is reduced in both visual (*p=0.01; in line with previous work; van den Maagdenberg 
et al 2004) and motor cortex (*p=0.04) of R192Q (visual; N=16, motor; N=16) compared with WT (visual; N=13, motor; 
N=14) mice. (D) Representative DC-potential traces of CSD threshold assessment. Data are presented as mean ± SD, 
except for CSD threshold data that are presented as medians. Statistical differences were determined by one-way ANOVA 
followed by Bonferroni correction (for CSD frequency) and Mann-Whitney U-test (for CSD threshold).
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and control in animals that were accustomed to either regular or shifted day-night regimes. Under 
these conditions, KCl-induced CSD frequency, assessed in the visual cortex, was compared for R192Q 
and WT mice at the start of the light and at the start of the dark period. Visual cortex CSD frequency 
was enhanced in R192Q compared with WT mice at the start of the light period (R192Q, 15.7±2.4 
CSD/hr, N=5 vs WT, 8.6±2.5 CSD/hr, N=5; p=0.0001, one-way ANOVA Bonferroni correction), 
and also at the start of the dark period (R192Q, 14.5±1.3 CSD/hr, N=5 vs WT, 9.5±1.5 CSD/hr, 
N=7; p=0.002, one-way ANOVA Bonferroni correction) (Figure 4A). However, within-genotype 
comparisons revealed similar CSD susceptibility measures for the start of the light (p=1, one-way 
ANOVA Bonferroni correction) as well as the start of the dark period (p=1, one-way ANOVA 
Bonferroni correction), suggesting that the enhanced CSD susceptibility of R192Q compared with 
WT mice is uniform throughout the day. 
To ensure that the mice were in the correct periods after the shifted day-night regimes, corticosterone 
plasma levels were measured and their motor activity monitored. As expected for nocturnal animals, 
we found higher corticosterone plasma levels in mice of the dark group compared with mice of 
the light group (Maywood et al 2007). In particular, R192Q mice of the dark group had higher 
corticosterone levels compared with R192Q mice of the light group (R192Q dark, 206.8±90.2 ng/
mL, N=11 vs R192Q light, 14.4±10.6 ng/mL, N=11; p=0.0001, Mann-Whitney U-test). The results 
were similar for WT mice (WT dark, 135.9±32.6 ng/mL, N=14 vs WT light, 17.7±17.5 ng/mL, N=9; 
p=0.001, Mann-Whitney U-test). There were no differences in corticosterone levels among light and 
dark groups between R192Q and WT mice (R192Q dark vs WT dark, p=0.09; R192Q light vs WT 
light, p=0.2, Mann-Whitney U-test).
Anesthetized R192Q mice kept under full physiological control display enhanced CSD 
susceptibility in both visual and motor cortex in R192Q compared with WT mice. 
We observed that in the majority of cases, spontaneous CSD events in R192Q mice appeared first 
in the visual cortex, then in the motor cortex, suggesting that the events had originated in the visual 
cortex. We, therefore, determined whether CSD susceptibility would be different for visual compared 
with motor cortex by measuring the threshold and frequency of KCl-induced CSD at both locations 
in anesthetized R192Q and WT mice under full physiological control. CSD threshold was lower 
(p=0.001, Mann-Whitney U-test) in the visual cortex of R192Q compared with WT mice in line 
with earlier findings (van den Maagdenberg et al 2004). Notably, R192Q mice had a lower CSD 
threshold also in the motor cortex compared with WT (p=0.043, Mann-Whitney U-test). However, 
within-genotype comparisons revealed similar CSD thresholds for the visual compared with motor 
cortex in both WT and R192Q mice (Figure 4C). R192Q mice displayed higher CSD frequency 
values in the visual cortex compared with WT (R192Q, 16±3.4 CSD/hr, N=6 vs WT, 9.9±1.1 CSD/
hr, N=6; p=0.005, one-way ANOVA Bonferroni correction), in agreement with previous findings 
(Eikermann-Haerter et al 2009). Again, also in the motor cortex, R192Q mice displayed higher CSD 
susceptibility as shown by higher frequency values compared with WT (R192Q, 14.9±3.3 CSD/hr, 
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N=8 vs 9.9±2 CSD/hr, N=6; p=0.01, Mann-Whitney U-test; Figure 4A). Therefore, with 2 different 
but complementary methods for assessing CSD susceptibility, R192Q mice displayed enhanced CSD 
susceptibility compared with WT in both the visual and motor the cortex, but did not show a more 
prominent CSD susceptibility in the visual cortex. 
Table 3. Physiological parameters and CSD amplitude and duration values of R192Q and WT 
mice from CSD threshold and CSD frequency measurements











R192Q motor 16 7.39 ± 0.05 30.4 ± 5.4 128.6 ± 29.0 91.6 ± 13.7 22.3 ± 6.9 50.9 ± 36.9
R192Q visual 16 7.42 ± 0.04 28.7 ± 3.9 131.8 ± 24.8 91.9 ± 11.4 25.3 ± 5.4‡ 51.5 ± 17.6
WT motor 14 7.41 ± 0.04 29.9 ± 3.4 137.2 ± 23.6 91.3 ± 16.7 18.8 ± 4.9 30.4 ± 8.6
WT visual 13 7.41 ± 0.04 31.1 ± 4.5 135.5 ± 26.5 94.2 ± 16.0 25.4 ± 3.3† 41.0 ± 9.1
CSD frequency
R192Q motor 8 7.36 ± 0.06 31.5 ± 6.4 110.4 ± 20.9 82.5 ± 12.6 17.8 ± 5.8 29.3 ± 15.0
R192Q visual 6 7.38 ± 0.03 31.8 ± 4.2 114.4 ± 10.5 83.6 ± 9.6 20.7 ± 5.2 34.6 ± 9.9
WT motor 6 7.40 ± 0.03 30.2 ± 3.8 124.2 ± 18.0 91.5 ± 13.2 12.8 ± 3.4 21.0 ± 7.3
WT visual 6 7.39 ± 0.03 32.0 ± 4.0 124.6 ± 28.8 84.1 ± 13.2 22.8 ± 3.2§ 27.8 ± 5.8
R192Q light 5 7.37 ± 0.02 31.2 ± 6.1 112.2 ± 15.4 84.4 ± 11.2 20.8 ± 2.4 25.4 ± 7.6
R192Q dark 5 7.40 ± 0.03 31.5 ± 2.2 128.9 ± 14.6 85.7 ± 9.0 22.4 ± 2.6 29.9 ± 12.2
WT light 5 7.39 ± 0.03 30.3 ± 2.6 120.7 ± 6.5 87.7 ± 7.0 21.5 ± 1.8 21.4 ± 4.4
WT dark 7 7.40 ± 0.03 32.0 ± 3.0 118.1 ± 9.8 90.5 ± 12.4 23.6 ± 3.3 39.9 ± 13.1*
WT dark 7 7.40 ± 0.03 32.0 ± 3.0 118.1 ± 9.8 90.5 ± 12.4 23.6 ± 3.3 39.9 ± 13.1*
DISCUSSION  
In this study we combined cortical electrophysiological recordings in freely behaving and anesthetized 
FHM1 R192Q mutant mice to study the effects of FHM1 mutations on cortical network excitability 
and CSD susceptibility. Analysis of long-term intracortical DC-EEG and MUA recordings in freely 
behaving mice revealed increased power in the EEG gamma frequency band for both visual and motor 
cortex in R192Q compared with WT mice. In addition, power in the delta band was reduced for R192Q 
Table 3. Values are shown as mean±SD. CSD duration was measured at half-maximal amplitude. Mice were physiologically 
monitored (via femoral artery catheterization) and controlled by mechanical ventilation. Physiological parameters were 
maintained within normal range by adjusting ventilation parameters. There were no significant differences between groups 
except for a smaller CSD amplitude in WT motor compared with WT visual (†p=0.01) and R192Q visual (‡p=0.01 for 
both comparisons, one-way ANOVA, Bonferroni correction) for CSD threshold and smaller CSD amplitude in WT motor 
compared with WT visual (§p=0.008, one-way ANOVA, Bonferroni correction) for CSD frequency. For time-of-day CSD 
frequency measurements there was a longer CSD duration in WT dark compared with WT light group (*p=0.04, one-way 
ANOVA, Bonferroni correction). MABP, mean arterial blood pressure.
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mice in motor cortex during REM and non-REM sleep. Spontaneous CSD events were observed in 
a subset of R192Q, but never in WT mice. The occurrence of CSD events in freely behaving R192Q 
mice did not show an apparent correlation to the time-of-day. For the majority of events the CSD 
was observed first in the visual cortex. Parallel DC-recordings performed under anesthesia showed 
enhanced visual cortex CSD frequency in R192Q mice compared with WT both at the start of the 
light and at the start of the dark period. CSD susceptibility was enhanced to a comparable extent 
for both visual and motor cortex in R192Q mice compared with WT. Taken together, our findings 
indicate that the FHM1 R192Q mutation results in measurable alterations in cortical network activity 
patterns under freely behaving conditions in both visual and motor cortex that may contribute to the 
episodic occurrence of CSD. 
Neuronal hyperexcitability has been proposed as an underlying mechanism for increased susceptibility 
to migraine attacks (Welch et al 1990, Vikelis and Mitsikostas 2007, Aurora & Wilkinson 2007). In 
agreement with this, the gain-of-function FHM1 R192Q mutation results in increased calcium entry 
into pre-synaptic terminals with concomitant increased glutamate release into the synaptic cleft (Tottene 
et al 2002, van den Maagdenberg et al 2004, Tottene et al 2009), with apparent little effect on inhibitory 
neurotransmission (Tottene et al 2009, Vecchia et al 2014). Our present data indicate that these synaptic 
changes infer significant changes in cortical network activity patterns and predispose the cortex for 
occurrence of spontaneous CSD events, adding translational value to the FHM1 mouse model. 
The spontaneous CSD events showed DC and neuronal activity changes similar to those of induced 
CSD events (Somjen 2001). Specifically, the spontaneous CSD events showed a characteristic DC-
EEG negative deflection coinciding with a peak in neuronal activity, immediately followed by a 
near-complete suppression of neuronal activity which gradually increase to pre-CSD levels. To our 
knowledge, the detection of spontaneous CSD events in freely behaving mice is the first report of 
such events in an animal model. From our recordings, we did not identify factors that may have 
triggered the spontaneous occurrence of CSD. One possibility that cannot be excluded is that abrupt 
movements of the mouse might have caused friction of the intracortical electrodes, triggering a 
mechanically-induced CSD. This, however, seems rather unlikely since there was no correlation 
between the occurrence of CSD and mouse movements as detected by the movement sensor. In fact, 
most CSD events were preceded by sleep. It can also not be excluded that an enhanced inflammatory 
response around the intracortical electrodes may have contributed to the occurrence of the CSD 
events, since FHM1 R192Q were shown to exhibit a pronounced pro-inflammatory phenotype, at 
least in trigeminal ganglia neurons (Franceschini et al 2013). Histological analysis of GFAP staining, 
however, did not reveal overt genotypic differences in tissue reaction to implanted electrodes between 
R192Q mice that experienced CSD events and those that did not, nor between R192Q and WT mice. 
Although we cannot exclude that the presence of electrodes in the cortex contributed to occurrence 
of spontaneous CSD events via some other mechanism, at present, we lack the technical means to 
reliably detect CSD non-invasively e.g., via stable through-the-skull DC-EEG recordings. 
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The spontaneous occurrence of CSD events in R192Q mice suggests that such events are initiated 
by physiological fluctuations in brain activity. Although diurnal and seasonal alterations in neuronal 
excitability have been reported (Herzog 2007, Farajnia et al 2014), our data did not indicate a 
particularly enhanced CSD susceptibility in relation to certain times of the day. The overall EEG 
spectral changes that we observed, in particular enhanced power in the EEG gamma frequency band, 
are in line with the concept of cortical hyperexcitability. A correlation between enhanced EEG gamma 
power and decreased delta power with neuronal hyperexcitability is supported by earlier findings in 
mice deficient of K
V
3.1 voltage-gated K+ channels. K
V
3.1 voltage-gated channels are expressed in 
cortical GABAergic interneurons that are thought to enhance release of GABA from interneurons 
(Perney et al 1992, Kanemasa et al 1995). Hence, loss of K
V
3.1 function is expected to yield 
hyperexcitability. Indeed 24-hr EEG recordings in K
V
3.1 deficient mice revealed increased gamma 
and reduced delta EEG power (Joho et al 1999). These findings indicate that in the context of neuronal 
ion channel mutations that promote cortical hyperexcitability, as is the case for the R192Q mutation, 
EEG gamma power is increased whereas delta power may be decreased. Spectral changes in R192Q 
mice were most pronounced for the EEG gamma band, which showed enhanced power across cortical 
regions and vigilance states. Notably, in transgenic mice lacking functional Ca
V
2.1 Ca2+ channels, 
i.e., displaying an opposite effect at the cellular level to the gain-of-function effect of the R192Q 
mutation, a substantial reduction in gamma EEG power was observed (Llinas et al 2007). In general, 
gamma oscillations in neuronal networks are linked to enhanced glutamatergic neurotransmission 
as illustrated by studies on the generation of gamma oscillations in the hippocampus (Whittington 
et al 1995, Martin 2001, Herrmann & Demiralp 2005). The association of cortical gamma activity 
with hyperexcitability is further exemplified by enhanced gamma oscillatory activity during seizure 
initiation and chronification in epilepsy, a disorder characterized by enhanced neuronal network 
excitability (Parra et al 2003, Tolner et al 2005).  
The question remains whether these findings in R192Q mice have relevance for the understanding 
of migraine in patients. Early EEG studies in migraine patients have not shown uniform EEG power 
changes, neither between (interictal) or during (ictal) attacks (Lauritzen et al 1981). More recent 
reports indicate enhanced interictal theta band activity (Bjørk et al 2011), and fluctuations in alpha 
band power (de Tommaso 1998) as well as slowing down of EEG activity in relation to upcoming 
attacks (Bjørk et al 2011). Furthermore, a loss of EEG complexity indicative of enhanced EEG 
synchrony has been reported for migraineurs (Strenge et al 2001). In this context, enhancement of 
EEG gamma power may be interpreted as an enhancement of cortical network synchrony. Notably, 
for visual evoked potential responses, enhanced EEG gamma power has been reported for visual 
evoked potential responses in migraineurs (Coppola et al 2007), which was proposed to be related 
to a putative functional disconnection of the thalamus to the cortex. In animal models, Ca
V
2.1 Ca2+ 
channels were shown to play a key role in generation of thalamocortical oscillatory activity (Llinas 
et al 2007), suggesting that the enhanced EEG gamma power in FHM1 mice may involve altered 
thalamocortical function. Given the reported integration of visual and nociceptive inputs at the level 
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of the thalamus in rodents (Noseda et al 2010, Noseda et al 2014), it is tempting to speculate that a 
combination of sensory triggers and overall (genetically) enhanced cortical excitability may contribute 
to cyclic occurrence of CSD events. 
The majority of observed spontaneous CSD waves appeared first in the visual cortex and then in 
motor cortex suggesting that the visual cortex might be particularly susceptible to CSD initiation. 
Our data in anesthetized mice, however, did not reveal a difference in threshold or frequency for KCl-
induced CSD between the visual and motor cortex. If indeed spontaneous CSD waves are more readily 
inititated in the visual cortex, intrinsic changes in the level of neuronal activity in the visual cortex 
or relative differences in potassium and glutamate buffering capacities between cortical regions may 
play a role. As we cannot determine the exact point-of-origin of the CSD waves in our experiments, it 
remains a possibility that CSD waves are initiated in a cortical or even subcortical brain area outside 
of the visual and motor cortex location. The near-simultaneous occurrence of some CSD events at 
both visual and motor cortex sites is in line with this idea. Clinical studies indicate that auras can be 
“silent” and become apparent only when invading the visual cortex (Hansen et al 2013). 
The presence of increased gamma power at the cortical network level suggests an elevated baseline 
cortical network excitability in the migraine susceptible brain. On top of such baseline hyperexcitability, 
physiological cycles in neuronal activity together with effects of external stimuli may occasionally 
create the conditions where the threshold for initiation of CSD is exceeded in specific brain regions. 
The spontaneous occurrence of CSD events in FHM1 mice marks the first evidence for episodic 
neuronal abnormalities in an animal model for migraine, which allows studying mechanisms of CSD 
and the migraine aura phase in patients.
ACKNOWLEDGEMENTS 
This work was supported by the EU "EUROHEAD" grant (LSHM-CT-2004-504837; M.D.F. & 
A.M.J.M.v.d.M.), the EU “EUROHEADPAIN” grant (nr 602633; M.D.F. & A.M.J.M.v.d.M.), the EU 
Marie Curie Career Integration Grant (nr 294233; E.A.T.), the Center for Medical Systems Biology 
(CMSB) established in the Netherlands Genomics Initiative/Netherlands Organisation for Scientific 
Research (NGI/NWO) (nr 050 - 060 - 409; A.M.J.M.v.d.M.), an LUMC Fellowship (E.A.T.) and the 
CURE SUDEP research award (nr 280560; E.A.T. & A.M.J.M.v.d.M.).
075
REFERENCES
Alstadhaug K, Salvesen R, Bekkelund S. 2008. 24-hour distribution of migraine attacks. Headache 
48:95-100
Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, et al. 2010. Genome-wide association 
study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet. 42:869-73
Aurora SK, Cao Y, Bowyer SM, Welch KM. 1999. The occipital cortex is hyperexcitable in migraine: 
experimental evidence. Headache 39:469-76
Aurora SK, Wilkinson F. 2007. The brain is hyperexcitable in migraine. Cephalalgia 27:1442-53
Badawy RA, Jackson GD. 2012. Cortical excitability in migraine and epilepsy: a common feature? 
J. Clin. Neurophysiol. 29:244-9
Bartko JJ. 1966. The intraclass correlation coefficient as a measure of reliability. Psychol. Rep. 19:3-
11
Bjørk M, Stovner LJ, Hagen K, Sand T. 2011 What initiates a migraine attack? Conclusions from four 
longitudinal studies of quantitative EEG and steady-state visual-evoked potentials in migraineurs. 
Acta Neurol Scand Suppl. 191:56-63. 
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. 2002. Intrinsic brain activity 
triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8:136-42
Chang JC, Shook LL, Biag J, Nguyen EN, Toga AW, et al. 2010. Biphasic direct current shift, 
haemoglobin desaturation and neurovascular uncoupling in cortical spreading depression. Brain 
133:996-1012
Cho CH. 2012. Molecular mechanism of circadian rhythmicity of seizures in temporal lobe epilepsy. 
Front. Cell. Neurosci. 6:55
Coppola G, Ambrosini A, Di Clemente L, Magis D, Fumal A, et al. 2007. Interictal abnormalities 
of gamma band activity in visual evoked responses in migraine: an indication of thalamocortical 
dysrhythmia? Cephalalgia 27:1360-7
Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, et al. 2009. Genetic and hormonal 
factors modulate spreading depression and transient hemiparesis in mouse models of familial 
hemiplegic migraine type 1. J. Clin. Invest. 119:99-109
Farajnia S, van Westering TL, Meijer JH, Michel S. 2014. Seasonal induction of GABAergic excitation 
in the central mammalian clock. Proc. Natl. Acad. Sci. USA 111:9627-32
Fisher SP, Godinho SI, Pothecary CA, Hankins MW, Foster RG, Peirson SN. 2012. Rapid assessment 
of sleep-wake behavior in mice. J. Biol. Rhythms 27:48-58
Fox AW, Davis RL. 1998. Migraine chronobiology. Headache 38:436-41
Franceschini A, Vilotti S, Ferrari MD, van den Maagdenberg AM, Nistri A, Fabbretti E. 2013. 
TNFalpha levels and macrophages expression reflect an inflammatory potential of trigeminal 
076Chapter 3
ganglia in a mouse model of familial hemiplegic migraine. PloS One 8:e52394
Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine--current understanding and treatment. N. Engl. 
J. Med. 346:257-70
Granziera C, DaSilva AF, Snyder J, Tuch DS, Hadjikhani N. 2006. Anatomical alterations of the 
visual motion processing network in migraine with and without aura. PLoS Med. 3:e402
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, et al. 2001. Mechanisms of migraine 
aura revealed by functional MRI in human visual cortex. Proc. Natl. Acad. Sci. USA 98:4687-92
Hansen JM, Baca SM, Vanvalkenburgh P, Charles A. 2013. Distinctive anatomical and physiological 
features of migraine aura revealed by 18 years of recording. Brain 136:3589-95
Herrmann CS, Demiralp T. 2005. Human EEG gamma oscillations in neuropsychiatric disorders. 
Clin. Neurophysiol. 116:2719-33
Herzog ED. 2007. Neurons and networks in daily rhythms. Nat. Rev. Neurosci. 8:790-802
ICHD. 2004. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 
Suppl 1:9-160
Joho RH, Ho CS, Marks GA. 1999. Increased gamma- and decreased delta-oscillations in a mouse 
deficient for a potassium channel expressed in fast-spiking interneurons. J. Neurophysiol. 82:1855-
64
Kanemasa T, Gan L, Perney TM, Wang LY, Kaczmarek LK. 1995. Electrophysiological and 
pharmacological characterization of a mammalian Shaw channel expressed in NIH 3T3 fibroblasts. 
J. Neurophysiol. 74:207-17
Lau D, Vega-Saenz de Miera EC, Contreras D, Ozaita A, Harvey M, et al. 2000. Impaired fast-
spiking, suppressed cortical inhibition, and increased susceptibility to seizures in mice lacking 
Kv3.2 K+ channel proteins. J. Neurosci. 20:9071-85
Lauritzen M, Trojaborg W, Olesen J. 1981. EEG during attacks of common and classical migraine. 
Cephalalgia. 1:63-6.
Lauritzen M. 1994. Pathophysiology of the migraine aura. The spreading depression theory. Brain 
117 ( Pt 1):199-210
Leao A. 1944. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7:359-90
Llinas RR, Choi S, Urbano FJ, Shin HS. 2007. Gamma-band deficiency and abnormal thalamocortical 
activity in P/Q-type channel mutant mice. Proc. Natl. Acad. Sci. USA 104:17819-24
Maniyar FH, Sprenger T, Monteith T, Schankin CJ, Goadsby PJ. 2015. The Premonitory Phase of 
Migraine - What Can We Learn From It? Headache 
Martin SJ. 2001. Activation of metabotropic glutamate receptors induces gamma frequency oscillations 
in the rat dentate gyrus in vivo. Neuropharmacology 40:634-7
Maywood ES, O’Neill JS, Chesham JE, Hastings MH. 2007. Minireview: The circadian clockwork 
077
of the suprachiasmatic nuclei--analysis of a cellular oscillator that drives endocrine rhythms. 
Endocrinology 148:5624-34
Noseda R, Kainz V, Borsook D, Burstein R. 2014. Neurochemical pathways that converge on thalamic 
trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, 
stress and anxiety. PloS One 9:e103929
Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, et al. 2010. A neural mechanism for 
exacerbation of headache by light. Nat. Neurosci. 13:239-45
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, et al. 1996. Familial hemiplegic 
migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. 
Cell 87:543-52
Parra J, Kalitzin SN, Iriarte J, Blanes W, Velis DN, Lopes da Silva FH. 2003. Gamma-band phase 
clustering and photosensitivity: is there an underlying mechanism common to photosensitive epi-
lepsy and visual perception? Brain  126:1164-72
Perney TM, Marshall J, Martin KA, Hockfield S, Kaczmarek LK. 1992. Expression of the mRNAs 
for the Kv3.1 potassium channel gene in the adult and developing rat brain. J. Neurophysiol. 
68:756-66
Sarabdjitsingh RA, Conway-Campbell BL, Leggett JD, Waite EJ, Meijer OC, et al. 2010. Stress 
responsiveness varies over the ultradian glucocorticoid cycle in a brain-region-specific manner. 
Endocrinology 151:5369-79
Shyti R, Eikermann-Haerter K, van Heiningen SH, Meijer OC, Ayata C, Joëls M, Ferrari MD, van 
den Maagdenberg AM, Tolner EA. 2015. Stress hormone corticosterone enhances susceptibility 
to cortical spreading depression in familial hemiplegic migraine type 1 mutant mice. Exp Neurol 
263:214-220.
Somjen GG. 2001. Mechanisms of spreading depression and hypoxic spreading depression-like 
depolarization. Physiol. Rev. 81:1065-96
Stankewitz A, May A. 2009. The phenomenon of changes in cortical excitability in migraine is not 
migraine-specific--a unifying thesis. Pain 145:14-7
Strenge H, Fritzer G, Göder R, Niederberger U, Gerber WD, Aldenhoff J.2001 Non-linear 
electroencephalogram dynamics in patients with spontaneous nocturnal migraine attacks. Neurosci 
Lett. 309:105-8.
Tolner EA, Kloosterman F, van Vliet EA, Witter MP, Silva FH, Gorter JA. 2005. Presubiculum 
stimulation in vivo evokes distinct oscillations in superficial and deep entorhinal cortex layers in 
chronic epileptic rats. J. Neurosci. 25:8755-65
de Tommaso M, Sciruicchio V, Guido M, Sasanelli G, Specchio LM, Puca FM. 1998. EEG spectral 
analysis in migraine without aura attacks. Cephalalgia. 18:324-8. 
Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, et al. 2009. Enhanced excitatory transmission 
078Chapter 3
at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine 
mice. Neuron 61:762-73
Tottene A, Fellin T, Pagnutti S, Luvisetto S, Striessnig J, et al. 2002. Familial hemiplegic migraine 
mutations increase Ca(2+) influx through single human CaV2.1 channels and decrease maximal 
CaV2.1 current density in neurons. Proc. Natl. Acad. Sci. USA 99:13284-9
van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, et al. 2004. A Cacna1a 
knockin migraine mouse model with increased susceptibility to cortical spreading depression. 
Neuron 41:701-10
van den Maagdenberg AM, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M, et al. 2010. High 
cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L 
mice. Ann. Neurol. 67:85-98
Vecchia D, Tottene A, van den Maagdenberg AM, Pietrobon D. 2014. Mechanism underlying unaltered 
cortical inhibitory synaptic transmission in contrast with enhanced excitatory transmission in 
Ca
V
2.1 knockin migraine mice. Neurobiol. Dis. 69:225-34
Vikelis M, Mitsikostas DD. 2007. The role of glutamate and its receptors in migraine. CNS Neurol 
Disord Drug Targets. 6:251-7. 
Welch KM, D’Andrea G, Tepley N, Barkley G, Ramadan NM. 1990. The concept of migraine as a 
state of central neuronal hyperexcitability. Neurol. Clin. 8:817-28
Whittington MA, Traub RD, Jefferys JG. 1995. Synchronized oscillations in interneuron networks 
driven by metabotropic glutamate receptor activation. Nature 373:612-5
Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. 2011. Activation of central 
trigeminovascular neurons by cortical spreading depression. Ann. Neurol. 69:855-65
Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. 2010. Activation of meningeal 





Stress hormone corticosterone enhances susceptibility  
to cortical spreading depression in familial  
hemiplegic migraine type 1 mutant mice 
Reinald Shyti1, Katharina Eikermann-Haerter5, Sandra H. van Heiningen1, Onno C. Meijer2, Cenk 
Ayata4,5, Marian Joëls6, Michel D. Ferrari3, Arn M.J.M. van den Maagdenberg1,3‡, Else A. Tolner3‡
Departments of 1Human Genetics, 2Endocrinology, and 3Neurology, Leiden University Medical Center, 
Leiden, The Netherlands
4Neurovascular Research Laboratory, Department of Radiology and 5Stroke Service and Neuroscience 
Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
Charlestown, USA
6Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Rudolf Magnus 
Institute of Neuroscience, Utrecht, The Netherlands
‡equal contribution




Stress is a putative migraine trigger, but the pathogenic mechanisms involved are unknown. Stress 
and stress hormones increase neuronal excitability by enhancing glutamatergic neurotransmission, 
but inhibitory effects have also been reported. We hypothesise that an acute rise in stress hormones, 
such as corticosteroids which are released after stress, increase neuronal excitability and thereby 
may increase susceptibility to cortical spreading depression (CSD), the mechanism underlying 
the migraine aura. Here we investigated effects of acute restraint stress and of the stress hormone 
corticosterone on CSD susceptibility as surrogate migraine marker, in a transgenic mouse model 
of familial hemiplegic migraine type 1 (FHM1), which displays increased glutamatergic cortical 
neurotransmission and increased propensity for CSD. We found that 20-min and 3-hr restraint stress 
did not influence CSD susceptibility in mutant or wild-type mice, despite elevated levels of plasma 
corticosterone. By contrast, subcutaneous administration of 20 mg/kg corticosterone increased CSD 
frequency exclusively in mutant mice, while corticosterone plasma levels were similarly elevated 
in mutants and wild-types. The effect of corticosterone on CSD frequency was normalized by pre-
administration of the glucocorticoid receptor (GR) antagonist mifepristone. These findings suggest 
that corticosteroid-induced GR activation can enhance susceptibility to CSD in genetically susceptible 
individuals, and may predispose to attacks of migraine. Although corticosterone levels rise also 
during acute stress, the latter likely triggers a spatiotemporally more complex biological response 
with multiple positive and negative modulators which may not be adequately modeled by exogenous 
administration of corticosterone alone. 
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INTRODUCTION  
Migraine is a common disabling brain disorder typically characterised by recurring attacks of severe 
head pain and associated symptoms of autonomic and neurological dysfunction (Goadsby et al 
2002, IHCD 2004). In one-third of patients, attacks are associated with neurological aura symptoms 
(Launer et al 1999). Migraine auras are likely caused by cortical spreading depression (CSD) that is 
defined as a slowly spreading cortical wave of neuronal and glial depolarization (Lauritzen 1994). 
Hyperexcitability of the cortex has been described in migraine patients (Aurora and Wilkinson 2007) 
compared to healthy controls, but much less is known how migraine attacks come about. It is still 
unclear whether acute stress is in fact one of the trigger factors for attacks, although often reported 
by patients (Sauro and Becker 2009, Hauge et al 2011). Moreover, it is unknown how hormones that 
are released upon stress may precipitate attacks (Borsook et al 2012). 
Corticosteroid hormones (cortisol in humans and corticosterone in rodents), which are released in 
high amounts after stress, act by binding to mineralocorticoid (MR) and glucocorticoid receptors 
(GR) and are known to increase neuronal excitability (Popoli et al 2011, Joels et al 2012). Unlike 
MRs, GRs are quite abundantly expressed in several layers of the cerebral cortex, and GR pathways 
are known to mediate excitatory effects of stress hormones on neurotransmission, particularly after 
acute stress (Joels and Baram 2009). It is therefore plausible that possible effects of stress hormones 
on cortical excitability in the migraine brain are GR mediated.
Earlier we generated transgenic knock-in mice with an R192Q missense Ca
V
2.1 (P/Q-type) Ca2+ channel 
mutation (van den Maagdenberg et al 2004), identified in patients with Familial Hemiplegic Migraine 
type 1 (FHM1; Ophoff et al 1996); these mice are considered a relevant model of migraine. We have 
shown that the enhanced susceptibility to CSD in mutant animals (van den Maagdenberg et al 2004, 
Eikermann-Haerter et al 2009) was caused by increased cortical glutamatergic neurotransmission 
(Tottene et al 2009). In the present study, we used CSD as a migraine-relevant readout for stress-
induced changes in cortical hyperexcitability in the FHM1 R192Q mouse model. We investigated 
whether acute moderate or severe restraint stress may further enhance CSD susceptibility in R192Q 
mice and whether corticosteroid activation of GR pathways has comparable effects. Our findings 
provide insight into the mechanisms by which corticosteroids could contribute to triggering migraine 
attacks via influencing CSD susceptibility.
MATERIALS AND METHODS
Animals
Male homozygous Cacna1a FHM1 R192Q knock-in (“R192Q”) and wild type (“WT”) mice of 
2-4 months were used. The knock-in mice were generated as previously described by introducing 
the human FHM1 pathogenic R192Q mutation in the orthologous mouse Cacna1a gene using a 
gene targeting approach (van den Maagdenberg et al 2004). Mice were assigned to the different 
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experimental groups: (1) 20-min restraint, (2) 3-hr restraint, (3) untreated, (4) corticosterone, (5) 
vehicle, (6) mifepristone + vehicle or (7) mifepristone + corticosterone. For each of these experimental 
paradigms, WT and R192Q mice were tested, separately. For most experimental groups, a sample size 
of 8 animals was used per genotype, except for the WT untreated (N=10), WT 20-min restraint (N=7) 
and the R192Q corticosterone+THDOC group (N=6). All experiments were approved by the Animal 
Experiment Ethics Committee of Leiden University Medical Center.
Assessment of corticosterone plasma levels
Mice were habituated to single housing for at least 4 days after which baseline blood samples from 
the tail (20 µL) were collected at 10:00 am four days before follow-up procedures. Corticosterone 
plasma levels were determined by a commercial radioactive immunoassay (MP Biomedicals Inc., 
Costa Mesa, CA) according to manufacturer’s instructions (Sarabdjitsingh et al 2010).
Restraint stress paradigms
Restraint stress experiments were performed in R192Q and WT mice using a single restraint paradigm 
(Sarabdjitsingh et al 2012) starting between 10:00 and 10:30 am. Mice were restraint in custom made 
Plexiglas cylinders (3 cm diameter) (1) for a single period of 20 min (moderate restraint) and then 
returned to the home cage for nearly 3 hr, after which they were prepared for CSD surgery, or (2) for 
3 hr (severe restraint), after which they were immediately prepared for CSD surgery. Blood samples 
for corticosterone plasma measurements were collected prior to the start of CSD surgery (i.e., 3 hr 
after the end of the 20-min restraint or immediately after the 3-hr restraint procedure) and at the end 
of CSD recordings. The immediate effect of moderate restraint stress on corticosterone plasma levels 
(Table 1) was determined in separate groups of R192Q and WT mice by collecting blood samples 
from the tail 30 min after the end of the 20-min restraint period. In pilot studies, a separate group of 
animals was weighed (“handled controls”) after which blood samples were collected from the tail 30 
min later. Since these handled controls showed slightly elevated levels of plasma corticosterone (data 
not shown), untreated mice were used as controls for the CSD experiments in restraint mice.
Corticosterone, mifepristone and tetrahydrodeoxycorticosterone injections
On the day of the CSD experiment, corticosterone (Sigma-Aldrich, St. Louis, MO; 20 mg/kg, in 
arachidonic oil) or vehicle was subcutaneously injected between 10:00 and 10:30 am when endogenous 
corticosterone levels are low (Table 1) after which the mouse was returned to its home cage. A tail blood 
sample was collected 3 hr after corticosterone or vehicle injection just before surgical preparation. 
Surgery for CSD measurements started 3 hr after corticosterone or vehicle injection. Mifepristone (10 
mg/kg; RU486, Sigma-Aldrich) diluted in 1,2-propanediol was injected subcutaneously 50 min prior 
to corticosterone/vehicle injection. Tetrahydrodeoxycorticosterone (THDOC; Sigma-Aldrich) was first 
diluted in 45% hydroxypropyl-β-cyclodextrin (Sigma-Aldrich) in distilled water before further dilution 
in 0.9% saline, and was injected intraperitoneally at 20 mg/kg shortly after the start of surgery for CSD 
measurements, approximately 3 hr after corticosterone (20 mg/kg subcutaneously) injection.  
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Table 1. Corticosterone plasma levels in WT and R192Q mice at baseline, after a 20-min and 
3-hr restraint stress paradigm.
Time Baseline 30 min 3 hr Post-CSD
WT 14.3 [6,38] (N=11)





























CSD recordings under physiological control
CSD susceptibility measurements were performed as described in detail elsewhere (Eikermann-




O with full physiological 
control (i.e., using a femoral artery lead for continuous blood pressure monitoring and blood sampling, 




) and pH were measured at 
the start and end of CSD recordings and were maintained within normal limits by adjusting ventilation 
when necessary (Table 3). For CSD susceptibility measurements, the mouse was transferred into a 
stereotactic frame after which the skull was exposed and 2 burr holes were prepared over the right 
hemisphere for (1) CSD recording from the motor cortex (0.5 mm anterior from bregma; 2 mm 
lateral) and (2) CSD induction on the occipital cortex (3.5 mm posterior, 2 mm lateral). CSD was 
induced by application of a cotton ball soaked in 300 mM KCl on the occipital cortex for 30 min 
while DC-potential recordings were made from the motor cortex (Figure 1). Data were sampled 
Table 1. Values are corticosterone plasma levels in ng/mL, shown as medians with [minimum, maximum] values; group 
sizes are indicated in italics. Corticosterone plasma levels were determined from tail blood. Blood samples were collected 
from R192Q and WT mice at baseline, 30 min and 3 hr after 20-min restraint stress and immediately after 3-hr restraint 
stress. Pairwise comparisons were made using Mann-Whitney U-test corrected for multiple testing (adjusted p-value 
0.008). Significant differences compared to baseline are indicated with # . Note that 3 hr after 20-min restraint stress 
corticosterone plasma values had decreased to baseline levels, as indicated by the lack of a significant difference between 
baseline and the 30 min after 20-min restraint samples. There were no differences between R192Q and WT corticosterone 
plasma levels at any of the time-points.
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(200 Hz), amplified (10x) and low-pass filtered at 4 Hz and analyzed offline using LabChart (AD 
Instruments, Colorado Springs, CO). 
Statistical analysis
Data are presented as median (corticosterone plasma data and CSD latency) or mean ± SD. Statistics 
were calculated using SPSS (version 17; SPSS Inc., Chicago, IL).  Effects of moderate (20 min) 
and severe (3 hr) restraint stress on CSD frequency (Figure 1) as well as the effect of genotype 
and corticosterone treatment on CSD frequency (Figures 2A, B) were tested with two-way ANOVA 
and post hoc Bonferroni correction. The effect of corticosterone and THDOC in R192Q mice was 
tested with one-way ANOVA and post hoc Bonferroni in comparison to the R192Q corticosterone 
and R192Q vehicle groups only. Systemic physiological data and CSD amplitude and duration (Table 
3) were compared among groups using one-way ANOVA and Bonferroni correction. For skewed 
parameters (corticosterone plasma data and CSD latency), corresponding non-parametric tests were 
used (Kruskal-Wallis, followed by Mann-Whitney U-test). Significance was set at 0.05 and corrected 
for multiple testing where applicable. 
RESULTS 
Acute restraint stress does not influence CSD frequency in FHM1 R192Q and WT mice
We investigated whether an acute moderate or severe stressor influences CSD susceptibility in FHM1 
mice, by using a single-restraint stress paradigm of 20 min or 3 hr duration in separate groups of R192Q 
and WT mice, with untreated mice as controls. Plasma corticosterone levels that were determined 30 
min after the end of a moderate stressor (20-min restraint) were elevated compared to baseline in 
both R192Q and WT mice, with no difference between genotypes. Shortly before the start of the CSD 
experiments, i.e., 3 hr after the end of the 20-min restraint period, corticosterone plasma levels had 
normalized to baseline values in both R192Q and WT mice (Table 1). We observed no effect of the 
20-min restraint procedure on CSD frequency in R192Q mice (R192Q untreated, 16.6±1.9 CSD/hr, 
N=8 vs R192Q 20-min restraint, 16.7±3.5 CSD/hr, N=8) nor in WT mice (WT untreated, 10.0±1.9 
CSD/hr, N=10 vs WT 20-min restraint, 10.0±1.1 CSD/hr, N=7; Figure 1). CSD latency (min) was 
reduced in R192Q untreated compared to WT untreated mice but was not influenced by the 20-min 
restraint procedure (Table 3).  
In contrast to 20 min restraint stress, a more severe 3 hr restraint stress caused increased corticosterone 
plasma levels compared to baseline levels just prior to CSD measurements (Table 1). In both R192Q 
and WT, this severe stressor resulted in corticosterone plasma levels close to those obtained after 
corticosterone injection (Table 2). As with the 20-min paradigm, 3 hr restraint stress did not influence 
CSD frequency compared to untreated controls in R192Q mice (R192Q untreated, 16.6±1.9 CSD/hr, 
N=8 vs R192Q 3-hr restraint 17.1±2.4 CSD/hr, N=8) or WT (WT untreated, 10.0±1.9 CSD/hr, N=10 
vs WT 3-hr restraint, 9.7±2.5 CSD/hr, N=8; Figure 1). CSD latency (Table 3) was also not influenced 
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Figure 1. Moderate or severe restraint stress does not influence CSD susceptibility in FHM1 R192Q mice. (A) 
Schematic of the CSD induction site (KCl application) on the occipital cortex and DC-recording site in the motor cortex. 
(B) Specimen recordings showing CSD events measured in untreated and 3 hr restraint groups of WT and R192Q mice, 
illustrating comparable CSD frequencies in untreated compared to the 3-hr restraint animals. Scale bar applies to all 
traces. (C) Bar diagram (mean ± SD) showing CSD frequency (number of CSD/hr) results from CSD recordings carried 
out 4 hr after a 20 min (moderate) and 1 hr after a 3 hr (severe) restraint stress in WT and R192Q mice (WT untreated 
N=10; R192Q untreated N=8; WT 20 min restraint N=6; R192Q 20 min restraint N=8; WT 3 hr restraint N=8; R192Q 3 
hr restraint N=8). Moderate or severe restraint stress did not influence CSD susceptibility in R192Q or WT mice (2-way 
ANOVA), suggesting that other neurosteroids released during stress may counteract effects of corticosterone on CSD 
susceptibility in R192Q mice. CSD frequency was increased in R192Q mice compared to WT mice in all treatment 




















































R192Q corticosterone R192Q vehicle 
WT corticosterone WT vehicle 
Figure 2. Corticosterone enhances CSD susceptibility in FHM1 R192Q mutant mice via glucocorticoid receptor 
activation. (A) Specimen recordings showing CSD events measured in the different treatment groups of WT and R192Q 
mice, illustrating enhanced CSD frequency in R192Q mice that were subcutaneously injected 4 hr earlier with 20 mg/kg 
corticosterone (CORT). Scale bar applies to all traces. (B) Bar diagram (mean ± SD) showing CSD frequency (number 
of CSD/hr) results from R192Q and WT mice in the different treatment groups (N=8 mice/group; except for mifepristone 
pretreated mice injected with vehicle, MIF-VEH which are N=7 mice/group). Corticosterone administration enhanced 
CSD frequency in R192Q mice only (*p=0.02 vs R192Q VEH), an effect that was prevented by pre-administration of the GR 
antagonist mifepristone (*p=0.004 vs R192Q CORT). There was a significant main effect on CSD frequency of genotype, 
corticosterone treatment and the interaction between genotype and treatment. Note the higher CSD frequency in the 
R192Q vehicle group compared to WT vehicle-injected mice (†p=0.025), in line with earlier findings from unchallenged 
R192Q and WT mice (Eikermann-Haerter et al 2009), as well as the higher CSD frequency for R192Q compared to WT 
mice for the CORT treated (‡p=0.000), MIF-VEH treated (§p= 0.000) and MIF-CORT treated mice (8p= 0.003). 
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After both the 20-min and 3-hr restraint procedure, CSD duration (sec) and amplitude (mV), as well 




) were similar to values 
from untreated animals except for a higher pCO
2
 (mm Hg) value in WT untreated compared to 
R192Q 3-hr restraint mice and a lower MABP (mm Hg) in R192Q 3-hr restraint compared to WT 
3-hr restraint mice (Table 3).  
Table 2. Corticosterone plasma levels in WT and R192Q mice in the CORT, VEH and MIF 
treatment groups before and after CSD experiments

















































Table 2. Values are corticosterone plasma levels in ng/mL, shown as medians with [minimum, maximum] values; group 
sizes are indicated in italics. Corticosterone plasma levels were determined from tail blood. Blood samples were collected 
from R192Q and WT mice at 3 hr after a single subcutaneous administration of 20 mg/kg corticosterone (CORT) or vehicle 
(VEH), with or without pretreatment with the GR antagonist mifepristone (MIF). Post-CSD samples were taken at the 
end of CSD recordings under isoflurane anesthesia. Group comparisons were done with Kruskal-Wallis test: χ2=51.942, 
p=0.000. Pairwise comparisons were made using a Mann-Whitney U-test, corrected for multiple testing (p=0.005). 
Significant increases compared to baseline (see Table 1) are indicated by # (Mann-Whitney U-test). For corticosterone-
injected animals, corticosterone plasma levels were comparable between R192Q and WT mice in the different treatment 
groups, including at the end of the experiment, except for post-CSD levels of vehicle-injected mice which showed slightly 
higher corticosterone plasma levels for R192Q compared to WT mice (*p=0.0013 Mann-Whitney U-test). Both for 
corticosterone and vehicle-injected animals, there was no correlation between corticosterone plasma levels at the end of 
surgery and CSD frequency (Spearman’s ρ=0.192, p=0.224). 
090Chapter 4
Corticosterone administration increases CSD frequency exclusively in FHM1 R192Q 
mice via GR activation
We next investigated the acute effect of the stress hormone corticosterone on CSD susceptibility, 
by administering a dose of 20 mg/kg corticosterone in the morning 3 hr before surgery was started 
to determine CSD frequency in R192Q and WT mice. Corticosterone plasma levels at baseline and 
after injection of corticosterone were comparable between R192Q and WT mice. In both genotypes, 
corticosterone injection resulted in strongly elevated corticosterone plasma levels, while no significant 
plasma corticosterone increase was observed after injection of vehicle (Table 2).
We observed a significant main effect on CSD frequency of genotype (F[1,54]=105,98; p=0.000), 
corticosterone treatment (F[3,54]=5,22; p=0.003), and the interaction between genotype and 
corticosterone treatment (F[3, 54]=3.39; p=0.024). Post-hoc testing revealed that corticosterone 
injection resulted in a significantly increased CSD frequency in R192Q mice (19.9±2.3 CSD/hr; N=8) 
compared to vehicle (15.6±3.8 CSD/hr; N=8; p=0.02), while there was no effect of corticosterone in WT 
mice (WT corticosterone, 10.7±2.1 CSD/hr; N=8; WT vehicle, 11.4±2.9 CSD/hr; N=8; Figure 2A, B).
To investigate a possible role of GR activation on the observed corticosterone effects in R192Q mice, 
the GR antagonist mifepristone (10 mg/kg) was injected 50 min prior to corticosterone injection. 
Mifepristone pre-treatment normalized CSD frequency in R192Q mice (15.0±1.0 CSD/hr; N=8) to 
the level of vehicle-controls (15.6±3.8 CSD/hr; N=8; Figure 2B). Mifepristone did not influence 
CSD frequency in vehicle-injected R192Q mice (15.6±2 CSD/hr; N=7), vehicle-injected WT mice 
(8.9 ±1.2 CSD/hr; N=7), or corticosterone-injected WT mice (9.9±2.1 CSD/hr; N=8). Since the CSD 
frequencies of mice in the combined mifepristone with vehicle group were comparable to those 
in the vehicle-control group, no separate controls for mifepristone injection were included. CSD 
duration (sec), amplitude (mV), latency (min) and physiological parameters were not influenced by 
corticosterone, vehicle or mifepristone injection (Table 3). 
To investigate whether neurosteroids as a stress mediator may counteract effects of corticosterone 
on CSD frequency, we administered tetrahydrodeoxycorticosterone (THDOC), a neurosteroid with 
anticonvulsant properties (Kokate et al 1994, Kokate et al 1996, Reddy and Rogawski 2002) that is 
synthesized from corticosterone precursor 11-deoxycorticosterone (Kaminski and Rogawski 2011), at 
a dosage of 20 mg/kg, 40 min prior to CSD measurements in an additional group of R192Q mice (N=6) 
that received a 20 mg/kg corticosterone injection 3 hr earlier. In these mice, corticosterone plasma 
levels 3 hr after corticosterone injection were strongly elevated (781.3±312.0 ng/mL). The additional 
administration of THDOC did not change CSD frequency (18.8±3.1 CSD/hr; N=6) compared to that 
observed for the group of R192Q mice injected with corticosterone alone (see above and Figure 2, 
19.9±2.3 CSD/hr; N=8; p=1).
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Table 3. Systemic physiological parameters and CSD characteristics in WT and R192Q mice in 
the different treatment groups

















WT untreated 10 7.38±0.03 32.4±1.73† 120.5±12.3 83.9±13.1 16.9±4.1 30.4±9.2 1.3 [1.2-1.5]




















8 7.36±0.01 29.8±1.5 128.5±17.6 93.7±4.5 17.1±1.7 31.1±6.9
1.0 
[0.5-2.5]
WT VEH 8 7.37±0.01 33.9±2.5 127.9±15.1 80.5±6.0 21.7±3.3 23.9±6.0 1.4 [1.3-2.4]
R192Q VEH 8 7.36±0.03 32.2±4.0 119.7±14.3 82.2±7.8 22.6±1.7 22.3±4.0 1.1
# 
[1.0-1.4]
WT CORT 8 7.35±0.01 35.5±2.0 127.9±13.1 85.7±6.8 21.2±4.8 22.9±8.6 1.5 [1.2-2.1]




















8 7.36±0.03 32.3±3.2 127.2±21.4 80.2±7.0 21.0±3.0 25.9±7.3
1.2  
[1.1-2.3]
Table 3. Values shown are mean ± SD. Because CSD latency values (min) were not normally distributed and variances 
were unequal, these are shown as median with [minimum, maximum] values. Physiological parameters during CSD 
frequency recordings were kept within physiological ranges. In the restraint stress treated mice there were no significant 
differences in physiological parameters except for a slightly higher pCO
2
 value (mm Hg) for WT untreated (indicated by 
†) compared to R192Q 3-hr restraint (p=0.028) and a lower MABP (mean arterial blood pressure; mm Hg) in WT 3-hr 
restraint (indicated by ‡) compared to R192Q 3-hr restraint (p=0.013). R192Q untreated mice had a reduced CSD latency 
compared to WT untreated mice (§p=0.009). In the corticosterone injection experiments, there was a slightly lower blood 
pH in the R192Q CORT group compared to WT VEH (*p=0.03) and R192Q MIF-VEH (p=0.01). Note that lower pH, if 
effective in the brain, would reduce rather than enhance neuronal excitability. Except for MIF-CORT groups (p=0.08), 
R192Q mice showed a reduced CSD latency compared to WT across all treatment groups (significance indicated by #; 
CORT p=0.003, VEH p=0.005 and MIF-VEH p=0.0006). 
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DISCUSSION  
 Transgenic FHM1 R192Q knock-in mice display an increased susceptibility to experimentally 
induced CSD (van den Maagdenberg et al 2004, Eikermann-Haerter et al 2009) that can be explained 
by an enhanced cortical glutamate release (Tottene et al 2009). The enhanced CSD susceptibility 
serves as a measure of excitability and surrogate migraine marker. Stress and stress hormones 
can also cause direct changes in glutamatergic neurotransmission, leading to increased neuronal 
excitability (Popoli et al 2011), but it is not known if this can explain why acute stress may enhance 
propensity to migraine attacks. Our data show that acute restraint stress does not influence CSD 
frequency in R192Q or WT mice, despite elevated plasma corticosterone levels. Administration of 
the stress hormone corticosterone, however, increases CSD frequency within 3-4 hr in R192Q mice 
and not in WT mice, without affecting blood pressure or blood-gas parameters. The corticosterone-
induced increased CSD susceptibility in R192Q mice was prevented by pre-administration of the GR 
antagonist mifepristone. These findings illustrate that corticosterone-induced GR pathway activation 
can enhance susceptibility to CSD in genetically susceptible individuals and may predispose to 
attacks of migraine. Although corticosterone levels rise during acute stress, the latter likely triggers a 
spatiotemporally more complex biological response with multiple positive and negative modulators 
(Joels and Baram 2009), which may not be adequately modeled by exogenous administration of 
corticosterone alone.
The absence of a CSD effect after a 20 min moderate restraint may be related to the fact that 
corticosterone plasma levels were only transiently increased with this paradigm and had returned to 
baseline values shortly before start of the CSD experiment. The 3 hr restraint paradigm however did 
not influence CSD susceptibility either, in both R192Q and WT mice, despite corticosterone plasma 
levels that were elevated to a similar extent as observed after 20 mg/kg corticosterone injection. It is 
possible that the biokinetics of corticosterone in case of restraint stress do not mimic those achieved 
by external corticosterone administration since plasma levels do not necessarily reflect effects at the 
cortical or cellular level. In addition, in case of an acute stress paradigm apart from corticosterone 
other stress mediators, such as neurosteroids like THDOC and allopregnanolone (Purdy et al 1991, 
Zimmerberg and Brown 1998) and the neuropeptide corticotropin-releasing hormone (CRH; Vale et al 
1981), are known to be elevated which could have interfered with the effect of corticosterone on CSD. 
Although THDOC and allopregnanolone have been shown to modulate the physiological response 
to stress by promoting GABAergic inhibitory neurotransmission (Bitran et al 1995, Stromberg et 
al 2005) and can suppress hyperexcitability in mouse seizure models (Kokate et al 1994, Kokate 
et al 1996, Reddy and Rogawski 2002), the administration of THDOC  to R192Q mice that were 
earlier injected with corticosterone did not seem to affect the corticosterone-induced increase in CSD 
frequency in our study. This outcome is not entirely surprising, since GABAergic agonists in general 
do not suppress CSD susceptibility (van Harreveld and Stamm 1953, Brand et al 1998, Kitahara et al 
2001). Possibly, suppressed release of the endogenous stress hormone CRH in the aftermath of stress 
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may contribute to the lack of change in CSD frequency upon restraint stress; this would fit with the 
notion that high levels of CRH generally excitatory actions (Blank et al 2003). 
The exact mechanisms by which corticosterone influences CSD susceptibility in FHM1 mice are 
unknown, but the involvement of GR suggests interaction at the level of excitatory glutamatergic 
neurotransmission. GR activation by stress or corticosterone has been shown to influence 
glutamatergic neurotransmission mainly by increasing postsynaptic glutamate responses (Karst and 
Joels 2005, Yuen et al 2009) and L-type Ca2+ currents (Chameau et al 2007). The FHM1 R192Q 
gain-of-function mutation leads to increased Ca2+ influx pre-synaptically, resulting in increased 
glutamate release (Tottene et al 2009, van den Maagdenberg et al 2004). When corticosterone is 
administered to FHM1 R192Q mice, an additive effect of GR activation and the FHM1 Ca
V
2.1 gain-
of-function on glutamatergic transmission might cause even higher CSD frequencies than achieved 
by either condition alone. In WT mice, that lack the genetically increased level of glutamatergic 
neurotransmission, corticosterone apparently does not have sufficient effect by itself to influence 
CSD susceptibility. 
The finding that mifepristone pre-treatment prevented the corticosterone-induced increase in CSD 
frequency in R192Q mice indicates that the corticosterone effect on CSD susceptibility is specific and 
mediated by activation of GR pathways. The corticosterone effect emerged in the time-period related 
to delayed effects mainly involving GR, and not MR, actions (de Kloet et al 2005, Joels and Baram 
2009, Joels et al 2012). Observations that mifepristone is generally ineffective in blocking membrane-
receptor–mediated events (Di et al 2003, Liu et al 2007, Zhang et al 2012), make it plausible that the 
observed GR mediated effects on CSD in R192Q mice were genomically mediated, although non-
genomic actions cannot be ruled out.
In conclusion, this study showed that an acute stressor does not influence CSD susceptibility in our 
FHM1 mouse migraine model, while acute administration of corticosterone specifically enhances 
CSD susceptibility in FHM1 mutants and not in WT. This could reflect the fact that both the FHM1 
mutation and corticosterone, via GR activation, exert their effect at the level of glutamatergic 
neurotransmission, thus providing a possible mechanistic underpinning of their interaction. It can 
be hypothesised that susceptible individuals may be protected against migraine in cases of acute 
stress as long as other stress-induced factors counteract GR-mediated actions of corticosteroids on 
glutamatergic transmission. This protection may fall short when a disbalance between corticosteroids 
and such other stress hormones occurs. Future work should reveal the complex interplay of 
corticosterone with other stress mediators in the context of acute stress and CSD susceptibility, as 
well as mechanisms underlying effects of chronic stress (Borsook et al 2012), as opposed to acute 
stress, on migraine characteristics. 
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MALDI mass spectrometry can simultaneously measure hundreds of biomolecules directly 
from tissue. Using essentially the same technique but different sample preparation strategies, 
metabolites, lipids, peptides and proteins can be analyzed. Spatially correlated analysis, imaging 
MS, enables the distributions of these biomolecular ions to be simultaneously measured in tissues. 
A key advantage of imaging MS is that it can annotate tissues based on their MS profiles and thereby 
distinguish biomolecularly distinct regions even if they were unexpected or are not distinct using 
established histological and histochemical methods e.g., neuropeptide and metabolite changes 
following transient electrophysiological events such as cortical spreading depression (CSD), which 
are spreading events of massive neuronal and glial depolarisations that occur in one hemisphere of 
the brain and do not pass to the other hemisphere, enabling the contralateral hemisphere to act as 
an internal control. A proof-of-principle imaging MS study, including 2D and 3D datasets, revealed 
substantial metabolite and neuropeptide changes immediately following CSD events which were absent 
in the protein imaging datasets. The large high dimensionality 3D datasets make even rudimentary 
contralateral comparisons difficult to visualize. Instead non-negative matrix factorization (NNMF), 
a multivariate factorization tool that is adept at highlighting latent features, such as MS signatures 
associated with CSD events, was applied to the 3D datasets. NNMF confirmed that the protein dataset did 
not contain substantial contralateral differences, while these were present in the neuropeptide dataset. 
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 INTRODUCTION
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) can generate bio-
molecular profiles directly from tissue that contain hundreds of distinct biomolecular ions (Chaurand 
et al 2004). Spatially-correlated analysis, imaging MS, can simultaneously record the distribution of 
each of these ions in heterogeneous tissue samples (Cornett et al 2007, McDonnell & Heeren 2007). 
There is growing evidence that imaging is having an impact in disease detection and investigation 
(McDonnell et al 2010, Schwamborn & Caprioli 2010). By combining imaging MS with histology the 
differential MS profiles found in specific histopathological entities can be used to identify candidate 
biomarkers (Cazares et al 2009). 
A major advantage of imaging MS is that it can annotate tissues based on their MS profiles and thereby 
distinguish biomolecularly distinct regions even if they are not distinct using established histological 
and histochemical methods (Mathur et al 2009). Imaging MS-based molecular histology has been 
used to differentiate histologically overlapping/identical tumors, identify patient subgroups (Willems 
et al 2010), reveal intratumor heterogeneity that may indicate clonal development (Deininger et al 
2008, Jones et al 2011, Willems et al 2010) and uncovered evidence of early infiltration at tumor 
interface zones (Kang et al 2010, Oppenheimer et al 2010). These capabilities offer enormous potential 
to investigate the biomolecular changes that take place prior to, or without, morphological change, 
or for which a molecular specific stain is unavailable. This may be especially true for metabolic 
and neuropeptide changes following transient events, for instance for neurological diseases such as 
migraine or epilepsy that are defined by their episodic nature, and which may lack histopathological 
features and stains for specific metabolites/neuropeptides.   
In many neurological diseases the pathophysiology is not entirely known and would benefit from 
systematic investigations of the biomolecular differences between diseased and healthy tissue. 
Information of such biomolecular differences can guide the search for reliable biomarkers in 
neurological diseases that are currently lacking.
Cortical Spreading Depression (CSD) is a self-propagating wave of intense neuronal and glial cell 
depolarization that occurs in one hemisphere of the cerebral cortex which is followed by a marked 
neuronal silencing (Leao 1944, Somjen 2001), which in humans is associated with for instance the 
aura phase during migraine attacks (Hadjikhani et al 2001, Lauritzen 1994). Apart from migraine, 
spreading depression can occur in brain tissue in relation to ischemic insults or seizures (Dreier et al 
2012, Lauritzen et al 2011, Somjen 2001). CSD can be easily induced experimentally in animals by 
local stimulation of the cortex by current injection or by topical application of a high concentration of 
K+ on the brain surface (Lauritzen 1994, Somjen 2001). When induced in one hemisphere, CSD does 
not cross to the other hemisphere (Eikermann-Haerter et al 2009, Somjen 2001). Previous studies 
have described a number of neuropeptides and metabolites that are transiently released after CSD 
such as changes in lactate (Scheller et al 1996) and glutamate (Fabricius et al 1993). However the 
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spatial distributions of these peptides and metabolites, and the evolution of their spatiotemporal 
signatures, have not been established. 
Here we report the results of a proof-of-principle imaging MS study of the biomolecular changes 
following CSD, including metabolites, neuropeptides and proteins. CSD was unilaterally induced, 
enabling the contralateral hemisphere to be used as an internal control, as introduced by Andrén and 
workers for Parkinson’s disease research (Nilsson et al 2007, Sköld et al 2006) and recently used by 
(Hanreider et al. 2011). A SHAM-operated mouse, in which Na+ instead of K+ is applied to the brain 
surface and which does not result in CSD events, is included to control for possible changes related 
to the surgical procedures.
METHODS
CSD Experiments
Two male C57Bl/6 mice of 3 months of age were used. In one animal 7 CSDs were evoked by repeated 
application of 1 M KCl onto the right visual cortex with a 5-min interval. The other animal received 
SHAM treatment by repeated application of 1 M NaCl which does not induce CSDs. CSD induction 
and monitoring was carried out by topical KCl application as described previously (Eikermann-
Haerter et al 2011) with some modifications. In short, surgery was carried out using 1.5% isoflurane 
anesthesia in surgical air. After preparing a cranial window above the occipital cortex of the right 
hemisphere (ca. 3.5 mm posterior, 2 mm lateral from bregma) 7 CSD were evoked with a 5-min 
interval between two successive applications. For this, a cotton ball soaked in 1 M KCl was placed 
for 30 sec on the dura overlaying the occipital cortex followed by a wash with 150 mM NaCl. The 
CSDs were monitored by recording cortical DC-potential changes via a glass microelectrode placed 
in the frontal sensorimotor cortex (0.5 mm anterior, 2 mm lateral from bregma; depth 300 μm). 
Immediately after the 7th CSD the mouse was decapitated, the brain was removed and flash-frozen 
on dry ice in less than 1 min and stored at -80 °C. The SHAM-treated mouse underwent the same 
procedure with NaCl application instead of KCl.
Imaging MS Data Acquisition
For the MALDI imaging MS experiments 12 μm thick tissue sections were cut at -20 °C and thaw-
mounted onto conductive glass slides (Delta Technologies, Stillwater, MN, USA). The tissues were 
then slowly brought to room temperature in a desiccator and prepared for MALDI analysis.
Peptide imaging
A uniform coating of α-cyano-4-hydroxycinnamic acid (CHCA) was added using an ImagePrep 
device (Bruker Daltonics, Bremen, Germany) and a solution of 10 mg/ml CHCA in 70:30 AcN: 
0.1% TFA(aq.). MALDI imaging MS was then performed using an UltrafleXtreme MALDI-ToF/
ToF (Bruker Daltonics), 100 mm pixel size, and 800 laser shots per pixel (50 laser shots per position 
of a random walk within each pixel). Data acquisition, preprocessing (smoothing and baseline 
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subtraction of each pixel’s MALDI mass spectrum), and data visualization were performed using 
the Flex software suite (FlexControl 3.3, FlexAnalysis 3.3, FlexImaging 2.1). The SavitskyGolay 
algorithm was used for mass spectral smoothing (width 0.02 m/z, 2 cycles) and the TopHat algorithm 
used for baseline subtraction.
Protein imaging
The tissues were washed in isopropanol and sinapinic acid (SA) matrix added using the ImagePrep 
device and a solution of 20 mg/ml SA in 70% isopropanol: 0.1% TFA(aq.). MALDI Imaging MS 
experiments were then performed using an Autoflex III MALDI-ToF (Bruker Daltonics), 100 mm 
pixel size, and 600 laser shots per pixel (50 laser shots per position of a random walk within each 
pixel). Data acquisition, preprocessing and data visualization were performed using the Flex software 
suite (FlexControl 3.0, FlexAnalysis 3.0, FlexImaging 2.1). The Gaussian algorithm was used for 
mass spectral smoothing (width 2 m/z, 4 cycles) and a ConvexHullV3 for baseline subtraction.
Metabolite Imaging
A uniform coating of 9-aminoacridine was added using the ImagePrep and a solution of 10 mg/
ml 9-aminoacridine 7:3 MeOH:H
2
O. Metabolite imaging MS experiments were performed using an 
UltrafleXtreme MALDI-ToF/ToF in negative-ion mode, a 100 mm pixel size with 500 laser shots per 
pixel (100 laser shots per position of a random walk within each pixel). Data acquisition, preprocessing 
and data visualization were performed using the Flex software suite (FlexControl 3.3, FlexImaging 
2.1, FlexAnalysis 3.3). The SavitskyGolay algorithm was used for mass spectral smoothing (width 
0.005 m/z, 2 cycles) and the TopHat algorithm for baseline subtraction.
After the imaging MS experiments the remaining matrix was removed and the tissues stained with 
Hematoxylin & Eosin (H&E) (Schwamborn et al 2007). High resolution optical images of the H&E 
strained tissues were then aligned to the imaging MS datasets. 
3D Imaging MS Reconstruction
Approximately 20 coronal tissue sections, sampled in 200 mm steps – covering a region in between 
the CDS induction and CSD recording sites, between 0.5 mm anterior and 3.5 mm posterior from 
bregma - were analyzed to create 3D imaging MS datasets of the biomolecular changes that occur 
between the occipital cortex (where the CSDs were initiated) and the sensorimotor cortex (location 
of the recording site of cortical DC-potential changes related to CSD). The 3D imaging MS dataset 
was reconstructed from the serial 2D imaging MS datasets by first aligning each individual tissue 
section’s imaging MS dataset to an optical image of the H&E stained tissue, and then aligning the 
serial sections on the basis of their histology. The coordinates of the pixels in each tissue’s imaging 
MS dataset were then converted into the aligned 3D space.
In order to efficiently analyze the full 3D imaging MS datasets automated feature identification and 
extraction was used to reduce the imaging MS data to the MS features with a S/N>5. First an automated 
feature identification routine was applied to each tissue section’s imaging MS dataset (McDonnell et 
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al 2010). The peak-lists obtained from each tissue were then collated into a final 3D-project peak 
list, which was then used to extract all MS features (S/N>5) from every tissue’s imaging MS dataset. 
Thus the final reduced 3D imaging dataset contains the coordinates of each pixel, a peak list of all 
MS peaks with a S/N>5, and the intensity of each of the peaks in every pixel. 
To identify regions of the 3D imaging MS datasets containing similar MS profiles Non-Negative 
Matrix Factorization (NNMF) was applied to the reduced 3D imaging MS dataset using the David 
Ross’s (University of Toronto: http://www.cs.toronto.edu/~dross/) implementation of Lee & Seung's 
Non-Negative Matrix Factorization algorithm (Lee & Seung 1999). The number of iterations was set 
to 100 and typically resulted in a stable solution. NNMF decomposes the data into a sum of additive 
non-negative components (explicit requirement, scores and loadings must be non-negative) (Lee & 
Seung 1999). 3D score plots of NNMF were obtained by projecting each pixel’s NNMF score onto 
its pixel coordinates.
RESULTS AND DISCUSSION
The non-targeted nature of imaging MS led us to investigate whether it could be used to investigate 
the chemical and spatial extent of the disturbances that follow CSD, evoked in one hemisphere 
leaving the other contralateral hemisphere as an internal control. Seven CSD, spaced 5 min apart, 
were evoked in one hemisphere of C57Bl/6 mice, after which the animals were immediately sacrificed 
and the brains removed and flash frozen (< 1 min postmortem time). 
MALDI Imaging MS is able to analyze different molecular classes using essentially the same technique 
but different sample preparation strategies, and in which the mass spectrometer is optimized for the 
mass range of the molecular class of interest. Figure 1 shows examples of metabolite, neuropeptide 
and protein imaging MS results obtained after CSD. The mean average mass spectrum, displaying 
which peaks were detected, and a selection of MS images is displayed for each molecular class. CSD 
was invoked in the right hemisphere of each tissue section. 
Each peak in the average mass spectra corresponds to a distinct biomolecular ion, the spatial 
distribution of which is contained in the imaging MS datasets. It is evident that a large number of 
metabolite, peptide and protein ions were obtained, and that marked changes in the distributions 
of specific metabolites and peptides were present in the ipsilateral hemisphere in which CSD was 
induced. Contralateral differences were evident in cortical structures, but less so in the subcortical 
structures far away from the cortex in any of the datasets, e.g., the peptide ion detected at m/z 1635.
Figure 2 shows 3D MS images of proteins following CSD, as well as a schematic of the alignment 
procedure. Coronal tissue sections spaced 200 μm through the middle region of the cortex of the mouse 
brain, in between the sites of CSD induction and CSD recording - were analyzed. The placement of 
the thin tissue sections on the conductive glass slides for the MALDI imaging MS experiments leads 
to significant variability in placement and orientation. The tissues were first approximately aligned 
by aligning their midpoints and rotating the tissues into a common orientation. The relative tissue 
positions were then fine adjusted on the basis of their anatomical structure (as revealed by H&E 
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staining). The offsets and rotations applied to each tissue section was then transposed into the imaging 
MS coordinate system and used to create the 3D imaging MS datasets.
The 3D imaging MS data demonstrate the high reproducibility of the MALDI imaging MS protocol. 
The visualization of 3D datasets has been performed using a thresholded surface rendering function 
– if the intensity of the peak is below threshold then that voxel (3D pixel) is set to transparent; if 
the intensity is above threshold then the intensity is set to 1. A smoothed surface is then fitted to the 
voxels containing the peak of interest. The advantage of such a surface rendering is that it efficiently 
depicts the 3D locations containing the MS peak, the disadvantage is that it does not communicate 
the relative intensity of the MS peak within the surface enclosed area. Caprioli and coworkers have 
used single color gradients (Andersson et al 2008) and heat maps (Sinha et al 2008) to depict relative 
concentrations in relatively simple 3D structures, but these are less suited to the highly structured 
surfaces such as those shown in Figure 2.     
3D imaging MS datasets consist of a many individual 2D imaging MS datasets (of tissue sections), 
each of which contains a very large number of mass spectra and discrete MS peaks. It was found that 
even a rudimentary contralateral comparison of the CSD hemisphere relative to the control hemisphere 
was complicated by the large number of peaks and tissue sections, making it difficult to visualize 
specific molecular features. Instead the multivariate factorization technique non-negative matrix 
factorization (Lee & Seung 1999) (NNMF) was used to summarize the latent molecular classes, each 
defined by specific MS profiles, which were found in the 3D imaging MS dataset, as shown in Figure 
3. NNMF of the 3D protein imaging MS dataset distinguished multiple distinct regions of the mouse 
brain but differences between the ipsi- and contralateral side were not detected.
The NNMF calculation was performed using an NVidia Tesla C2070 Graphical Processing Unit to 
provide the high processing speed necessary to analyze these very large datasets (Jones et al 2012). 
The corrected Akaike information criterion was used to estimate the number of classes present in the 
dataset, as has been reported previously (Hanselmann et al 2008). Increasing the number of factors 
could generate latent class images that included apparent contralateral differences but were prone 
to over-fitting of the data; the Akaike information criterion guards against over-fitting of the data by 
increasing the cost of models with increased parameter space – the NNMF factor analysis that led to 
contralateral differences were significantly disfavored by the Akaike information criterion. 
Figure 4 shows 3D imaging MSI images of neuropeptides obtained from an animal after CSD. The 
peptide at m/z 2273 shows no ipsi vs contralateral differences in the cortex, and only very minor 
differences in subcortical regions. In contrast the peptide at m/z 2220 shows differences between the 
ipsi- and contralateral sides in the cortex.
The triggering of CSD waves involves a surgical procedure; a cotton ball soaked in 1 M KCl is 
applied topically on the dura overlying the visual cortex through a cranial window, followed by 
a wash with NaCl. CSDs were monitored using a microelectrode placed in the frontal cortex. To 
differentiate changes due to the surgical procedure, but not CSD, 3D analysis of SHAM-operated 
106Chapter 5
Figure 1. MALDI imaging MS datasets of metabolites (top), peptides (middle) and proteins (bottom) after cortical 
spreading depression in wild type mice. Figures on the left show example images with the 2D distribution of different 
metabolites, peptides or proteins. *indicates CSD side. The metabolite dataset was recorded in negative ion mode with 
a reflectron ToF and using 9-aminoacridine as the matrix. The peptide dataset was recorded in positive ion mode with 
a reflectron ToF and using α-cyano-4-hydroxycinnamic acid as the matrix. The protein dataset was recorded in positive 
ion mode in linear ToF mode using sinapinic acid as the matrix. CSD was invoked in the right hemisphere of each tissue. 
Contralateral differences are evident in both the metabolite and peptide datasets but not in the protein dataset. Assignments 
of the metabolite peaks based on previous MALDI imaging MS of metabolites using the same matrix [36,42]:- m/z 89, 




metabolites (9 - AA matrix)
107
animals was also performed. The SHAM animals underwent an identical procedure except KCl was 
replaced with NaCl, which does not induce CSD. Figure 5 shows examples of 3D distributions that 
are unchanged between sham and CSD, as well as peptides that were detected at higher levels only in 
the CSD hemisphere of the KCl-treated animal.
Changes in protein content have previously been detected following CSD (Kawahara et al 1999, 
Obrenovitcha et al 2002) but have involved longer intervals between CSD induction and animal 
sacrifice, thus allowing sufficient time for the expression of new proteins. The very short time delay 
(45-60 min) in the current experiments limits significant expression of new proteins in response to 
CSD. The changes after CSD observed for neuropeptides are consistent with the vesicular release of 
neuropeptides from (sub)cellular vesicles and presynaptic terminals after depolarization of neuronal 
membranes during initiation of CSD.
These results represent a proof-of-concept study that forms the foundation for a larger study on the 
consequences of CSD, for instance in relation to migraine, which will involve multiple animals 
in each group and multiple genotypes. The proof of concept is essential as all previous imaging 
MS studies have focused on biomolecular changes associated with either distinct histopathological 
entities or with known, irreversible changes e.g., cell death in the CA3 layer of the hippocampus 
following kainate induced seizures (Sugiura et al 2011). The CSD results represent the first example 
of imaging MS being used to reveal transient biomolecular changes. The 3D analysis demonstrates the 
high reproducibility that can be obtained, within a single animal, and the recent biomarker discovery 
experiments provide ample evidence of the inter-patient/animal reproducibility that may be attained 
Figure 2. Top row: preliminary alignment procedure for generation of 3D imaging MS datasets. Each tissue is first 
centered and then aligned to a common orientation. Fine alignment of the tissues is then performed on the basis of their 
anatomical structure, and the final transformation applied to each tissue’s imaging MS dataset. Bottom row. Examples of 
3D protein imaging MS datasets of a wild-type mouse brain following CSD.
rotate to
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Figure 3. Non-negative matrix factorization of the 3D protein imaging MS dataset of a mouse brain following CSD did 
not reveal cortical contralateral differences. Note: factor 3 revealed background signals of the target slide and so is not 
included here. 
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Figure 4. Example of 3D peptide imaging MS datasets of a wild-type mouse brain following CSD. The peptide ion 
detected at m/z 2273 was primarily detected far away from the cortical spreading depression, consequently no contralateral 
differences are observed. In contrast the peptide ion detected at m/z 2220 is located in the cortex and displays significant 
contralateral differences following CSD. A blown-up 3D figure is also provides to display the results of each tissue 
section’s individual imaging MS dataset.
Figure 5. Exclusion matrix of 3D peptide imaging MS data for highlighting peptide ions related to CDS. Left hand side; 
peptide ions not specific to CSD are observed in the sham and CSD operated mouse, and do not exhibit contralateral 
differences. Right hand side; CSD associated peptide ions are detected at higher  levels in the CSD animal and CSD 
hemisphere.
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(Meding et al 2012).
Since its introduction by Crecelius et al. (Crecelius et al 2005) 3D MALDI imaging MS experiments 
have grown in popularity, but at a much slower pace than 2D imaging MS experiments owing to the 
much greater demands placed on experimental reproducibility and data handling (Seeley & Caprioli 
2012). Andersson et al. have published an experimental workflow (Andersson et al 2008), and 
alignment procedures have been reported to combine 3D imaging MS with 3D magnetic resonance 
imaging (Sinha et al 2008) and 3D optical imaging techniques (Chughtai et al 2012). These studies 
have focused on reproducing the histo-architectures of the tissues, such as mouse or crustacean brain 
architecture (Andersson et al 2008, Crecelius et al 2005, Chen et al 2009) and localizing tumors 
(Sinha et al 2008). 
CONCLUSION
The results reported here represent the first 3D MALDI imaging MS that explicitly targets biomolecular 
changes that are not associated with distinct morphological features, and which includes the first 
multivariate analysis of 3D MALDI imaging MS datasets. The 2D and 3D imaging MS investigations 
revealed metabolite and peptide disturbances immediately following CSD in wild-type mice, but 
the analogous protein datasets did not show similar profound changes. The short time between CSD 
and animal sacrifice is insufficient for appreciable protein synthesis in response to CSD; metabolic 
pathways are able to respond much more rapidly to changing conditions and increased neuropeptide 
signals are consistent with peptide release from (sub)cellular vesicles following depolarization 
associated with CSD. These results indicate that the molecular histology capabilities of MALDI 
imaging MS may be used to reveal spatial extent of transient biomolecular disturbances that do not 
results in morphological change.
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Cortical spreading depression (CSD) is the electrophysiological correlate of migraine aura. Transgenic 
mice carrying the R192Q missense mutation in the Cacna1a gene, which in patients causes familial 
hemiplegic migraine type 1 (FHM1), exhibit increased propensity to CSD. Herein, mass spectrometry 
imaging (MSI) was applied for the first time to an animal cohort of transgenic and wild type mice 
to study the biomolecular changes following CSD in the brain. Ninety six coronal brain sections 
from 32 mice were analyzed by MALDI-MSI. All MSI datasets were registered to the Allen Brain 
Atlas reference atlas of the mouse brain so that the molecular signatures of distinct brain regions 
could be compared. A number of metabolites and peptides showed substantial changes in the brain 
associated with CSD. Among those, different mass spectral features showed significant (Student's 
t-test, p < 0.05) changes in the cortex, 146 and 377 Da; and in the thalamus, 1820 and 1834 Da, of 
the CSD-affected hemisphere of FHM1 R192Q mice. Our findings reveal CSD-and genotype-specific 
molecular changes in the brain of FHM1 transgenic mice that may further our understanding about 
the role of CSD in migraine pathophysiology. The results also demonstrate the utility of aligning MSI 




Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a label-
free technique capable of analyzing hundreds of biomolecular ions directly from tissue in a spatially 
correlated manner (Caprioli et al 1997). Main factors contributing to the increasing popularity of this 
technology include the ability to (1) analyze a large range of molecular classes (proteins, peptides, 
lipids, metabolites, pharmaceuticals); (2) reveal disease-related biomolecular changes in highly 
localized regions; and (3) unravel changes that are invisible to established histopathological methods 
(McDonnell &Heeren 2007, McDonnell et al 2012, Norris & Caprioli 2013). 
MSI has been applied to a multitude of tissues from various tumor tissues (Balluff et al 2011, 
McDonnell et al 2010) to plant tissues (Kaspar et al 2011), but rodent brain (Henrieder et al 2013, 
Shariatgorji et al 2014) is still the most frequently analyzed tissue type because of its widespread 
availability and use in neurological research (Hafezparast et al 2002). For instance, MALDI-MSI has 
been used to visualize spatiotemporal disturbances in rodent models of seizure (Sugiura et al 2011), 
stroke (Miura et al 2010), Alzheimer’s disease (Rohner et al 2005, Stoeckli et al 2006) and Parkinson’s 
disease (Ljungdahl et al 2011, Nilsson et al 2007, Pierson et al 2004). These studies demonstrate the 
potential of MSI for neurological research, and which have been further validated by studies using 
small animal cohorts (Henrieder et al 2013). The application of MSI to preclinical investigations 
of neurological disorders requires considerable multidisciplinary capabilities: MSI, statistics and 
knowledge of brain anatomy. The latter aspect is exacerbated by the high degree of variation in brain 
region size that exists between animals (Hager et al 2012) and the variability introduced during tissue 
sectioning and mounting. We recently demonstrated how MSI data could be automatically aligned to 
the Allen Brain Atlas, which allows the analyst to ensure all tissue sections of animals are obtained 
from a similar region of the mouse brain and to extract the mass spectral signatures from identical 
brain regions (Abdelmoula et al 2014). Here we demonstrate how this registration pipeline enables 
larger-scale preclinical investigations of neurological disorders. This first demonstration of such a 
cohort studied and analyzed by MSI concerns migraine.
Migraine is a common, severe episodic brain disorder that is characterized by attacks of severe 
unilateral throbbing headache associated with nausea, vomiting, photo- and phonophobia (Goadsby 
et al 2002, ICHD 2004). An aura, which consists of transient neurological symptoms, including 
visual and sensory disturbances, can accompany a migraine attack in one-third of patients. The aura 
is caused by cortical spreading depression (CSD), a slow, self-propagating wave of neuronal and 
glial cell depolarization in the cerebral cortex of one hemisphere followed by neuronal depression 
(Hadjikhani et al 2001, Lauritzen 1994, Pietrobon & Moskowitz 2013). CSD causes a temporary 
dramatic failure of brain homeostasis, efflux of neurotransmitters, and changes in metabolism. Several 
metabolites, such as labile phosphate compounds (ATP, ADP, AMP, their cyclic analogues, cGMP, 
and phosphocreatine) and glycolytic metabolites (lactate, pyruvate, glucose and glycogen) have been 
associated with CSD (Selman et al 2004). 
118Chapter 6
In 2012 Jones et al. (Jones et al 2012) reported a proof-of-concept MALDI-MSI investigation of the 
biomolecular changes in C57BL/6J wild-type (WT) mouse brain following CSD. The study included 
2D- and 3D-MSI datasets, including an exclusion matrix to highlight apparent CSD-related changes, 
but omitted any form of statistical analysis because of the small number of animals involved in the 
study. Accordingly, the results obtained provided limited information regarding the biological aspects 
and changes associated with CSD. Here we report, for the first time, the application of MSI to a large 
scale animal cohort of a neurological disease, in particular CSD as the neurobiological correlate of 
the migraine aura. To this end, we make use of a relevant mouse model of migraine, (i.e., knock-in 
transgenic mice carrying the pathogenic human R192Q missense mutation in the Cacna1a gene that 
encodes the α
1
 subunit of voltage-gated neuronal Ca
V
2.1 Ca2+ channels (Ferrari et al 2015, van den 
Maagdenberg et al 2004). Ca
V
2.1 Ca2+ channels with a R192Q-mutated α
1
 subunit cause familial 
hemiplegic migraine type 1 (FHM1) (Ophoff et al 1996), a monogenic subtype of migraine with aura 
characterized by a prominent transient hemiparesis during the aura (ICHD 2004). FHM1 R192Q 
mice exhibit an increased propensity to CSD, most likely because of an enhanced glutamatergic 
neurotransmission (Eikermann-Haerter et al 2009, Ferrari et al 2015, Tottene et al 2009, van den 
Maagdenberg et al 2004). In addition, unlike in WT mice, CSD waves can reach subcortical areas 
in R192Q mice, which correlate with the clinical phenotype (Eikermann-Haerter et al 2011). We 
hypothesized that CSD could induce the expression of different biomolecular profiles in the brains 
of R192Q mice compared with wild-type. We measured and compared the biomolecular profiles of 
both mouse strains at specific cortical and subcortical brain regions and were able to show different 
consequences of CSD on the brains of R192Q and wild-type mice. 
MATERIALS AND METHODS
Animals
Male 2-to 4-month-old transgenic FHM1 R192Q mice (carrying the human pathogenic missense 
mutation R192Q) and corresponding non-transgenic wild-type (WT) mice were used. Transgenic 
mice were generated by introducing the human pathogenic mutation in the mouse Cacna1a gene using 
a gene targeting approach, as described in (van den Maagdenberg et al 2004). All mice were kept in 
a normal 12:12 light/dark regime and food and water were available ad libitum. The 32 animals used 
in this study were divided into different groups according to the experimental conditions: WT-Naïve 
(5 animals); WT-Sham (6 animals); WT-CSD (5 animals); R192Q-Naïve (5 animals); R192Q-Sham 
(6 animals); R192Q-CSD (5 animals). All experiments were approved by the Animal Experiment 
Ethics Committee of Leiden University Medical Center. 
CSD experiments 
CSD experiments were performed as previously described (Jones et al 2012). In brief, the mice 




) and mounted on a 
stereotactic frame (David Kopf, Tujunga, CA, USA); 1.5% isoflurane was used for maintenance of 
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the anesthesia. A midline incision was made to expose the skull. Two burr holes were drilled over the 
following coordinates (from bregma): 0.5 mm anterior, 2 mm lateral for DC recordings and 3.5 mm 
posterior, 2 mm lateral for KCl or NaCl application. Seven CSDs were induced by applying a cotton 
ball soaked in 1M KCl (CSD) or NaCl (Sham) for 30 sec followed by extensive saline washing. 
The interval between two successive applications was 5 min. DC-potential signals were measured 
with respect to an Ag/AgCl reference electrode placed subcutaneously in the neck and amplified 
10x (Molecular Devices, Sunnyvale, CA, USA). The DC signal was low-pass filtered at 4 Hz and 
digitized at 100–200 Hz using PowerLab 16/30 hardware (AD Instruments, Inc., Colorado Springs, 
CO, USA). Data were recorded and analyzed off-line using LabChart Pro (AD Instruments).
Sample collection and tissue preparation
Following 7 CSD/Sham events the mice were decapitated 5 min after the last CSD/Sham event, the 
brains quickly removed (within < 2 min), immediately snap-frozen on powdered dry ice and stored at 
-80oC until further processing. Coronal tissue sections, 12-μm thick, were cut at -12°C using a cryostat 
microtome (Leica Microsystems, Wetzlar, Germany), thaw-mounted onto poly-L-lysine coated 
indium-tin-oxide (ITO) glass slides (Bruker Daltonics, Bremen, Germany), and stored at -80°C. In 
order to exclude the effect of electrode insertion and KCl or NaCl application only sections from the 
middle part of the brain (posterior from bregma, in between locations -1.22 and -1.94 mm) were used 
for MSI analysis. For the selection of sections in this part of the brain, the brain was trimmed in 25 
μm slices and individual sections were visually inspected under a microscope and compared with the 
Paxinos Mouse Brain Atlas reference (3rd Edition; ISBN 978-0-12-374244-5) to judge their location 
along the anteroposterior axis, based on histological landmarks. Once the level corresponding to the 
location -1.22 posterior from Bregma was reached, 12μm thick coronal sections were collected for 
the MSI experiments. For each animal, consecutive tissue sections were collected on different ITO 
slides for the analysis of proteins, peptides and metabolites. Each ITO slide contained tissue sections 
from four animals.  A semi-supervised block randomization was used to distribute the sections in a 
random way across and within slides while maximizing the group heterogeneity within a slide. This 
included the position of each sample on the MALDI slides and the measurement order within a slide 
– in order to minimize any potential sources of bias during MSI data acquisition (see Supplementary 
Information for the pseudo-code).
Mass spectrometry imaging
Tissue sections were collected from storage at -80°C and equilibrated to room temperature (RT, 
23°C) for 30 min in a vacuum desiccator. The slides were prepared for MALDI-MSI according to 
the molecular class to be analyzed. For peptide and protein imaging the tissue sections were washed 
as follows: (1) dip in 70% ethanol for 30 sec; (2) dip in 96% ethanol for 30 sec; (3) five short dips 
in deionized water; (4) dip in 70% ethanol for 30 sec; (5) dip in 96% ethanol for 30 sec; and finally 
(6) dried in a vacuum desiccator for 15 min. No washing procedure was applied to the samples used 
for the analysis of metabolites. MALDI matrix was uniformly applied over the brain sections using 
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the SunCollect sprayer (SunChrom, Friedrichsdorf, Germany) according to the analyzed molecular 
class: sinapinic acid (SA; 5 mg/mL in 50% acetonitrile/ 0.3% TFA) was used for proteins; α-cyano-
4-hydroxycinnamic acid (CHCA; 5 mg/mL in 50% acetonitrile/ 0.3% TFA) was used for peptides; 
and 9-aminoacridine (9AA; saturated solution in 70% methanol) was used for metabolites. MSI 
analyses of peptides (600 – 2000 Da) and metabolites (50 – 1000 Da) were performed using an 
UltrafleXtreme MALDI-TOF/TOF (Bruker Daltonics) in the reflectron positive (for peptides) or 
negative (for metabolites) ion mode with 100 μm raster width, 500 laser shots per pixel. MSI of 
proteins (3000 – 20,000 Da) was performed in an Autoflex III MALDI-TOF (Bruker Daltonics) in 
the linear positive ion mode with 100 μm raster width, 500 laser shots per pixel. Data acquisition, pre-
processing and visualization were performed using the flex software package from Bruker Daltonics: 
flexImaging 3.0 was used for experiment definition; flexControl 3.4 was used for data acquisition; and 
flexAnalysis 3.4 was used for on-the-fly mass spectral processing – metabolite/peptide datasets were 
preprocessed using a Gauss smoothing algorithm (width 0.02 m/z, 2 cycles) and a TopHat baseline 
subtraction algorithm; protein MSI spectra were preprocessed identically except the parameters of 
the Gauss smoothing algorithm were adapted for the lower mass resolution (width 2 m/z, 4 cycles).
After the MSI experiments, the matrix was washed off with 70% ethanol and the tissue samples 
stained with cresyl violet (Nissl staining). High-resolution histological images were recorded using 
a Pannoramic MIDI digital slide scanner (3D Histech, Budapest, Hungary). 
Processing and reduction of MSI datasets
High-resolution histological images were co-registered to the MSI data with flexImaging using 
fiducial markers applied at defined positions on each ITO slide with water-based correction fluid 
(Tipp-Ex, Ecolutions, BIC, Clichy, France) before MSI analyses. A list of all mass spectra contained 
within each brain section was extracted into an XML file for further processing in MATLAB R2011a 
(MathWorks, Natick, MA, USA). The preprocessed mass spectra contained in the MSI datasets were 
then read into Matlab. 
Metabolite datasets: the spectra were normalized to their total-ion-count (TIC) on a pixel-by-pixel 
basis and aligned on common peaks that are present in at least 85% of the samples. Peak picking and 
feature extraction was performed using the global base peak mass spectrum (McDonnell et al 2010). 
Briefly, this routine distils the original MSI data into an image cube containing the spatial distribution 
of every detected peak. Finally, a logarithmic-based variance-stabilizing transformation was applied 
to the peak intensities in order to reduce the impact of Poisson noise in the datasets (Keenan et al 
2004, Veselkov et al 2014).
Peptide and protein datasets: except for the logarithmic transformation of peak intensities, which 
was not performed for these datasets, all processing steps were as described above including TIC 
normalization on a pixel-by-pixel basis, with minor modifications in the thresholds used for peak 
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picking to account for the different characteristics of the peptide and protein datasets. 
Image processing and registration to the mouse Allen Brain Atlas
The reduced MSI datasets and the aligned histological images were registered to the mouse Allen Brain 
Atlas (ABA; http://www.brain-map.org/) using our recently developed pipeline (Abdelmoula et al 
2014). In brief, the histological images are first preprocessed to reduce background noise and acquisition 
artifacts. Then the ABA corresponding histological image is selected based on the maximum cord 
length of the hippocampus. Image registration is performed by applying a rigid affine transformation 
(correct for translation, shearing, rotation and scaling), followed by non-linear registration based on a 
B-Spline transform (correct for local deformations). Finally, the transformation matrix used to register 
the sample and ABA histological images is applied to the respective MSI datasets.
Anatomy driven data analysis
The anatomic annotations contained in the ABA were used to define four anatomical regions of 
interest (ROI) in the MSI datasets: cortex (C), striatum (S), hippocampus (H) and thalamus (T). MS 
data were extracted from each ROI from every ABA-aligned MSI dataset for statistical analysis: (1) 
a non-paired Student’s t-test was used for comparisons between independent groups; and (2) a paired 
Student’s t-test was used for comparisons (left vs right hemispheres) within each independent group 
of animals. The Benjamini-Hochberg procedure was used to correct for multiple testing. All statistical 
analyses were done in R (R Foundation for Statistical Computing, Vienna, Austria) and Matlab, in 
which p-values < 0.05 were considered statistically significant.
RESULTS
CSD induction and MSI analysis
Seven CSD events were evoked each with a 5 min interval in the occipital cortex of WT and transgenic 
FHM1 R192Q mice; equivalent Sham experiments utilizing aqueous NaCl instead of aqueous KCl, 
which does not evoke a CSD, were performed in parallel so as to clearly differentiate CSD-related 
from non-CSD-related biomolecular changes. As shown in Table S1 (Supplementary Information), 
there were no significant differences between R192Q and WT mice regarding the CSD characteristics 
and time under anesthesia. All animals were sacrificed 5 min after the last CSD event and the brains 
were immediately removed and frozen on dry ice to limit post-mortem degradation effects. Previous 
studies have indicated that the analysis of metabolites can be significantly impaired by post-mortem 
degradation (Blatherwick et al 2013, Hattori et al 2010, Sugiura et al 2014). These results indicated 
that labile metabolites, such as AMP, ADP and ATP that act as energy reserves in the brain can be used 
as a measure of the post-mortem degradation effects. We measured the AMP/ATP ratios across the 
different mouse brains but found no correlation with the short post-mortem times of these experiments, 
which indicated that any variability associated with the isolation of the mouse brain had a negligible 
effect on the MSI data. 
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Alignment of MSI datasets to a single reference system 
Preclinical studies typically compare a number of animals per test group to guard against the individual 
variation in any animal population. We have analyzed a total of 96 mouse brain sections from 32 
animals from 16 R192Q and 16 WT mice. We registered all histological images and MSI datasets 
to the mouse brain reference atlas contained within the Allen Brain Atlas (Abdelmoula et al 2014) 
in order to (1) reduce the impact of variance attributable to differences in brain region size (Hager 
et al 2012); (2) check if all tissue sections came from a similar region of the brain; and (3) correct 
for any tissue-processing artifacts introduced during the experiment (e.g., folds, tears). The 96 brain 
sections were registered to just 3 of 132 different coronal sections present in the ABA reference atlas, 
corresponding to a tissue-section sampling accuracy between animals of 200 μm, and thus indicating 
we sampled similar regions of the mouse brain. The registration itself was performed with an accuracy 
of less than 30 μm, which is below the spatial resolution used for the MSI measurements (100 μm) 
(see Figure 5, reference Abdelmoula et al 2014). A scheme of the workflow is presented in Figure 1.
Anatomy based data-analysis
The distribution of proteins, peptides and metabolites after CSD and Sham operations was 
investigated across the whole brain and in four particular brain regions that are of relevance to 
migraine pathophysiology (Eikermann-Haerter et al 2011): cortex, striatum, hippocampus and 
thalamus. Electrophysiology measurements indicate that when induced in one hemisphere CSD does 
not cross to the other hemisphere (Eikermann-Haerter et al 2009, Somjen 2001), accordingly the left 
(unaffected) hemisphere was used as control for the CSD/Sham-affected right hemisphere.
Protein datasets
Comparison between right (CSD-affected) and left (control) hemispheres within the R192Q-CSD 
group revealed moderate differences in the distribution of m/z feature 11,302 Da and statistically 
significant differences in the distribution of m/z feature 11,344 Da (p < 0.05, Student’s t-test), as 
shown in Figure 2. In both cases, the ion intensities are lower in the CSD-affected hemisphere (R). 
These changes were not observed in the WT and Sham groups. Poté et al. (Poté et al 2013) have 
previously identified the same molecular features as histone H4 and respective acetylated form while 
analyzing hepatocellular carcinoma. Although their experiment concerned human tissue samples, a 
Basic Local Alignment Search Tool (BLAST) search (in UniProt database) revealed 100% homology 
with murine histone H4. 
Peptide datasets
Intra-group comparison between right (CSD-affected) and left (control) hemispheres showed 
significant differences occurring in the thalamus region for m/z features 1819.96 Da and 1833.96 Da 
(p < 0.05, Student’s t-test) only in R192Q-CSD mice (Figure 3). A decrease in ion intensities was 
observed in the CSD-affected brain hemisphere in both cases. Similarly to the protein dataset, also 
these biomolecular features share the same spatial distribution and are separated by 14 Da, which 
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is compatible with a methylation post-translational modification. Moderate differences were also 
observed in the R192Q mouse brains after CSD, in particular m/z 1713.8 with increased expression 
in the cortex of the CSD-affected hemisphere, and m/z 1754.85 and its K+ adduct m/z 1792.85 with 
decreased expression in the striatum of the CSD hemisphere. No significant biomolecular changes 
were observed for the Sham and Naïve mouse groups.
Metabolite datasets
Intra-group comparisons between control and CSD-affected hemispheres revealed differences 
associated with CSD in WT and R192Q mice (Supplementary Information, Figure S1). Biomolecular 
features present at 89.03 Da showed an increase in signal intensity in the CSD- affected hemisphere, 
whereas m/z features at 146.07 Da, 339.01 Da, 360.97 Da and 376.97 Da presented a decrease in 
intensity in the CSD-affected hemisphere. Interestingly, significant changes were only found in the 
distribution of 2 m/z features for R192Q-CSD mice (p < 0.05, Student’s t-test), particularly m/z 146.07 
Da and 376.97 Da as shown in Figure 4. In order to more confidently assign the m/z features observed 
we performed high-resolution MS analysis by MALDI Fourier transform ion cyclotron resonance 
(FTICR) directly from tissue. Accurate masses were then searched in the metabolite database METLIN 
revealing the presence of glutamate ([M-H]- 146.0459 Da), fructose 1,6-bisphosphate ([M-H]- 338.9888 
Da) and fructose 1,6-bisphosphate K+ adduct ([M+K-2H]- 376.9447 Da) among other isobaric species.
Figure 1. Schematic of workflow developed to analyze the effect of CSD in WT and R192Q mouse brains. Ninety-six 
coronal brain sections were obtained from a total of 32 mouse brains (3 consecutive sections per animal). Proteins, 
peptides and metabolites were independently analyzed by MSI using optimized sample treatment for each molecular class 
as described in the Materials and Methods section. Each section was stained with Nissl reagent after matrix removal and 
the MSI datasets, and histological images were aligned to the Allen Brain Atlas of mouse brain (Abdelmoula et al 2014). 
Automatic anatomical annotation of regions of interest allowed the extraction of MSI data from specific brain regions of 
interest and statistical analysis.
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Figure 2. Protein MSI dataset: differences between CSD (right, R) and control hemisphere (left, L) in R192Q-CSD mouse 
brain. Each image corresponds to the visualization of the average distribution of a particular m/z feature in five mouse brains 
after alignment to the ABA. (*p < 0.05, Student’s t-test). C: cortex, T: thalamus; H: hippocampus, S. Striatum.
Figure 3. Peptide MSI dataset: differences between CSD (right, R) and control hemisphere (left, L) in R192Q-CSD mouse 
brain. Each image corresponds to the visualization of the average distribution of a particular m/z feature in five mouse brains 
after alignment to the ABA. (*p < 0.05, Student’s t-test) C: cortex, T: thalamus; H: hippocampus, S. Striatum.
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DISCUSSION
MSI is a non-targeted methodology that allows the analysis of different biomolecular classes directly 
from tissue. One of the main advantages of MSI is its ability to unravel biomolecular changes 
independently of histology. This is of particular interest to the study of migraine, a neurological 
disorder characterized by recurrent attacks and lack of clear histopathological features. Many 
metabolites, amino acids and neuropeptides have been measured in the brain during and after CSD 
experiments (Selman et al 2004). However, the effects of CSD are still not fully understood, namely: 
(1) How are the proteome, peptidome and metabolome profiles affected by CSD? (2) How are the 
CSD changes affected by the genetic background of the mice (i.e., a comparison between mice with 
a genetic predisposition to migraine and WT mice)? And (3) does CSD induce biomolecular changes 
in subcortical areas? To answer these questions, we measured and compared the biomolecular profiles 
of FHM1 R192Q and WT mice after CSD induction in the occipital cortex.  
The biomolecular profiles recorded by MSI presented disturbances that may be associated with the 
CSD wave progression only in R192Q mouse brain. Given the short time between CSD induction 
and animal sacrifice, ca. 40 min after the first CSD event, significant changes in protein expression 
level were not expected. Indeed, the only significant change revealed by MSI is associated with a 
post-translational modification in histone H4: acetylated histone H4 (11,344 Da) showed a decreased 
intensity in the cortical region of the CSD-affected hemisphere. Likewise, previous reports showed 
that CSD induction in rats affected methylation levels in the cortex, although this was evident 24 
hr following CSD induction (Passaro et al 2010, Rana et al 2012). Histone modifications, such as 
acetylation, methylation, ubiquitination, and phosphorylation  have an important role in the epigenetic 
regulation of transcription and have been associated with neurological diseases such as Alzheimer’s 
Figure 4. Metabolite MSI dataset: differences between CSD (right, R) and control hemisphere (left, L) in R192Q-CSD mouse 
brain. Each image corresponds to the visualization of the average distribution of a particular m/z feature in five mouse brains 
after alignment to the ABA. (*p < 0.05, Student’s t-test). C: cortex, T: thalamus; H: hippocampus, S. Striatum.
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disease, Huntington’s disease and Parkinson’s disease (Konsoula & Barile 2012). Therefore, the 
effect of CSD on post-translational modification of histones, and consequently on the transcription 
mechanisms, may have relevance to migraine.
It is well known that CSD triggers the release of vasoactive peptides (Colonna et al 1994, Tozzi et 
al 2012). Trigeminal axons that innervate the dural vessels and are activated during CSD release 
calcitonin gene related peptide (CGRP), substance P (SP) and neurokinin-α (NKA), which all are 
potent vasodilators (Bolay et al 2002, Colonna et al 1994, Ho et al 2010, Raddant & Russo 2011, 
Wahl et al 1994). These vasoactive peptides are believed to be mediators of neurogenic inflammation, 
which is thought to be a mechanism relevant to the generation of migraine headache (Bolay et al 
2002). Interestingly, levels of CGRP and SP in the blood of migraine patients were found increased 
between and during attacks (Fusayasu et al 2007, Gallai et al 1995, Goadsby et al 1990). Although 
we did not observe significant changes in any of these compounds, the MSI peptide datasets revealed 
moderate differences in the distributions of a few biomolecular features (1392.75 Da; 1713.80 
Da,1754.85 Da;1871.88 Da) in mouse brain hemispheres affected by CSD, which is in agreement 
with the idea that CSD induction triggers a substantial redistribution of peptides in the extracellular 
space. Additionally, a significant decrease in the intensity of m/z features 1819.96 Da and 1833.92 Da 
was observed only in the thalamus region of R192Q mice. Although the identity of these m/z features 
is currently unknown, their similar distribution and m/z shift consistent with a methylation post-
translational modification indicate that these may be different forms of the same peptide. 
In the peptide datasets, we detected changes in subcortical regions (striatum and thalamus) as a result of 
CSD. This is in agreement with previously published data indicating that CSD induction in the cortex 
may also easily spread to subcortical regions in FHM1 R192Q but not WT mice (Eikermann-Haerter et 
al 2011). Therefore, the differential distribution of peptides in the striatum, thalamus and hippocampus 
identified after CSD might reflect a subcortical spread of CSD waves. Yet, the possibility for a transport 
of peptides released in the cortex to subcortical structures cannot be excluded at this time.   
Several metabolites, such as ATP, ADP, AMP, cGMP, lactate, pyruvate, glucose and glycogen have 
been associated with CSD (Selman et al 2004). In addition, CSD can also trigger the release of 
amino acids and change their brain regional distribution. During single episodes of CSD in rat brain, 
interstitial levels of several amino acids (e.g., alanine, arginine, aspartate, glutamate, glycine) were 
found to be elevated, highlighting the massive changes in biomolecular distribution that occur in 
the brain during episodes of CSD (Fabricius et al 1993). Our MSI metabolite datasets revealed a 
significant decrease in the intensity of m/z feature 146.07 in the cortical region of R192Q mice after 
CSD. Owing to the high number of isobaric molecules in this mass region, it is virtually impossible 
to identify small metabolites directly from tissue with MS/MS analysis. Yet, after high-resolution 
MS analysis and assignment based on previous reports, this biomolecule was assigned as glutamate. 
Glutamate plays a major role in CSD and elevated levels of glutamate and glutamic acids have been 
detected in plasma (Ferrari et al 1990) and cerebrospinal fluid (CSF) (Martinez et al 1993, Peres et 
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al 2004) of migraine patients. Of note, pharmacological targeting of glutamate receptors is currently 
being explored as a potential migraine therapy (Andreou & Goadsby 2009). Glutamate is a well-
known trigger of CSD (Van Harreveld 1959), and during CSD propagation in the cortex there is 
a release of glutamate to the extracellular space (Basarsky et al 1999, Fabricius et al 1993). Given 
the above, the down-regulation of glutamate in cortex of CSD affected brain hemispheres observed 
by MSI analysis may seem contradictory, at first. Previous quantitative proteomics studies in naïve 
FHM1 R192Q mice, however, revealed an up-regulation of major glutamate transporters, EAAT1 and 
EAAT2, when compared to WT mice (Klychnikov et al 2010). These findings, together with the MSI 
results reported here, suggest that a compensatory mechanism in the brain might be in place to clear 
excessive glutamate from the synaptic space by glial cells using glutamate transporters.  
Besides the putative identification of glutamate changes, our MSI data revealed significant differences 
in the spatial localization of m/z 376.96 Da in the R192Q brain after CSD. Database search based on 
high-resolution MS indicated that this molecular feature is probably associated with different forms 
of fructose 1,6-biphosphate, which is a byproduct of fructose and glucose metabolism common to 
all cells. In a previous publication, this m/z feature was also assigned as fructose 1,6-bisphospate by 
MSI in a rat model of ischemic stroke (Miura et al 2010). Interestingly, the distribution of fructose 
1,6-biphosphate and glutamate in the ischemic brain is similar to the distribution observed after CSD 
in both R192Q and WT mice. Recently Eikermann-Haerter et. al. (Eikermann-Haerter et al 2012) 
studied the link between stroke and migraine using the same transgenic FHM1 R192Q mice and 
demonstrated that FHM mutations do not only enhance susceptibility to CSD but also to ischemic 
depolarizations, leading to stroke. Therefore, the MSI results reported here in combination with 
previous work by Miura et al. (Miura et al 2010) seem to suggest that there is indeed a link between 
CSD and stroke events, although more work is required to prove this hypothesis. 
CONCLUSIONS
Here we used MALDI-MSI combined with a newly developed pipeline that allows the automatic 
registration of MS datasets to mouse data contained in the Allen Brain Atlas (Abdelmoula et al 
2014), to investigate the biomolecular distribution in the brain after CSD in a relevant mouse model 
of migraine. Our results revealed that CSD events affect the distribution of metabolites, peptides 
and proteins, not only in the cortex but also in subcortical structures. The finding that changes in 
biomolecules distribution were only evident in R192Q mice that had undergone CSD indicates that 
these changes are both genotype- and CSD-specific. Future work should reveal the identities of 
biomolecules that are affected by CSD events and might provide more in-depth insights in migraine 
pathophysiology. In conclusion, our results show that CSD induction in FHM1 R192Q mice is 
associated with a substantial redistribution of biomolecules in the brain and highlight that MALDI-
MSI can be instrumental in preclinical animal models of disease.
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SUPPLEMENTARY INFORMATION
Table S1. CSD characteristics and average time under anesthesia for the different mouse groups. 
Seven CSD events were evoked by topical application of 1M KCl in the occipital cortex of the right 
hemisphere of the brain with 5 minutes interval (equivalent Sham experiments were performed with 
topical application of 1M NaCl). Significant differences between R192Q and WT mice regarding the 
CSD characteristics and time under anesthesia were not observed.






WT-CSD 5 22.9±2.4 44.2±19.4 62.0±6.3
WT-Sham 6 62.0±2.2
R192Q-CSD 5 22.0±1.2 31.2±3.3 61.5±2.9
R192Q-Sham 6 65.1±4.3
Pseudo-code of the semi-supervised block randomization
• s = number of samples
• Define n * m experimental design matrix M
m = maximum number of samples that can be placed on a slide
n = number of slides needed for the project =  ceiling(s/m)
• Sort groups into list L according to amount of samples
• Fill up M iteratively by column
o As long as there are empty places in a column, do
 select next group from L 
 draw randomly x samples from the selected group where x <= n
 place the selected samples randomly within the empty positions in the column
 delete already taken samples from the initial sample list
• When done, permute samples within slides
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Figure S1: The effect of CSD on the distribution of a number of metabolites in coronal sections of WT and R192Q mouse 
brain. Seven CSDs (and equivalent Sham experiments) were evoked in the right (R) hemisphere of WT and R192Q 
mouse brain. Twelve μm thick coronal brain sections were homogeneously sprayed with 9AA matrix and analyzed by 
MALDI-TOF-MS in the negative mode. MS-images refer to a single mouse example per experimental group. Lightning 
bolt indicates the hemisphere (right hemisphere) where the CSD event was evoked.
Figure S2: Representative spectra from different MSI datasets. A) Protein dataset – positive linear mode; 2000 – 20 
000 Da. B) Peptide dataseet – positive reflectron mode; 600 – 2000 Da. C) Metabolite dataset – negative reflectron 
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Migraine is a common brain disorder characterized by recurrent attacks of severe headaches and other 
neurological symptoms. In one-third of patients headaches are accompanied by auras, which consist 
of transient visual and sensory disturbances, believed to be caused by cortical spreading depression 
(CSD). CSD is characterized by a wave of neuronal and glial depolarization with concomitant 
changes in metabolite concentrations in the brain and cerebrospinal fluid. It remains unknown whether 
CSD-induced brain metabolic changes can be captured outside the central nervous system, i.e., in 
peripheral fluids. This study investigated plasma metabolic changes in transgenic mice that harbor a 
gene mutation in voltage-gated Ca
V
2.1 Ca2+ channels previously identified in patients with familial 
hemiplegic migraine, a subtype of migraine with aura. The use of a mouse model allows investigation 
of molecular changes occurring shortly after CSD, which is notoriously difficult in patients. Capillary 
electrophoresis - mass spectrometry was used for the analysis of plasma samples to obtain, for the 
first time, a comprehensive view of molecular changes immediately after experimentally induced 
CSD. Multivariate data analysis showed a clear distinction between profiles of transgenic and 
wild-type animals after CSD. Two metabolites considered important for this discrimination were 
tentatively identified as being lysine and its by-product pipecolic acid with additional confidence 
provided by hydrophilic interaction chromatography combined with tandem mass spectrometry. 
The changed metabolites suggest a compensatory increase in GABAergic neurotransmission upon 
enhanced excitatory neurotransmission. These results show that CSD induces metabolic remodeling 
in transgenic migraine mice that can be captured and measured in plasma. 
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INTRODUCTION
Migraine is a common debilitating brain disorder characterized by episodic recurrent attacks of 
severe headaches often accompanied by nausea, vomiting, photophobia, and phonophobia (Goadsby 
et al 2002, ICHD 2004). In one-third of patients attacks are accompanied by transient neurological 
dysfunction called an aura that consists of visual, sensory or aphasic symptoms. Familial hemiplegic 
migraine (FHM), a monogenic subtype of migraine with aura with reversible pronounced motor 
weakness during the aura, is considered a valid model for common forms of migraine (Ferrari et 
al 2015). FHM type 1 is caused by mutations in the CACNA1A gene that encodes the pore-forming 
α
1
 subunit of neuronal Ca
V
2.1 (P/Q-type) voltage-gated calcium channels (de Vries et al 2009, 
Ducros et al 2001, Ophoff et al 1996, van den Maagdenberg et al 2007). The underlying cause of 
the aura is cortical spreading depression (CSD), which consists of a wave of glial and neuronal 
depolarization that slowly propagates through the cortex and is followed by a long-lasting (ca. 1 hr) 
neuronal silencing. Experiments in animals have shown that CSD can activate trigeminovascular 
pathways in the brainstem involved in headache generation (Karatas et al 2013, Zhang et al 2011), 
but such evidence is lacking in humans. CSD leads to a disruption of cellular ionic balance and is 
associated with changes in extracellular levels of ions, neurotransmitters, and metabolites (Davies 
et al 1995, Somjen 2001). Furthermore, it has been shown that a CSD event can change blood-brain 
barrier permeability (Gursoy-Ozdemir et al 2004), which may indicate that CSD events and their 
consequences may be traced beyond the central nervous system (CNS), e.g., in peripheral fluids such 
as blood or urine. Metabolomics appears a logical approach for testing this assumption; indeed, the 
response of an organism to any biological effect is ultimately reflected in alterations of metabolic 
composition of body fluids. Profiling of CSD-induced molecular changes may give relevant molecular 
insight into the pathophysiological mechanisms of migraine and lead to relevant (putative) biomarkers 
for diagnosis, monitoring, or prognosis of migraine events in patients. Surprisingly, even though 
the clinical importance of metabolomics-based studies has been widely demonstrated for various 
neurological disorders, migraine remains a largely unexplored area (Lionetto et al 2013).
Performing metabolomics studies in mice poses technical challenges that need to be addressed. For 
instance, non-terminal blood collection provides only minute amounts (i.e., few μL) of plasma, a 
miniaturized analytical workflow is thus mandatory. Capillary electrophoresis hyphenated to mass 
spectrometry (CE-MS) presents numerous advantages, including high-separation efficiency and 
selectivity, as well as low sample and solvent consumption. The feasibility of  CE-MS as an analytical 
method for metabolic profiling of the volume-restricted samples has been shown multiple times; it 
is particularly well-suited for the analysis of polar and ionizable compounds, such as amino acids, 
phosphorylated compounds, tricarboxylic acid cycle intermediates, as well as nucleosides and 
nucleotides in biosamples (Bonvin et al 2012, Hirayama et al 2014, Kohler et al 2013, Kok et al 
2014). The high sensitivity and resolution required for such bioanalytical applications can be reached 
by using online sample preconcentration techniques and a sheathless nanospray ionization interface. 
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A prototype based on a porous sheathless interface, first proposed by Moini (Moini 2007), has been 
successfully used for metabolomics applications (Hirayama et al 2012, Nevedomskaya et al 2010, 
Ramautar et al 2012). This sheathless interface was shown to display a mass-flux sensitive response 
at flow rates lower than 25 nL min-1, suggesting a maximum sensitivity and reduced ion suppression 
at very low flow rates usually observed with CE (Busnel et al 2010). 
In this study, CE-MS was used for metabolic profiling of plasma from a FHM1 transgenic mouse 
model carrying a R192Q missense mutation that was introduced in the CACNA1A gene (van den 
Maagdenberg et al 2004). The mutant mice exhibit migraine-relevant features including an increased 
susceptibility to CSD that is the consequence of enhanced excitatory neurotransmission due to 
hyperactive Ca
V
2.1 channels (Eikermann-Haerter et al 2009, Tottene et al 2009, van den Maagdenberg 
et al). CSD-induced metabolite changes significantly differed between mutants and wild-type (WT) 
control animals. Hydrophilic interaction chromatography (HILIC) combined with tandem mass 
spectrometry (MS/MS) was used for platform-independent and orthogonal confirmation of the 
identity of lysine and pipecolic acid (PA), the two metabolites that were considered important for the 
discrimination of mutant and WT metabolite profiles. Changed levels of lysine and PA may reflect 
a compensatory increase in GABAergic neurotransmission as a consequence of enhanced excitatory 
neurotransmission that is particularly prominent in mutant mice upon CSD. 
MATERIALS AND METHODS
Chemicals
Potassium chloride, sodium chloride, sodium hydroxide, methanol (MeOH), ethanol (EtOH), 
isopropanol (i-PrOH), 28% ammonium hydroxide (m/v), L-lysine monohydrochloride, and L-PA 
were of analytical grade and purchased from Sigma-Aldrich (Schnelldorf, Germany). Water and 
acetonitrile (MeCN) were of LC-MS grade and were obtained from Sigma-Aldrich. Formic and acetic 
acid were of ULC-MS grade and were purchased from Biosolve (Valkenswaard, The Netherlands).
Animals 
Male 2-to 4-months-old FHM1 R192Q and WT control mice were used and genotyped as previously 
described (van den Maagdenberg et al 2004). Mice were kept in a standard 12:12 light dark cycle; 
water and food were available ad libitum. All the animal experiments were approved by the Animal 
Experiment Ethics Committee of Leiden University Medical Centre. 
Induction and recording of  cortical spreading depression 




) for induction and 
1.5% for maintenance. Mice were placed in a stereotactic frame (David Kopf, Tujunga, CA, USA) 
and a midline incision was made to expose the skull. Two burr holes were drilled with a microdriller 
at the following coordinates from bregma: 3.5 mm posterior and 2 mm lateral for CSD induction in 
the occipital cortex and 0.5 mm anterior and 2 mm lateral for CSD recording in the frontal cortex. 
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CSD events were induced by application of a cotton ball soaked in 1M KCl over the dura for 30 sec, 
immediately removed prior to thorough washing with saline solution. In sham-operated mice, a cotton 
ball soaked in 1M NaCl was applied for 30 sec, immediately removed prior to thorough washing with 
saline solution. This procedure was repeated 7 times each with a 5-min interval for both CSD- and sham-
operated mice. The experimental design, illustrated in Figure S1, included 24 mice, i.e., two groups 
consisting of 12 sham- and 12 CSD-operated mice, each group containing 6 WT and 6 R192Q animals. 
CSD events were measured as DC-potential changes that were recorded at 300 μm depth using a glass 
electrode filled with 150 mM NaCl in the frontal cortex. Data were sampled at 200 Hz, amplified (10x) 
and low-pass-filtered (100 Hz) using a Powerlab (AD Instruments Inc, Colorado Springs, CO, USA). 
Sample collection and preparation
Five minutes after the 7th CSD (in the case of KCl application) or 7th sham (in the case of NaCl 
application), mice were decapitated and a minimum of 40 μL of blood was collected from the trunk in 
heparinized blood collection capillaries (Sarstedt Microvette CB 300, Nümbrecht, Germany). Plasma 
samples were obtained after centrifugation of blood for 10 min with 4000 rpm at 4oC and then snap-
frozen in liquid N
2
 and stored at -80oC. Prior to CE-MS analysis, plasma samples were thawed at room 
temperature. Protein precipitation (PP) was carried out with addition of cold EtOH to the plasma (3:1, 
v/v) followed by vortex agitation. After 20 min, samples were centrifuged for 10 min at 4000 rpm 
prior to the collection of supernatant and its evaporation to dryness. The obtained dried extracts were 
dissolved by addition of 100 mM ammonium acetate at pH 4.0 to a volume corresponding to the 
original one. The prepared samples were randomized prior to CE-MS analysis, which also included 
quality control (QC) samples consisting of a pool of all plasma samples prepared in the same way to 
evaluate the analytical variability of the CE-MS experimental set-up.  
Capillary electrophoresis – mass spectrometry
CE-MS experiments
CE experiments were performed using a PA800 Plus instrument (Beckman Coulter, Brea, CA, USA) 
equipped with a temperature-controlled sample tray, capillary cooling liquid, and a power supply 
able to deliver up to 30 kV. CE separations were carried out with neutrally-coated capillaries (30 
μm i.d.  150 μm o.d.  100 cm) consisting of a bilayer with polyacrylamide as the outer layer and 
the end proximal to the mass analyzer made porous to ion flow, in development and supplied by 
Beckman Coulter at the time of this study. CE was hyphenated to a MaXis 4G UHR-TOF mass 
analyzer (Bruker Daltonics, Bremen, Germany) via a porous CE-electrospray (ESI)-MS sheathless 
interface. The prototype interface set up as well as daily system suitability tests are described in 
details elsewhere (Busnel et al 2010, Heemskerk et al 2012). The background electrolyte (BGE) was 
composed of 10% acetic acid (v/v). Samples were hydrodynamically introduced at 2.5 psi for 65 
sec (corresponding to 3% of the capillary volume, 25 nL) using a transient isotachophoresis (t-ITP) 
online pre-concentration previously described (Heemskerk et al 2012). Separation was carried out in 
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65 min with an applied voltage of 25 kV and a pressure of 2 psi to ensure the ESI spray stability. MS 
acquisition was performed in ESI positive mode over the range 50 to 1500 m/z with an acquisition 
rate of 1 Hz. ESI capillary voltage was set at -1200 V and drying flow rate and temperature at 2 L/
min and 180oC, respectively. A hydro-organic solution of H
2
O/i-PrOH 50:50 (v/v) containing sodium 
formate clusters was infused at the beginning of each analysis to allow for mass recalibration. 
Data analysis
All MS data files were recalibrated based on sodium formate m/z clusters. The CE-MS data files were 
exported in mzxml format and aligned with the in-house developed alignment algorithm msAlign2 
available on www.ms-utils.org/msalign2 (Nevedomskaya et al 2009). Peak picking was performed 
with XCMS package (The Scripp Research Institute, La Jolla, CA, USA) based on the centWave 
algorithm using the following settings: maximal tolerated m/z deviation in consecutive scans, 5 ppm; 
electrophoretic peak width, 5-15 sec; scan range to process, 70-1500 m/z; noise, 15,000; prefilter step, 
at least 3 peaks with intensity >20,000; m/z center of the feature, wMean (intensity weighted mean of 
the feature m/z values); signal-to-noise ratio threshold, 50; minimum difference in m/z for peaks with 
overlapping migration time, 0.05 min; integration method, peak limits found through descent on the 
Mexican hat filtered data; no Gaussian fitted to each peak (Smith et al 2006, Tautenhahn et al 2008). 
Probabilistic Quotient Normalization method was used to account for the dilution of the samples 
(Dieterle et al 2006). Data were mean centered and a square root transformation was used to correct 
for the heteroscedasticity.
Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and 
orthogonal partial least squares discriminant analysis (OPLS-DA) were computed using SIMCA-P+ 
software version 12.0 (Umetrics, Umeå, Sweden). The validity of the PLS-DA model was checked 
using a permutation test containing 200 iterations. Features responsible for the separation between 
classes in OPLS-DA were determined based on the S-plot visualization method and the Variable 
Influence on Projection (VIP) values, which both highlight the importance of the variables for the 
classification. In order to identify the classifiers of interest, rational chemical formulae were generated 
based on the internally calibrated monoisotopic mass within 5 ppm mass error and submitted to 
METLIN Metabolite Search (http://metlin.scripps.edu; Smith et al 2005) and the Human Metabolome 
Database (HMDB, http://www.hmdb.ca; Wishart et al 2009). The confirmation of the identity of 
metabolites of interest was carried out by HILIC-MS/MS.  
Hydrophilic interaction chromatography-tandem mass spectrometry
HILIC-MS/MS experiments were performed with a LC-MS Advance™ UHPLC hyphenated to an 
EVOQ Elite™ Triple Quadrupole (QqQ), both from Bruker Daltonics. Confirmatory analyses were 
carried out with a Luna NH
2
 column (Phenomenex, Utrecht, The Netherlands) of 100 mm  2.00 mm 
i.d., 3 μm, and 100 Å. The mobile phase was composed of a 20 mM ammonium acetate buffer at pH 
9.0 (A) and MeCN (B). The flow rate was set to 600 µL min-1 with the following gradient profile: 95% 
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B for 1 min, 95-5% B for 5 min, and 5% B for 1 min. Equilibration of the column was performed with 
95% B for 5 min. Analyses were carried out at 40oC. MS/MS experiments were performed in positive 
ESI mode with a collision energy of 10 eV and a dwell time of 200 ms. ESI source parameters were: 
an ESI capillary voltage of 4500 V, a cone gas voltage of 20 V, a cone gas temperature of 25 0C, a 
probe gas voltage of 20 V, a probe gas temperature of 300 0C, and a nebulizer gas pressure of 200 
psi. N
2
 was used for collision-induced dissociation at a pressure of 1.5 mTorr. Sample preparation 
included plasma PP prior to solid-phase extraction (SPE). PP was carried out by adding 1.5 mL of 
MeOH to 500 μL of pooled plasma collected from naïve WT control mice and centrifuged at 13000 





0 5:95 (v/v). SPE was performed on precipitated sample with Strata Strong Anion 
Mixed Mode (Strata-X-A, Phenomenex) cartridges containing 100 mg sorbent mass. SPE cartridges 




0 5:95 (v/v) prior 





0 5:95 (v/v) and 1 mL of MeOH, respectively. Compounds of interest were then eluted 
with 1 mL of a mixture of HCOOH/MeOH 2:98 (v/v). The organic eluate was evaporated to dryness 
and reconstituted in 25 μL of a solution of MeCN/0.1 M HCl 9:1 (v/v). Two μL of this solution were 
eventually injected for subsequent HILIC-MS/MS experiments. 
RESULTS AND DISCUSSION
Plasma metabolic profiling by CE-MS
In order to reach the highest sensitivity and separation efficiency, leading to an enhanced plasma 
metabolic coverage, an integrated CE  nanospray  MS approach was used in combination with t-ITP 
online pre-concentration (Heemskerk et al 2012). The use of neutrally-coated capillaries, which almost 
entirely suppress the electro-osmotic flow (EOF), also allowed for the highest separation efficiencies 
while keeping the CE effluent to very low flow rates (<25 nL min-1) which are necessary to observe 
a mass-flux sensitive detector response (Busnel et al 2010). A typical base peak electropherogram 
obtained with the analysis of precipitated mouse plasma is shown in Figure 1. 
Compared to widely used chromatographic techniques, CE-MS, especially at very low EOF, suffers 
from a poorer migration time repeatability which can affect the statistical data analysis and, eventually, 
the identification of putative compounds of interest. Therefore, most of the available algorithms and 
software packages previously developed for LC-MS and routinely used for non-linear correction of 
retention times are usually not fully adapted to CE-MS data. Prior to subsequent data pre-processing 
and analysis, CE-MS data were thus aligned using a dedicated, in-house, and open source alignment 
tool, msalign2 (Nevedomskaya et al 2009). 
The analytical consistency of the CE-MS workflow was evaluated via analysis of QCs composed of 
a pool of all samples repeatedly analyzed at regular intervals throughout the sequence runs (Dunn et 
al 2012, Naz et al 2014). To this end, a PCA model was built on the whole data set, i.e., 20 samples 
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and all QCs. Four samples, i.e., two from the CSD and two from the sham group, were discarded 
prior to the data analysis as no satisfactory data were acquired due to instrumental issues. As shown 
by the score plot obtained for the first two principal components (covering 50% of the total variation) 
presented in Figure S2, the variation present in the group of mouse samples was much larger than the 
variation between QCs. The analytical variability was thus considered having a negligible influence 
on the data matrix. QCs were then removed from the data set for subsequent data analysis. 
The initial PCA analysis of the entire data set did not show any trend or tendency relevant to the 
experimental design (data not shown). Thus, in order to dissect CSD-triggered differences in the 
metabolic composition of plasma samples of FHM1 R192Q mice in comparison to WT mice, the 
PCA models were built for sham and CSD mice separately (Figure 2). Visual inspection of the PCA 
plots revealed important differences between the models. Figure 2A presents the score-plot of the 
first two principal components for PCA obtained for the combined FHM1 R192Q and WT sham 
group where the samples were randomly distributed. This result was anticipated as no CSD event 
was induced in this group of mice. However, the PCA score plot obtained for the combined FHM1 
R192Q and WT CSD group (Figure 2B) showed a clear trend in sample clustering. Two PLS-DA 
models (i.e., for sham and CSD groups) with WT and FHM1 R192Q mice as class identifiers were 
built to confirm these observations. As expected, the PLS-DA model built on sham samples proved 
to be statistically poor, while the statistical descriptors of the CSD data indicated a solid model ( cum 
= 0.417,  cum = 0.996,  = 0.712). Figure 3A presents the cross-validated score-plot PLS-DA model 
built on CSD data. The metabolites responsible for this classification were highlighted by OPLS-DA 
regression and the derived S-plot (Figure 3B). The S-plot is a visualization method that combines 
the modelled covariance (X-axis) and modelled correlation (Y-axis) from the OPLS-DA on a scatter 
plot, allowing for pinpointing of interesting variables. The variables showing the highest p and p 











Migration time [min] 
Figure 1: Base peak electropherogram obtained by CE-ESI-MS for the analysis of 25 nL of precipitated mouse plasma. 
See Section 2.5 for experimental conditions. 
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(corr) values are considered the most relevant metabolites for the classification between samples. 
According to the S-plot and Variable Importance on Projection (VIP) values, two metabolites were 
ranked as the most important variables responsible for the separation between FHM1 R192Q and WT 
groups after CSD. The first metabolite (VIP value = 4.1), measured at m/z 130.0860 with a migration 
time of 14.5 min, showed a higher peak area in FHM1 R192Q group relative to WT controls, after 
CSD. Based on the monoisotopic mass, the isotope distribution, the nitrogen rule, the hydrogen/
carbo ratio rule (Kind & Fiehn 2007), as well as research in METLIN Metabolite Search and HMDB 






, exact m/z 
130.0863, Δ = 2 ppm), a non-protein imino acid. Another important metabolite responsible for the 
samples classification (VIP values = 1.1 and 2.1 for most abundant and second most abundant isotope, 
respectively), biochemically correlated to PA and detected at m/z 147.1128 with a migration time of 








, exact m/z 147.1128, Δ = 0 ppm), which showed 
a significantly lower peak area in FHM1 R192Q samples compared to WT after CSD. Figure 4 shows 
the box-plots constructed for both metabolites with integrated peak areas, highlighting the significant 
difference observed between FHM1 R192Q and WT plasma after CSD, with significantly higher peak 
areas for PA (Figure 4A) and lower areas for lysine (Figure 4B), respectively, in the FHM1 R192Q 
group compared to WT control. 
A. B. 
Figure 2: PCA score plots with experimental condition as a class identifier. (A) Sham-operated group and (B) CSD-
operated group. Samples are colored according to their phenotype; RQ (red diamonds), plasma from transgenic mice 
carrying the FHM1 R192Q mutation; WT (blue diamonds), plasma from wild-type non-transgenic mice. t-scores 
represent the score vectors for the first (t[1]) and the second (t[2]) principal components after PCA. The first two principal 
components cover 48% and 42%  of the total variability in (A) and (B), respectively. 
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Confirmatory analysis by HILIC-MS/MS
The use of an orthogonal analytical technique such as liquid chromatography, i.e., based on a different 
mechanism of separation than CE, as well as information on the fragmentation pattern via MS/MS 
experiments provides an additional confidence of the identification of both compounds (Sumner et 
al 2007). Contrary to widely used reversed-phase liquid chromatography, where a poor retention and 
selectivity are usually observed for metabolites analysis, the HILIC chromatographic mode is well-
suited for the analysis of relatively polar compounds (Buszewski & Noga  2012, Hemstrom & Irgum 
2006, Kohler & Guillarme 2014, Rainville et al 2014). 
HILIC-MS/MS experiments were carried out on a QqQ mass analyzer with standard solutions of L-PA 
and L-lysine and naïve WT control mouse plasma. As the basal concentration of PA was observed 
to be relatively low in the plasma of WT mice, a sample preconcentration was necessary to reach 
the sufficient limit of detection for both compounds. The 20-fold preconcentration obtained with the 
developed PP-SPE procedure based on anion-exchange mechanism allowed for the detection of both 
A. B. 
Figure 3: Cross-validated PLS-DA model and S-plot obtained from OPLS-DA regression. (A) Cross-validated PLS-DA 
model built on CSD sub-group with  cum = 0.417,  cum = 0.996, and  = 0.712; samples are colored according to their 
phenotype; RQ (red diamonds), plasma from transgenic mice carrying the FHM1 R192Q mutation; WT (blue diamonds), 
plasma from wild-type non-transgenic mice. (B) S-plot obtained from OPLS-DA model. t-scores represent the cross-


























Figure 4: Box-plots displaying the differences in integrated peak areas observed for the two metabolites of interest after 
CSD events between the transgenic mice carrying the FHM1 R192Q mutation (labelled RQ) and the WT control group 
(labelled WT). Whiskers represent the standard deviation. (A) m/z 130.0860, corresponding to pipecolic acid. (B) m/z 
147.1128, corresponding to lysine.
A. B. 
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PR 130 m/z 
PR 130 m/z 
PR 147 m/z 
PR 147 m/z 
Figure 5: Extracted ion chromatograms (EICs) and MS/MS spectra obtained for both compounds for standard solutions 
at 100 μg mL-1 (upper EIC) and the prepared plasma sample (lower EIC). (A) Pipecolic acid, product ion (PR) MS/MS 
experiments on m/z 130. (B) Lysine, PR experiments on m/z 147. See Section 2.6 for experimental conditions. 
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compounds in plasma sample. Product ion scan (PR) mode, i.e., where the first quadrupole of the 
QqQ selects the parent ion(s) then fragmented in the collision cell prior to the detection of fragments 
in the third quadrupole operating in the full-scan mode, was used for MS/MS acquisition. Figure 5 
shows the extracted ion chromatograms (EICs) obtained for PA (Figure 5A) and lysine (Figure 5B) 
in the plasma sample with their respective MS/MS spectra obtained with a collision of energy of 10 
eV. The EICs obtained for m/z 130 and m/z 147 showed similar retention times for both compounds 
in plasma samples and standard solutions, i.e., 3.22 min and 3.61 min for PA and lysine, respectively. 
The identity of the compounds was confirmed by comparing the MS/MS spectra obtained for m/z 130 
and m/z 147 in plasma sample vs standard spectra. The MS/MS spectrum observed for PA in plasma 
showed the molecular ion at m/z 130 as well as a fragment at m/z 84, which corresponds to the loss of 
the carboxyl functional group. The MS/MS spectrum of lysine showed the molecular ion at m/z 147 
as well as fragments at m/z 130 and m/z 84. The fragment at m/z 130 is obtained with the loss of the 
secondary amine prior to cyclization of the molecule into PA (Argirov et al 2005) and, rationally, the 
subsequent loss of the carboxyl group to obtain the fragment at m/z 84. According to the Metabolomics 
Standards Initiative, a definitive (i.e., level 1) compound identification may be obtained by comparing 
two or more orthogonal properties (e.g., retention time, m/z ratio, fragmentation mass spectrum) of 
an authentic chemical standard vs the metabolite(s) of interest (Dunn et al 2013, Gika et al 2014). 
Due to the restricted sample volume available from mice, the orthogonal confirmatory analysis was 
performed on a WT material only. Therefore, additional studies may be required to increase the 
confidence in the identification of PA and lysine, although CE data usually provide a strong context 
for identification of amino acids, and lysine in particular.
Lysine and pipecolic metabolism and biological implications
In animals and humans, L-lysine has been shown to be predominantly metabolized to saccharopine 
(ε--[glutaryl-2]-L-lysine) in peripheral tissues, including liver and kidney, while the brain appears 
to mainly metabolize this amino acid to the intermediate of reaction L-PA. Both pathways lead to 
the formation of α-aminoadipic semialdehyde (α-ASAA), α-aminoadipic acid, and eventually 
acetyl-Co-A. The primary metabolic function of PA in human and mammals, however, is unknown. 
Nevertheless, PA was shown to be associated with several diseases, such as pyridoxine-dependent 
epilepsy, α-ASAA dehydrogenase deficiency, inherited peroxisomal disorders, and chronic liver 
dysfunction (Dalazen et al 2014, Sadilkova et al 2009). 
Peroxisomal disorders are characterized by a defect in peroxisome formation, leading to a deficiency 
or little activity of the peroxisomal PA oxidase, the enzyme responsible for oxidation of PA. A 
significant elevation of L-PA plasma concentration (normal range 0.1-4.0 µmol L-1) is observed and 
used for diagnosis purpose in combination with the determination of plasma very-long-chain fatty 
acids and plasmalogens (Peduto et al 2004, Poll-The & Gardner 2012, Stockler et al 2011). 
Pyridoxine-dependent epilepsy (PDE) is a recessive inherited condition that affects the γ-aminobutyric 
acid (GABA) pathway and is characterized by epileptic seizures that are not controlled with antiepileptic 
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drugs but stop with administration of pharmacological doses of pyridoxine (vitamin B
6
) (Baxter 
2003, Plecko et al 2005, Stockler et al 2011). Due to α-ASAA dehydrogenase deficiency caused by 
pathogenic mutations in the ALDH7A1 gene, elevated levels of α-ASAA are observed in plasma, 
CSF, and urine in patients with PDE. Increased concentrations of L-PA have also been observed in 
plasma (4.3 - 15.3 fold) and CSF (5.6 – 37.2 fold) of patients with PDE (Plecko et al 2000, 2005). 
In vitro experiments revealed that L-PA serves as a modulator of GABAergic neurotransmission by 
stimulating GABA release in the synaptic cleft, decreasing its uptake by the synaptosomes, and/or 
enhancing GABA
A
 receptor response likely by binding to another site on GABA
A
 receptor (Beitz & 
Larson 1985, Bernasconi et al 1986, Charles 1986, Gutierrez et al 1989, Kase et al 1980, Matsumoto 
et al 2003). PDE remains up to now the only paroxysmal episodic disorder for which a correlation 
between plasma PA concentrations and brain events has been shown. 
To the best of our knowledge, this is the first time that the lysine degradation pathway is suggested 
to be involved in migraine pathophysiology. Any relevance for migraine mainly comes from the 
observation that changes in plasma levels of lysine and PA were different in FHM1 R192Q mutant vs 
WT control mice after CSD induction only, and not after sham treatment. The higher level of PA after 
CSD induction in FHM1 R192Q mutant may hypothetically point towards a compensatory mechanism 
to counteract the effect of excessive glutamatergic neurotransmission via an enhancement of inhibitory 
GABAergic synaptic transmission; perhaps to restore the imbalance in cortical excitatory-inhibitory 
transmission that occurs with CSD. In this scenario, increased GABAergic synaptic transmission 
may be an attempt of the brain to restore homeostasis.  Increased GABAergic synaptic transmission 
may be the mere consequence of the excessive glutamatergic neurotransmission and subsequent 
activation of GABAergic neurons, without direct changes at the level of GABAergic transmission. 
Indeed, it has been already shown that the FHM1 R192Q mutation increases excitatory glutamatergic 
neurotransmission while having no effect on inhibitory GABAergic transmission (Tottene et al 2009). 
Enhanced glutamatergic neurotransmission was shown to underlie the increased susceptibility to CSD 
in FHM1 R192Q mutant mice (Tottene et al 2009). Finally, a proteomic analysis of synaptosomes 
from cortical neurons of FHM1 R192Q mutant mice showed compensatory up-regulation of glutamate 
transporters (Klychnikov et al 2010). These features seem to suggest that although GABAergic 
neurotransmission seems not primarily affected in FHM1 R192Q mice, it may kick in as part of the 
consequences of the enhanced excitatory transmission and may be involved in compensatory actions 
attempting to restore brain homeostasis, a hypothesis which would fit the episodic nature of migraine. 
This study also brings out that the mechanisms underlying CSD events can be captured beyond the 
CNS, for instance in plasma. It thus suggests that the investigation of metabolic changes in peripheral 
fluids may provide a useful strategy to monitor pathophysiological effects related to migraine that 
occur in the brain. 
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CONCLUDING REMARKS 
This study investigated the metabolic profiling in the plasma of transgenic migraine mice carrying 
the FHM1 R192Q mutation and WT controls following induction of multiple CSD events. Plasma 
samples collected after CSD induction were analyzed by CE-MS and highlighted significant changes 
in the concentration of two metabolites in FHM1 R192Q mutant that were tentatively identified as 
lysine and PA. The relative changes of PA concentration observed in FHM1 mutants mice compared 
to WT are consistent with the previously shown correlation between PA and inhibitory GABAergic 
neurotransmission, which in theory may serve to counteract the neuronal excitability and promote 
homeostasis recovery upon CSD in FHM1 mutant mice.  Notably, CSD events appear to induce a 
metabolic remodeling in peripheral fluids such as plasma. This opens new perspectives in the discovery 
of putative biomarkers in easily-accessible body fluids to improve the diagnosis and prognosis in 
migraine, as well as in proposing novel biomolecular targets for the development of new therapies. 
Further experiments are required to investigate the longitudinal evolution of the metabolic profile 
underlying CSD in peripheral fluids. 
ACKNOWLEDGEMENTS
This work was financially supported by the Dutch Organization for Scientific Research, EU Marie 
Curie IAPP Program “BRAINPATH” (nr 612360) (A.M.J.M.v.d.M.), EU “EUROHEADPAIN” grant 
(nr 602633) (M.D.F., A.M.J.M.v.d.M), an LUMC Fellowship (E.A.T.), Marie Curie Career Integration 
Grant (nr 294233) (E.A.T.) and the Center of Medical System Biology (CMSB) established by the 
Netherlands Genomics Initiative (NGI)/NWO (A.M.J.M.v.d.M.). I.K. was a recipient of a fellowship 
(P2GEP3_155633) supported by the Swiss National Scientific Foundation. Jeff D. Chapman from 
Beckman Coulter/AB Sciex is acknowledged for the kind loan of CE-MS sheathless prototype and 
valuable discussions.   
151
REFERENCES
Argirov OK, Leigh ND, Ortwerth BJ. 2005. Specific MS/MS fragmentation of lysine, arginine, and 
ornithine glycation products provides an opportunity for their selective detection in protein acid 
hydrolysates and enzymatic digest. Ann. N Y Acad. Sci. 1043:903
Baxter P. 2003. Pyridoxine-dependent seizures: a clinical and biochemical conundrum. Biochim. 
Biophys. Acta 1647:36-41
Beitz AJ, Larson AA. 1985. Inhibition of intrathecally administered picrotoxin- and bicuculline-in-
duced convulsions in mice by pipecolic acid or GABA. Eur. J. Pharmacol. 114:181-7
Bernasconi R, Jones RS, Bittiger H, Olpe HR, Heid J, et al. 1986. Does pipecolic acid interact with 
the central GABA-ergic system? J. Neural Transm. 67:175-89
Bonvin G, Schappler J, Rudaz S. 2012. Capillary electrophoresis-electrospray ionization-mass 
spectrometry interfaces: fundamental concepts and technical developments. J. Chromatogr. 
A. 1267:17-31
Busnel JM, Schoenmaker B, Ramautar R, Carrasco-Pancorbo A, Ratnayake C, et al. 2010. High 
capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a porous 
sheathless interface with transient-isotachophoresis. Anal. Chem. 82:9476-83
Buszewski B, Noga S. 2012. Hydrophilic interaction liquid chromatography (HILIC)--a powerful 
separation technique. Anal. Bioanal. Chem. 402:231-47
Charles AK. 1986. Pipecolic acid receptors in rat cerebral cortex. Neurochem. Res.11:521-5
Dalazen GR, Terra M, Jacques CE, Coelho JG, Freitas R, et al. 2014. Pipecolic acid induces oxidative 
stress in vitro in cerebral cortex of young rats and the protective role of lipoic acid. Metab. Brain 
Dis. 29:175-83
Davies JA, Annels SJ, Dickie BG, Ellis Y, Knott NJ. 1995. A comparison between the stimulated 
and paroxysmal release of endogenous amino acids from rat cerebellar, striatal and hippocampal 
slices: a manifestation of spreading depression? J. Neurol. Sci.131:8-14
de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. 2009. Molecular genetics of migraine. 
Hum. Genet. 126:115-32
Dieterle F, Ross A, Schlotterbeck G, Senn H. 2006. Probabilistic quotient normalization as robust 
method to account for dilution of complex biological mixtures. Application in 1H NMR 
metabonomics. Anal. Chem. 78:4281-90
Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, et al. 2001. The clinical spectrum of familial 
hemiplegic migraine associated with mutations in a neuronal calcium channel. N. Engl. J. Med. 
345:17-24
Dunn WB, Erban A, Weber RJM, Creek DJ, Brown M, et al. 2013. Mass appeal: metabolite 
identification in mass spectrometry-focused untargeted metabolomics. Metabolomics 9:S44-S66
152Chapter 7
Dunn WB, Wilson ID, Nicholls AW, Broadhurst D. 2012. The importance of experimental design and 
QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis 
4:2249-64
Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, et al. 2009. Genetic and 
hormonal factors modulate spreading depression and transient hemiparesis in mouse models of 
familial hemiplegic migraine type 1. J. Clin. Invest. 119:99-109
Ferrari MD, Klever RR, Terwindt GM, Ayata C, Van den Maagdenberg AM. 2015. Migraine 
pathophysiology: lessons from genetic mouse models and human genetics. Lancet Neurol. 14:65-80
Gika HG, Theodoridis GA, Plumb RS, Wilson ID. 2014. Current practice of liquid 
chromatography-mass spectrometry in metabolomics and metabonomics. J. Pharm. Biomed. Anal. 
87:12-25
Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine--current understanding and treatment. N. Engl. 
J. Med. 346:257-70
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, et al. 2004. Cortical spreading 
depression activates and upregulates MMP-9. J. Clin. Invest. 113:1447-55
Gutierrez MC, Delgado-Coello BA. 1989. Influence of pipecolic acid on the release and uptake of 
[3H]GABA from brain slices of mouse cerebral cortex. Neurochem. Res. 14:405-8
Heemskerk AA, Busnel JM, Schoenmaker B, Derks RJ, Klychnikov O, et al. 2012. Ultra-low flow 
electrospray ionization-mass spectrometry for improved ionization efficiency in phosphoproteomics. 
Anal. Chem. 84:4552-9
Hemstrom P, Irgum K. 2006. Hydrophilic interaction chromatography. J. Sep. Sci. 29:1784-821
Hirayama A, Tomita M, Soga T. 2012. Sheathless capillary electrophoresis-mass spectrometry with a 
high-sensitivity porous sprayer for cationic metabolome analysis. Analyst 137:5026-33
Hirayama A, Wakayama M, Soga T. 2014. Metabolome analysis based on capillary electrophoresis-
mass spectrometry. TrAC 61:215-22
ICHD. 2004. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 
Suppl 1:9-160
Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Kocak E, et al. 2013. Spreading depression 
triggers headache by activating neuronal Panx1 channels. Science 339:1092-5
Kase Y, Takahama K, Hashimoto T, Kaisaku J, Okano Y, Miyata T. 1980. Electrophoretic study of 
pipecolic acid, a biogenic imino acid, in the mammalian brain. Brain Res. 193:608-13
Kind T, Fiehn O. 2007. Seven Golden Rules for heuristic filtering of molecular formulas obtained by 
accurate mass spectrometry. BMC Bioinformatics 8:105
Klychnikov OI, Li KW, Sidorov IA, Loos M, Spijker S, et al. 2010. Quantitative cortical synapse 
proteomics of a transgenic migraine mouse model with mutated Ca(V)2.1 calcium channels. 
153
Proteomics 10:2531-5
Kohler I, Guillarme D. 2014. Multi-target screening of biological samples using LC-MS/MS: focus 
on chromatographic innovations. Bioanalysis 6:1255-73
Kohler I, Schappler J, Rudaz S. 2013. Highly sensitive capillary electrophoresis-mass spectrometry for 
rapid screening and accurate quantitation of drugs of abuse in urine. Anal. Chim. Acta 780:101-9
Kok MGM, Somsen GW, de Jong G. 2014. The role of capillary electrophoresis in metabolic profiling 
studies employing multiple analytical techniques. TrAC 61:223-35
Lionetto L, Gentile G, Bellei E, Capi M, Sabato D, et al. 2013. The omics in migraine. J. Headache 
Pain 14:55
Matsumoto S, Yamamoto S, Sai K, Maruo K, Adachi M, et al. 2003. Pipecolic acid induces apoptosis 
in neuronal cells. Brain Res. 980:179-84
Moini M. 2007. Simplifying CE-MS operation. 2. Interfacing low-flow separation techniques to mass 
spectrometry using a porous tip. Anal. Chem. 79:4241-6
Naz S, Vallejo M, Garcia A, Barbas C. 2014. Method validation strategies involved in non-targeted 
metabolomics. J. Chromatogr. A. 1353:99-105
Nevedomskaya E, Derks R, Deelder AM, Mayboroda OA, Palmblad M. 2009. Alignment of capillary 
electrophoresis-mass spectrometry datasets using accurate mass information. Anal. Bioanal. 
Chem. 395:2527-33
Nevedomskaya E, Ramautar R, Derks R, Westbroek I, Zondag G, et al. 2010. CE-MS for meta-
bolic profiling of volume-limited urine samples: application to accelerated aging TTD mice. 
J. Proteome Res. 9:4869-74
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, et al. 1996. Familial hemiplegic 
migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene 
CACNL1A4. Cell 87:543-52
Peduto A, Baumgartner MR, Verhoeven NM, Rabier D, Spada M, et al. 2004. Hyperpipecolic 
acidaemia: a diagnostic tool for peroxisomal disorders. Mol. Genet. Metab. 82:224-30
Plecko B, Hikel C, Korenke GC, Schmitt B, Baumgartner M, et al. 2005. Pipecolic acid as a diagnostic 
marker of pyridoxine-dependent epilepsy. Neuropediatrics 36:200-5
Plecko B, Stockler-Ipsiroglu S, Paschke E, Erwa W, Struys EA, Jakobs C. 2000. Pipecolic acid 
elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. 
Ann. Neurol. 48:121-5
Poll-The BT, Gartner J. 2012. Clinical diagnosis, biochemical findings and MRI spectrum of 
peroxisomal disorders. Biochim. Biophys. Acta 1822:1421-9
Rainville PD, Theodoridis G, Plumb RS, Wilson ID. 2014. Advances in liquid chromatography 
coupled to mass spectrometry for metabolic phenotyping. TrAC 61:181-91
154Chapter 7
Ramautar R, Shyti R, Schoenmaker B, de Groote L, Derks RJ, et al. 2012. Metabolic profiling of 
mouse cerebrospinal fluid by sheathless CE-MS. Anal. Bioanal. Chem. 404(10):2895-900
Sadilkova K, Gospe SM, Jr., Hahn SH. 2009. Simultaneous determination of alpha-
aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for 
pyridoxine-dependent seizures and folinic acid-responsive seizures. J. Neurosci. Methods 184:136-41
Smith CA, O’Maille G, Want EJ, Qin C, Trauger SA, et al. 2005. METLIN: a metabolite mass spectral 
database. Ther. Drug Monit. 27:747-51
Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. 2006. XCMS: processing mass spectrometry 
data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. 
Chem. 78:779-87
Somjen GG. 2001. Mechanisms of spreading depression and hypoxic spreading depression-like 
depolarization. Physiol. Rev. 81:1065-96
Stockler S, Plecko B, Gospe SM, Jr., Coulter-Mackie M, Connolly M, et al. 2011. Pyridoxine dependent 
epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for 
diagnosis, treatment and follow-up. Mol. Genet. Metab. 104:48-60
Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, et al. 2007. Proposed minimum report-
ing standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics 
Standards Initiative (MSI). Metabolomics 3:211-21
Tautenhahn R, Bottcher C, Neumann S. 2008. Highly sensitive feature detection for high resolution 
LC/MS. BMC Bioinformatics 9:504
Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, et al. 2009. Enhanced excitatory transmission 
at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine 
mice. Neuron 61:762-73
van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD. 2007. Migraine: gene mutations and 
functional consequences. Curr. Opin. Neurol. 20:299-305
van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, et al. 2004. A Cacna1a 
knockin migraine mouse model with increased susceptibility to cortical spreading depression. 
Neuron 41:701-10
Wishart DS, Knox C, Guo AC, Eisner R, Young N, et al. 2009. HMDB: a knowledgebase for the 
human metabolome. Nucleic Acids Res. 37:D603-10
Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. 2011. Activation of central 













Figure S1. Illustration of the experimental design. (A) Mouse skull depicting the locations of KCl application (i.e., 
occipital cortex) and DC-potential recordings (i.e., frontal cortex). (B) Induction of 7 CSDs by application of 1M KCl 
with a 5-min interval. At the end of the CSD induction, ca. 40 μL of blood was collected from the mouse trunk. (C) 
Specimen example traces recordings following application of 1M KCl (upper part) and 1M NaCl (lower part) in FHM1 
R192Q and WT mice.
Figure S2. PCA score plot of the whole data set, including mice samples (labelled S, blue diamonds) and quality 






Migraine is a common brain disorder that is characterized by attacks of severe unilateral headaches 
and associated neurological symptoms. In about one third of patients, attacks are accompanied by an 
aura that is likely caused by cortical spreading depression (CSD). In this thesis, transgenic FHM1 
R192Q mice were used as a relevant migraine model to investigate mechanisms underlying the effects 
of CSD modulating factors, as well as the consequences of CSD (Figure 1). FHM1 mice carry an 
R192Q missense mutation in the α
1
 subunit of voltage-gated Ca
V
2.1 channels (van den Maagdenberg 
et al 2004), which was previously identified in patients with familial hemiplegic migraine (Ophoff et 
al 1996). The experimental approaches and outcomes as described in the chapters of this thesis are 
discussed below, also in relation to relevant literature and with a look forward to future research.
8.1 Should CSD susceptibility measurements be performed in anesthetized 
or in freely behaving mice? 
Technical progress has made it possible to investigate CSD in relation to cortical activity and behavior 
in freely behaving animals. Nevertheless, for certain research questions anesthesia can be the preferred 
regime. Possibilities and caveats of performing experiments under anesthesia and in freely behaving 
animals were investigated in various chapters of this thesis and are discussed in the paragraphs below. 
8.1.1 CSD studies under anesthesia 
Under anesthesia, CSD induction and monitoring are technically easier to control than in the 
longitudinal chronic recordings lasting days-weeks in freely behaving mice. Anesthesia was used 
for experiments where a fixed number of CSD events was induced by topical KCl application 
on the dura to study modulatory factors and consequences of CSD, in Chapters 5, 6 and 7. The 
possibility to precisely time CSD events is a great advantage when administering drugs/modulators, 
as performed for stress modulators in experiments described in Chapter 4. Moreover, when drugs 
are administered under anesthesia, stress and discomfort of the mice is avoided to a large extent. A 
drawback, however, is that anesthetics affect critical parameters of animal physiological status, such 
as blood pressure (BP), blood gases and pH, in particular during long-duration experiments. Changes 
in these parameters are known to affect properties of brain tissue that are relevant to initiate and 
sustain CSD (Somjen 2001). The implementation of physiological monitoring in Chapter 2 yields 
important information on physiological parameters in relation to CSD characteristics, and makes 
possible the exclusion of animals in which physiological parameters are out-of-range. The use of 
physiological control by adjusting breathing patterns by mechanical ventilation is superior to the use 
of monitoring alone in the sense that it ensures a more comparable physiological status between mice; 
especially when experimental designs are used in which anesthesia last longer. Physiological control 
was performed for experiments to assess effects of gender (Chapter 2), diurnal rhythm (Chapter 3) 
and stress hormone (Chapter 4). Physiological control may however influence CSD characteristics 
and can sometimes act as a double-edged sword. By keeping physiological parameters within tight 
ranges, these parameters are kept comparable across experiments. However, if the experimental 
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readout itself depends on differences in physiological parameters, controlling them will logically 
interfere with the experimental outcome. This is illustrated in Chapter 2, in which the increased CSD 
frequency in female compared with male FHM1 R192Q mice, as reported by Eikermann-Haerter et 
al. (Eikermann-Haerter et al 2009b), was only revealed in the presence of physiological control. In an 
opposite way, in Chapter 3, physiological control appeared to mask a putative effect of a difference 
in CSD susceptibility between the visual and motor cortex in mutant mice; an effect that was observed 
only when experiments were performed in an uncontrolled and non-monitored manner (Chapter 2).  
Since anesthetics suppress neuronal activity (Hertle et al 2013), CSD and its characteristics will 
be affected by anesthetics, and in many instances masked. Common anesthetics such as isoflurane, 
which is used in the CSD experiments of this thesis, in particular in combination with N
2
O (used in 
CSD experiments under full physiological control described in Chapters 2, 3 and 4) are known to 
suppress CSD susceptibility (Kudo et al 2013, Takagaki et al 2014). Anesthesia may also directly 
interfere with the experimental intervention, e.g., when studying effects of drugs that influence 
GABAergic function, which is known to be modulated by many anesthetics (Hoffmann et al 2011). 
There seems to be no ideal anesthetic to investigate the susceptibility of CSD.   
8.1.2 CSD studies in freely behaving mice
Studying CSD characteristics in freely behaving mice can overcome some of the disadvantages of 
studies under anesthesia. Since both autonomous and central functions are retained, the physiology 
and brain functions of the mouse are more likely to mimic the situation in patients. With chronic 
implantation of miniaturized electrodes and a counter-balanced EEG/MUA-cable with swivel, it has 
been possible to record both EEG and MUA activity from the cortex with minimal discomfort to 
the mouse for multiple days to weeks (Chapter 3). Such recordings in freely behaving mice enable 
correlations between CSD characteristics and changes in neuronal network activity, vigilance states 
and other behavioral characteristics that are not possible under anesthesia. In rats, a similar awake 
electrophysiology approach has been used to correlate induced events of spreading depression to 
migraine-relevant pain pathways (Fioravanti et al 2011, Tepe et al 2015) and epilepsy (Broberg et al 
2014). Our studies in Chapter 3 show that the freely behaving approach is now also feasible in mice. 
Thus, we could demonstrate the occurrence of spontaneous CSD events in FHM1 R192Q mice, which 
were not observed in WT mice. Studies on spontaneous CSD events in freely behaving mice will 
allow investigating how natural triggers and modulatory factors of migraine (e.g., changes in sleep 
patterns, stress, and light) affect CSD susceptibility, thus enabling better translation of observations 
from and to the clinic. Because recordings are possible for several days to weeks, multiple trigger 
paradigms and modulators can be studied in a single animal. This include the possibility for intra-
individual vehicle controls and assessment of repeatability. 
However, experiments in awake, freely behaving mice have also disadvantages. Chronic electrode 
implantation can cause variation among animals with respect to electrode depth and location. 













































CSD-induced compensatory mechanisms 
































Increased excitability and spontaneous CSD
  
Figure 1. Overview of key experimental findings in FHM1 R192Q mice described in this thesis.  (Center) FHM1 
R192Q gain-of-function mutation increases neuronal Ca2+ influx via P/Q-type Ca
V
2.1 Ca2+ channels that leads to increased 
release of excitatory neurotransmitters in the synaptic cleft. (A) We established an experimental platform to measure 
CSD susceptibility in anesthetized mice under continuous monitoring and control of critical physiological parameters, 
such as blood pressure and blood gases (Chapter 2). (B) In awake freely moving mice, long-term EEG recordings 
revealed increased cortical excitability and spontaneous CSD events in a subgroup of FHM1 R192Q mice but not in 
WT (Chapter 3). (C) Corticosterone injection in FHM1 R192Q mice increased CSD susceptibility compared to vehicle 
injection, via a GR-mediated mechanism (Chapter 4). (D) CSD induction resulted in changes of metabolite, peptide 
and protein distribution in the cortex and subcortical brain areas that were genotype-and CSD-specific (Chapter 6). 
(E) CSD induction in the cortex of FHM1 R192Q mice triggered an activation of compensatory mechanisms likely to 
restore inhibition/excitation misbalance that occurred following CSD and this could be measured in plasma (Chapter 7).
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in Chapter 3) may affect CSD characteristics (Sukhotinsky et al 2011). Another difficulty with 
experiments in awake mice is that implanted electrodes and the EEG cable may increase levels of 
stress hormones, which can affect CSD characteristics (Chapter 4 and see Section 10.2.3). What 
remains challenging as well is to standardize CSD induction paradigms in freely behaving animals. 
This is illustrated by the KCl infusion paradigm used in Chapter 3, which does not induce a single 
CSD but multiple CSD events with high variability. Due to their larger size, and willingness to be 
handled, it is easier to overcome such problems in rats when an implanted cannula for KCl infusion 
is used (Fioravanti et al 2011, Tepe et al 2015). The strength of an experimental CSD design lies in 
overcoming technical disadvantages by the integration of experimental platforms for the induction 
and monitoring of CSD that either use or do not use anesthesia, as illustrated in Chapter 3. Finally, 
the advent of novel technologies for modulation of neuronal activity, such as optogenetics (Williams 
& Deisseroth 2013), is expected to overcome at least some of the disadvantages thus far associated 
with chronic recordings. This is well illustrated by the recent implementation of optogenetics for 
induction of CSD in freely behaving mice (Tolner et al 2015).
8.2 Factors that modulate CSD susceptibility 
8.2.1 Gender
It is well established that women are more susceptible to migraine than men (Finocchi & Strada 
2014, Lipton et al 2001). The higher frequency of experimentally induced CSD events observed for 
female FHM1 R192Q mice in experiments with physiological control (Chapter 2) is in line with 
previous data (Eikermann-Haerter et al 2009b). A potential underlying mechanism for the higher 
CSD susceptibility in female mice (and the female preponderance of migraine) may be the response 
to female gonadal hormones changes (Borsook et al 2014). It is hypothesized that a sudden drop in 
estradiol level just before the start of menstruation (Somerville 1972a, Somerville 1972b) is involved 
in initiating attacks. This drop may lead to direct enhancement of glutamatergic neuronal excitability 
via up-regulation of NMDA receptor expression, down-regulation of glutamate uptake by astrocytes, 
and increasing the dendritic spine number (Kelly et al 2003, Sato et al 2003, Smith 1989, Woolley et 
al 1997). Vascular changes may also be involved in the effect of female hormones on CSD frequency 
in FHM1 R192Q mice. This is supported by the observation that a gender effect was only noticed 
in mutant mice when mechanical ventilation was performed and thus physiological parameters were 
controlled. A gender effect remained masked in physiologically monitored but not controlled mice 
that had a lower blood pressure (Chapter 2). It is known that mechanical ventilation can reduce brain 
blood volume and blood flow (Milan et al 2009), which in turn may have affected CSD characteristics 
(Ayata 2013). In addition, direct changes in vascular function may occur in relation to gender, since 
estradiol was shown to alter vascular responses to calcitonin gene-related peptide (CGRP) (Gupta et 
al 2007). In this context it is plausible that different neurovascular responses between physiologically 
controlled and uncontrolled experiments in female mice may be the reason that a gender effect on 
CSD frequency was observed only in the presence of physiological control. This gender effect in 
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mutant mice was detected irrespective of the phase in the estrous cycle, as mice were not investigated 
at a specific phase in the cycle (Chapter 2 and Eikermann-Haerter et al 2009b), which suggests 
that the increased CSD susceptibility in female mutant mice may in fact be due to intrinsic brain 
differences between females and males (Borsook et al 2014) and perhaps less to a sudden drop in 
estrogen level during a phase of the cycle.  
8.2.2 Diurnal changes 
Observations that sleep (Holland 2014) and hypothalamic function (Moulton et al 2014) are linked 
to migraine support the idea that attacks may be influenced by diurnal rhythm (Fox & Davis 1998). 
Analysis of 24-hr EEG periods in freely behaving FHM1 R192Q mice in Chapter 3 revealed an 
increased EEG gamma power, which had been related to increased neuronal excitability (Joho et 
al 1999, Lau et al 2000). This finding fits earlier data that excessive neuronal excitability underlies 
the increased susceptibility to CSD in these mutant animals (Tottene et al 2009). The idea of 
hyperexcitability has been proposed as a mechanism underlying migraine attack susceptibility in 
humans (Aurora & Wilkinson 2007). Notably, we could show that a subset of FHM1 R192Q, but 
not WT mice showed spontaneous (i.e., not experimentally-triggered) CSD events. The majority 
of the spontaneous CSD events occurred within 2 hr in the transition from dark-to-light or from 
light-to-dark phases in the animal facility. Paradoxically, results of parallel experiments, performed 
under anesthesia with physiological control, seem to rule out that CSD susceptibility is specifically 
increased at the start of the light or the dark phase. It cannot however be excluded that the anesthesia or 
mechanical ventilation used in the experiments may have caused changes in the animal’s physiology 
that mask a putative diurnal difference in CSD susceptibility. Further studies are needed to assess 
whether, in addition to the overall increase in EEG gamma power, other changes may be detected 
from EEG recordings that are present before or during these diurnal transitions that can be related to 
changes in cortical excitability. 
We hypothesize that diurnal fluctuations in hormones and neurotransmitters that occur around these 
transitions may contribute to changes in neuronal excitability leading to CSD events. It is tempting 
to speculate that the high level of corticosterone that is present at the beginning of the dark period 
(Maywood et al 2007) may correlate with an enhanced CSD susceptibility at that time point. Notably, 
adenosine, a neuromodulator that induces sleep and decreases neuronal excitability (Nehlig et al 
1992), exhibits a diurnal pattern opposite to that of corticosterone, with high levels at the beginning 
of the light period (and low levels at the beginning of the dark period) (Basheer et al 2004). FHM1 
R192Q mice were reported to be less sensitive to exogenous modulation of adenosinergic inhibition 
and exhibit an increase of waking episodes during the dark period (Deboer et al 2013). One can 
therefore rationalize that a reduction in inhibitory adenosinergic response in mutant animals can lead 
to transiently enhanced neuronal excitability leading to enhanced CSD susceptibility, particularly 
when adenosine levels are high, i.e., at the beginning of the light period. 
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8.2.3 Stress 
The majority of migraine patients report stress as a prominent trigger for their migraine attacks 
(Hauge et al 2011), although one might argue that such self-reported information is not very reliable. 
As stress is a complex response of the body and involves multiple neurotransmitters and hormones 
with different dynamics, it is not known which aspects of the body’s stress response, if any at all, may 
bring about migraine attacks. In Chapter 4, we could show that administration of stress hormone 
corticosterone (cortisol in humans) specifically increased CSD frequency in FHM1 R192Q mice 
and that this occurred via a glucocorticoid receptor-mediated mechanism. Given that corticosterone 
had no effect in WT mice, and it is thought to increase glutamatergic neurotransmission (Popoli et 
al 2011), suggest that corticosterone may have further enhanced the already present intrinsically 
enhanced (glutamatergic) excitability in FHM1 mice (Tottene et al 2009). It is tempting to speculate 
that in freely behaving mice, external triggers such as sensory inputs (e.g., light, sound) may cause 
enhanced levels of corticosterone (Ishida et al 2005, Kim et al 2008) and thereby enhanced excitation 
of thalamo-cortical pathways (Noseda et al 2010). The combined sensory input and intrinsically 
enhanced neuronal excitability in FHM1 R192Q mice may result in spontaneous CSD events, as 
described in Chapter 3. 
Effects of natural stressors on CSD susceptibility seem harder to identify since exposure of FHM1 
R192Q mice to mild or even severe restraint stress did not seem to affect CSD susceptibility. In 
Chapter 4, we provide evidence that such lack of an effect is not simply due to suppressive actions 
of neuromodulators such as tetrahydrodeoxycorticosterone, which like corticosterone is released 
during restraint stress. Although corticosterone levels rise both after exogenous administration and as 
a consequence of acute stress, the latter triggers a much more complex response with effects that may 
either enhance or suppress CSD susceptibility. 
It is speculated that in patients the recovery from chronic stress, and not so much from acute stress, 
triggers a migraine attack (Lipton et al 2014). The concept of a ‘rebound’ effect after stress refers to 
the emergence of a stress effect following a period of recovery after chronic exposure to a stressor or 
after chronic glucocorticoid administration. While acute stress has been shown to induce analgesia, 
thus having anti-nociceptive effects, effects of chronic stress or chronically elevated glucocorticoid 
levels appear less predictable (McEwen & Kalia 2010). The direct effect of chronic administration of 
glucocorticoids in rats was an increase in pain threshold (Pinto-Ribeiro et al 2009). This observation is 
in line with studies in chronically stressed patients that suffer from chronic back pain, which reported 
less pain in a series of pain tests in comparison to healthy controls (Clark et al 1986). However, children 
that were chronically stressed due to abdominal pain (Dufton et al 2008) were reported to exhibit an 
increased reaction to a pain test (i.e., hyperalgesia). The variable results of chronic stress studies 
may relate to a rebound-after-stress effect, either because of fluctuations in stress levels in patients 
or because of different time-points after chronic stress at which readout effects were measured. In 
a study in which rats were measured 24 hr following exposure to chronic stress, the pain threshold 
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was shown to be reduced (Gamaro et al 1998). In line with the variable reports of chronic stress 
effects on pain, effects of chronic stress on glutamatergic transmission are also variable with studies 
indicating both enhancement (Kerr et al 1991, Joëls et al 2004, Raudensky & Yamamoto 2007) and 
suppression (Moghaddam 2002, Yuen et al 2012) of glutamatergic transmission following chronic 
stress. The variation in outcome may relate to differences in the studied brain regions, with e.g., the 
prefrontal cortex showing a reduction and hippocampal regions typically showing an enhancement of 
glutamatergic function (Joëls et al 2007, Yuen et al 2012). In these experimental studies on chronic 
stress, measurements were performed directly after the chronic stress paradigm, and did not provide 
information on glucocorticoid levels at the end of the chronic stress paradigm. Taken together, thus 
far, not much is known about mechanisms that could explain a possible rebound effect of (chronic) 
stress on triggering a migraine attack.  
To gain insight into the rebound-after-stress phenomenon, we performed pilot experiments to investigate 
whether a time-delay after chronically elevated corticosterone levels affects CSD susceptibility (Figure 
2). In brief, male WT and FHM1 R192Q mice were implanted with corticosterone or control pellets 
for a time period of 21 days. After the 3-week period, the pellet was removed and CSD frequency was 
tested either directly (on day 21) or 4 or 7 days later, at days 25 or 28 respectively (Figure 2A). High 
corticosterone plasma levels were shown to be maintained for 21 days when corticosterone pellets 
were implanted. After pellet removal at day 21, corticosterone plasma levels were decreased by day 
28 in WT, but not in FHM1 R192Q mice in which corticosterone levels were found to remain high 
(Figure 2B). At none of the chosen time points after the 3-week corticosterone treatment however, 
CSD frequency was different in either WT or FHM1 mice in comparison to the respective frequency 
in naïve WT and FHM1 R192Q mice (Figure 2C, D). These preliminary findings suggest that a chronic 
elevation of systemic corticosterone levels followed by withdrawal is not a sufficient trigger to modulate 
CSD susceptibility. Since corticosterone levels remained elevated for several days after pellet removal 
in FHM1 R192Q mice, the rebound-after-stress paradigm may not have been sufficient to modulate 
CSD susceptibility. One may need to first determine the time point when corticosterone plasma levels 
show the steepest decline, and then assess CSD susceptibility around this transition point. 
In this context, our findings raise an important issue regarding the translation of observations on the 
time-relationship between stress and migraine in humans to the time-line of stress paradigms in mice. 
In humans, a decline in perceived stress was recently shown to correlate with an increased probability 
to experience a migraine attack in the subsequent 6, 12 and 18 hr (Lipton et al 2014). In our study, 
corticosterone plasma levels were still elevated several days after corticosterone pellet removal, more 
so in R192Q mice. Although no information was available on cortisol levels in the human study, it is 
possible that the dynamics of the stress response differs between humans and mice. Alternatively, it 
may be that recovery from chronically elevated levels of glucocorticoids is less relevant as a stress 
factor in migraine, if adaptation occurs in the period of chonic stress or in the period of recovery. In 
an animal model, after 3 weeks of daily restraint, adaptation was shown to occur as evidenced from 
165
plasma corticosterone levels that were no longer elevated (Joëls et al 2007). Overall, it is important to 
emphasize the complexity of physiological responses to chronic exposure to stress and glucocorticoids 
(Borsook et al 2012, Maleki et al 2012, Resmini et al 2013), some of which may cause compensatory 
effects at the level of neuronal excitation and CSD susceptibility.
8.3 Insight in migraine pathophysiology from investigating modulators of 
CSD 
Better insight in the modulating effects of e.g., female hormones, diurnal or circadian rhythm and 
stress on CSD susceptibility can give mechanistic insight in the interaction of various neurobiological 
systems relevant to migraine. Enhanced susceptibility to various migraine modulators, e.g., sleep, 
food intake and anxiety, which affect various neurochemical pathways, seem to converge at the level 
of thalamus (Noseda et al 2014). In addition, intrinsic differences in neuronal network excitability 
properties in specific brain regions may render the migraine brain more susceptible to attacks. As an 
example, neuroimaging studies have shown structural and functional alterations in the visual cortex 
of migraineurs (Aurora et al 1999, Granziera et al 2006), which may have relevance to explain the 
clinical observation that the far majority of migraine auras are visual (Eriksen et al 2005). Certain 
experiments in Chapter 2 seem to indicate that in FHM1 R192Q mice the visual cortex is more 
susceptible to CSD than the motor cortex. This difference, however, was only seen when experiments 
were carried out in the absence of physiological monitoring and control. Under other experimental 
conditions cortical regions, as tested for motor and visual cortex in the presence of physiological 
control in Chapter 3, appear equally susceptible to CSD induction, and cannot explain a preference 
for auras being visual. This finding fuels the idea that silent auras’ may exist (Ayata 2010; Denuelle et 
al 2008), i.e., spreading depression waves may affect (and may be initiated in) a cortical (or even non-
cortical) brain region that does not lead to an abnormal visual perception (Hansen et al 2013) and could 
have relevance for migraine without aura patients. Relevant to this idea are also first observations 
made in freely behaving mice in Chapter 3 that indicate that not all spontaneous CSD events are first 
observed in the visual cortex (sometimes they are first seen in the motor cortex), suggesting that a 
CSD may start at different brain locations. 
8.4 CSD-induced changes in biomolecular profiles detected by mass 
spectrometry imaging in the brains of mice 
Mass spectrometry imaging (MSI) is an advanced bioanalytical method that allows the simultaneous 
detection of hundreds of biomolecules from different molecular classes directly from brain tissue 
(McDonnell & Heeren 2007). MSI therefore offers great potential in revealing–in an untargeted 
manner–biomolecular changes in the brain that are related to migraine gene mutations, CSD, 
or migraine-relevant triggers, while preserving spatial information of the distribution of these 
compounds. In Chapter 5, we demonstrated in a proof-of-principle study the applicability of MSI 
by the identification of changes in brain metabolite and peptide profiles upon CSD induction. In 
Chapter 6, we implemented the matrix-assisted laser desorption/ionization (MALDI) MSI approach 
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in a larger study to investigate biomolecular changes in the brain following CSD in FHM1 R192Q 
mice. CSD triggered specific brain changes in metabolite, peptide and protein profiles in FHM1 
R192Q mice, which were not observed in WT brains that underwent the CSD procedure nor in 
WT and FHM1 R192Q brains that underwent a sham procedure (in which no CSDs were evoked). 
Metabolite m/z 146.0593, which was putatively identified as L-glutamate, appeared down-regulated 
in the CSD-affected hemisphere in FHM1 R192Q mice. This finding suggests an increased clearance 
of glutamate by the action of glial cells and glutamate transporters or an adaptation of glutamate 
Figure 2. CSD susceptibility 
upon chronic corticosterone 
exposure. (A) Experimental 
design of chronic corticosterone 
experiments. At least 4 days prior 
to pellet implantation a blood 
sample (BS) was collected from a 
tail cut to measure corticosterone 
levels at baseline. Additional blood 
samples were collected every 
week to measure corticosterone 
plasma levels following pellet 
implantation. The corticosterone 
pellet (50 mg corticosterone/50 
mg cholesterol) was implanted 
subcutaneously in the flank of the 
mouse while it was under brief 
isoflurane anesthesia. Control 
mice were implanted with a pellet 
containing 100 mg cholesterol. 
To maintain stable corticosterone 
release the pellet was replaced at 
day 10. The pellet was removed at 
day 21 and CSD frequency was measured at day 21, day 25, or day 28 to test for possible rebound effects following 
corticosterone pellet removal. (B) No significant differences in corticosterone plasma levels were detected between WT 
and FHM1 R192Q mice. Corticosterone plasma levels in mice implanted with the control pellet were low as expected 
(0, 7, 14, 21 days: WT N=5, R192Q N=4; 28 days: WT N=1, R192Q N=1). In mice implanted with corticosterone 
pellets, corticosterone plasma levels were strongly elevated in the first 14 days and then gradually dropped at day 21 
and even more at day 28. Note the drop at day 28 in corticosterone plasma level (9.5 ng/mL) in the WT mouse below 
the level reported for stressed animals (i.e., 50 ng/mL). In contrast, in FHM1 R192Q mice corticosterone plasma levels 
remained high for 2 of 3 mice with particularly  high corticosterone plasma levels at day 28 (~270 ng/mL; in line with 
values reported for stressed animals (Zalachoras et al 2013) (0, 7, 14, 21 days: WT N=6, R192Q N=8; 28 days: WT 
N=1, R192Q N=3). (C, D) Scatter plots (mean ± SD) depict CSD frequency measured at different time-points in WT 
(C) and FHM1 R192Q (D) mice. There was no significant differences in CSD frequency for WT (p=0.1) and FHM1 
R192Q (p=0.14, one-way ANOVA Bonferroni correction) for any of the days following corticosterone compared to 
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release, in reaction to the intense metabolic and synaptic demand during repeated CSD induction. Such 
compensatory mechanisms in FHM1 R192Q mice might already be in place under naive conditions, 
since cortical synaptosomes from naive FHM1 R192Q mice showed an up-regulation of both major 
glutamate transporters, EAAT1 and EAAT2 (Klychnikov et al 2010). Notably, the same m/z 146.0593 
compound was found down-regulated in the occluded cortical hemisphere in a rat middle cerebral 
artery occlusion model (Miura et al 2010). For the protein dataset, we detected a down-regulation of 
unidentified protein m/z 11343 following CSD in the ipsilateral hemisphere, only in FHM1 R192Q 
mice. The short time between the 7th CSD and sacrification of the mouse 5 min later suggests that this 
mass likely represents a protein modification of an already synthesized protein. In addition, several 
peptides were found to be down- or up-regulated following CSD in mutant mice in cortex and several 
subcortical regions relevant to migraine pathophysiology (i.e., cortex, hippocampus, striatum and 
thalamus). The finding of robust changes in the peptide dataset seem in line with reports showing 
peptide concentration changes associated with both migraine attacks in humans and with CSD 
induction in animals. Relevant peptides include calcitonin gene related peptide (CGRP), substance P 
(SP) and neurokinin A (NKA), of which levels were found to be altered in the cortical extracellular 
space of rodents after CSD (Bolay et al 2002, Colonna et al 1994, Tozzi et al 2012, Wahl et al 1994) 
and in blood plasma of patients (Fusayasu et al 2007, Gallai et al 1995, Goadsby et al 1990). The 
observation of peptide changes in subcortical areas after cortical induction of CSD in our study is 
perhaps not so surprising when considering the spread of CSD waves to subcortical areas, such as 
striatum and hippocampus, as was shown for FHM1 R192Q mice (Eikermann-Haerter et al 2011). 
Future experiments are expected to reveal the identity of the compounds that were differentially 
regulated after CSD. 
8.5 CSD-induced biomolecular changes captured in blood plasma of mice  
Changes in metabolite composition perhaps best reflect the response of an organism to a biological 
change. Relevant biomolecule changes that occur in brain may also be captured in cerebrospinal fluid 
(CSF), and even blood. Experiments in Chapter 7 revealed specific changes, obtained by capillary 
electrophoresis-mass spectrometry (CE-MS), in plasma metabolite profiles of FHM1 R192Q mice 
following CSD. Such changes were not observed in WT mice that underwent the same procedure. 
In particular, a decreased plasma level of lysine and an increased level of pipecolic acid (a by-
product of lysine catabolism) were found. Given the involvement of pipecolic acid in GABA-ergic 
neurotransmission (Gutierrez & Delgado-Coello 1989, Kase et al 1980), the observed changes in 
plasma, if reflecting similar metabolite changes in the brain, may indicate a compensatory response 
to effects of neuronal hyperexcitability in FHM1 R192Q mice. An inhibitory compensatory reaction 
seems in line with the observed down-regulation of L-glutamate following the same CSD induction 
paradigm in the MSI study from Chapter 6. When paralleled with microdialysis studies in freely 
behaving animals (Rogers et al 2013) and studies of plasma (Guldiken et al 2009), urine (Jacobsen et 
al 2013) or CSF (Fonteh et al 2011) obtained from patients, the analysis of CSD-induced changes in 
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plasma or other peripheral body fluids from migraine mice has great potential for migraine biomarker 
identification. 
8.6 New knowledge with respect to migraine-relevant pathways 
Events such as CSD trigger intense neurometabolic activity in the brain and are likely to affect the 
body in various ways. Our findings show that CSD induction causes specific changes of biomolecular 
distribution and gene expression in the brain, as well as specific changes in levels of metabolites in 
peripheral body fluid (i.e., plasma). Notably, some of the observed changes after CSD were different 
and/or only seen in FHM1 R192Q mice compared with WT mice, which suggest that these changes 
reflect specific CSD-induced changes relevant to migraine pathophysiology. 
Changes in brain biomolecular distribution, as revealed by MSI, and profiling of metabolites in 
plasma using CE-MS, pointed towards the activation of compensatory mechanisms in FHM1 R192Q 
mice following CSD induction. A reduced m/z value (likely L-glutamate) in the CSD-affected 
hemisphere and an increased plasma level of pipecolic acid (with a presumed function in GABA-
ergic neurotransmission) in FHM1 R192Q mice suggests that the induction of CSD triggers a body 
defense mechanism in order to restore the inhibition/excitation misbalance following CSD events. 
Our experiments cannot determine whether the observed reduction in glutamate is caused by an 
increased clearance of glutamate from glial cells by glutamate transporters, such as EAAT1 and 
EAAT2. The increased expression of EAAT1 and EAAT2 that was seen in the naïve brain of FHM1 
R192Q mice using a proteomics approach on synaptosome preparations (Klychnikov et al 2010), 
provides some support for this scenario. Notably, previous studies in brain slices proposed increased 
glutamatergic neurotransmission as a key underlying mechanism of increased CSD susceptibility in 
FHM1 R192Q mice, whereas GABAergic neurotransmission was considered unaffected by the gene 
mutation (Tottene et al 2009). 
Our results seem to indicate that the body is coping or counteracting the excess glutamatergic 
neurotransmission by: (i) increasing GABAergic neurotransmission, perhaps best reflected by the 
increased plasma level of pipecolic acid, and (ii) removal of excess glutamate  from the synaptic cleft 
possibly by glutamate transporters as shown in Chapter 6. A recent in vitro study on cortical tissue 
from FHM1 R192Q mice showed that the enhanced glutamatergic transmission caused enhanced 
recruitment of inhibitory neuronal networks (Vecchia et al 2014). This is in line with reports on a possible 








Photophobia Present Chanda et al 2013 Modified elevated plus maze was used 
for behavioural studies; mutant mice 
spent more time in open arms compared 
with brightly illuminated closed safe 
arms.
Hemiplegia Present Eikermann-Haerter 
et al 2009
Hemiplegia was observed and lasted 20 
min or more after recovery from a single 
CSD event induced under anesthesia. 
S218 mutants were more severely 
affected.
CSD susceptibility Increased van den 
Maagdenberg  
et al 2004, 2010, 
Eikermann-Haerter 
et al 2009b, 
Chapters 2 & 3
In Chapters 2 & 3 CSD susceptibility 
(frequency and threshold) was increased 
compared to WT both for experiments with 
and without physiological monitoring or 
control. S218L mice display enhanced 
CSD frequency compared to R192Q 
mutants (Eikermann-Haerter et al 2009b, 




Haerter et al 2009,  
Chapter 2
In S218L mice CSD frequency is also 
enhanced for female compared to male 
mice. In Chapter 2, gender effect 
on CSD frequency in R192Q mice is 
only observed for experiments with 
physiological monitoring and control.
Neuronal 
hyperexcitability
Present Tottene et al 2009, 
Hullugundi et al 
2014, Vecchia et al. 
2014, Vecchia et al 
2015, Chapter 3
In Tottene et al. and Vecchia et al. (2014) 
cortical slices and neuronal cultures were 
analysed in vitro; Vecchia et al. (2015) 
shows most severe effects in S218L 
homozygous mice; in Hullugundi et al. 
cultured trigeminal ganglia neurons in 
vitro, and in Chapter 3 EEG activity was 
analysed in vivo. 
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Signs of headache Present Langford et al 
2010, Chanda  
et al 2013
In Chanda et al. signs of headache were 
associated with novelty stress; S218L 
mutants showed stronger blink responses 
compared to R192Q mice.
Signs of 
inflammation
Present Franceschini et al 
2013




Present Dilekoz et al 2015      R192Q mice exhibited enhanced 
excitatory transmission and LTP in the 
hippocampus but impaired learning and 
memory
Migraine triggers
Stress Effective Chapter 4 Acute administration of corticosterone, 
but not a 3h restraint stress, results in 
enhanced CSD frequency within 3 hrs.
Circadian rhythm 
shift
Effective van Oosterhout  
et al 2008
R192Q mice showed enhanced phase 
resetting to 6-hr advance shifts of the 
light/dark cycle in freely behaving 
electrophysiology studies of EEG and 
SCN activity; no differences between 
mutants and WT mice were observed in 
in vitro recordings of the suprachiasmatic 
nucleus.
8.7 Relevance of FHM1 R192Q mice as a useful animal model to study 
migraine pathophysiology 
Migraine is a brain disorder with symptoms varying considerably between individuals (Goadsby et 
Table 1.  The FHM1 mouse model is a relevant animal model for migraine Summary of experimental findings that 
highlight the relevance of FHM1 R192Q mice as a useful animal model for FHM, and perhaps also for the common 
forms of migraine. FHM1 R192Q mice exhibit key migraine-related features, such as signs of headache, photophobia 
and increased susceptibility to CSD including occurrence of spontaneous CSD. In addition, the FHM1 R192Q mice 
phenotype can be modulated by relevant migraine triggers such as stress hormones or circadian phase shifts. For several 
readouts, as indicated in the remarks, the phenotype was more severe or effects were stronger in FHM1 S218L compared 
to FHM1 R192Q mice.
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al 2002), but there are core features of the disease. A good animal model of a disorder should ideally 
replicate (and allow the investigation) of such core features. The FHM1 R192Q mouse model used 
in this thesis displays various features that seem not only relevant to FHM but also to the common 
forms of migraine (Table 1). 
In brief, FHM1 R192Q mice exhibit:
signs of photophobia and unilateral headache (Chanda et al 2013), which are prominent symptoms 
in migraine patients (ICHD 2004). 
transient hemiplegia following induction of CSD (Eikermann-Haerter et al 2009b), thus  mimicking 
the characteristic motor problems in patients with FHM. 
enhanced CSD susceptibility and spontaneous CSD events, as both FHM1 transgenic mouse models 
exhibit enhanced CSD susceptibility compared to WT. Furthermore, as recorded, in this thesis for 
the first time, in freely behaving mutant mice (Chapter 3), which forms a reassuring translational 
paradigm to mimic the episodic nature of migraine. 
a CSD phenotype in FHM1 R192Q mice that is more pronounced in females, in line with the higher 
propensity of migraine in women; this can be explained by modulation by gender hormones and 
gonadectomy as shown by effects of ovariectomy in females (Eikermann-Haerter et al 2009b, Chapter 
2) and orchiectomy in males (Eikermann-Haerter et al 2009a). 
neuronal hyperexcitability as identified in cortical brain slices (Tottene et al 2009), cortical neuronal 
cultures (Vecchia et al 2014; Vecchia et al 2015) and, in this thesis, at the neuronal network level 
in freely behaving mice (Chapter 3), which is in agreement with the concept that hyperexcitability 
(Aurora & Wilkinson 2007), and possibly dynamic changes in neuronal excitability (Cosentino et al 
2014) underlies migraine.
signs of inflammation, as shown for trigeminal ganglia (Franceschini et al 2013)
signs of impaired learning and memory, which may explain cognitive changes associated with FHM 
and, possibly, common forms of migraine (Dilekoz et al 2015).
enhancement of migraine-relevant readouts in response to triggers of migraine, such as stress (and 
stress hormones) and sudden shifts in circadian rhythms, as shown by increased CSD susceptibility 
to acute corticosterone administration (Chapter 4) and an enhanced circadian adaptation (van 
Oosterhout et al 2008). 
Several of the functional readouts are impacted by allele dosage, and, most importantly, by the type 
of FHM1 mutation: strongest effects of the mutations are observed for S218L homozygous mice in 
comparison to homozygous R192Q mice (Eikermann-Haerter et al 2009b, van den Maagdenberg et al 
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2010, Chanda et al 2013, Vecchia et al 2014, Vecchia et al 2015, Dilekoz et al 2015). The observation 
of a more severe phenotype in S218L compared to R192Q mice is in line with the clinical presentation 
of symptoms in patients (Haan et al 2005, Stam et al 2009), thus underscoring the usefulness of 
FHM1 mice for studying mechanisms of migraine pathophysiology. The finding that effects of FHM1 
mutations can differ among neurons of specific brain regions (Fioretti et al 2011, Inchauspe et al 
2010) and, as shown for cortex, have strong effects on excitatory but not inhibitory neurons (Tottene 
et al 2009, Vecchia et al 2014, Vecchia et al 2015) provides a mechanistic basis for dissecting the role 
of various neuronal networks in migraine pathophysiology. 
8.8 Future perspectives 
An important finding in this thesis is the identification of spontaneous CSD events occurring in 
FHM1 R192Q mice but not WT mice. Future experiments should focus on revealing changes in 
neuronal firing properties and changes of neuronal network properties that precede spontaneous CSD 
events. Revealing such changes will be instrumental for a better understanding of neurobiological 
mechanisms that explain characteristics of CSD and migraine headache, and in combination with the 
identification of biomolecules and disease mechanisms, e.g., using the molecular tools used in this 
thesis, can be exploited to design novel therapies for migraine. 
Whereas our data revealed an increased susceptibility to CSD in FHM1 R192Q mice upon an acute, 
strong elevation in corticosterone plasma levels, we did not see an effect on CSD susceptibility when 
mutant mice were subjected to a single restraint stress (that also increased corticosterone levels) or 
chronically elevated corticosterone levels. These findings seem to indicate corticosterone exerts multiple 
effects on biological systems and that the administration of corticosterone does not faithfully mimic the 
exact consequence to a physiological stressor. In humans, stress has a strong subjective component 
and often consists of small every day stressors, instead of a single major stressor. Perhaps only their 
cumulative effects may sufficiently modulate the threshold for CSD. Clinical data indicate that the “let-
down” of stress can increase the likelihood of a migraine attack (Lipton et al 2014). Future research 
should focus on identifying every day (milder) stressors, which presumably affect factors in addition to 
cortisol, to better understand how stress affects migraine. From a clinical point of view it may still be 
relevant to identify the time point of corticosterone reduction following chronically high corticosterone 
levels (glucocorticoid withdrawal) and assess whether CSD susceptibility is changed at that transition. 
In addition, to stress and corticosterone, future experiments may also address effects of other known 
migraine-relevant trigger factors, such as drugs overuse (e.g., triptans overuse), changes in sleep patterns 
or specific foods, in modulating characteristics of CSD and other migraine-relevant outcomes. 
Finally, the identification of reliable disease biomarkers is important; not only for diagnosis of 
the disease but also for pinpointing potential novel drug targets. Such biomarkers do not exist for 
migraine, yet. The identification, in this thesis, of specific compounds that are differentially regulated 
following CSD induction in an animal model of migraine in peripheral body fluid and brain tissue, 
may have relevance to migraine biomarker discovery. Future research may use these compounds as 
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a starting point to perform a systematic targeted analysis and identify whether similar compounds 
are abnormally regulated during and between migraine attacks in patients. Such targeted approach 
may further our understanding of migraine pathophysiology and may aid in the development of more 
effective treatments for migraine. 
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The research in this thesis was aimed at identifying and understanding mechanisms underlying 
modulating factors for and consequences of cortical spreading depression (CSD), the pathophysiological 
substrate for migraine aura that occurs in one-third of migraine patients. In this thesis, experimental 
studies on CSD were performed in wild-type (WT) and transgenic migraine mice, which express 
Ca
V
2.1 Ca2+ channels with a mutated α
1
 subunit that contains the R192Q missense mutation. The 
R192Q mutation was previously identified in patients with familial hemiplegic migraine type 1 
(FHM1) and causes gain-of-function effects in terms of neuronal Ca2+ influx, neurotransmission, and 
susceptibility to experimentally induced CSD. Using various experimental strategies, in this thesis, the 
FHM1 R192Q mouse model was used to study pathophysiological mechanisms of the initiation and 
modulation of CSD as well as of neurobiological and molecular changes that accompany CSD events
In Chapter 2 we investigated in what way physiological factors that vary in animals during surgery 
affect readouts of CSD experiments, CSD frequency and threshold. We determined to what extent 
the composition of the gas mixture and the choice of the experimental paradigm, i.e., monitoring 




, pH and blood pressure, or no monitoring at all, 
affected the CSD readouts in FHM1 R192Q and WT animals. The physiological monitoring paradigm 
entails that physiological parameters are measured in femoral artery blood; the physiological control 
paradigm ensures that variations in physiological parameters are adjusted via subtle changes of 
the breathing condition of the animal by making adjustments in the mechanical ventilation using 
tracheotomy. We showed that physiological control unmasks a gender effect on visual cortex CSD 
susceptibility in R192Q mice that remained hidden when physiological parameters of the animal 





 or blood pressure. We could also show that CSD readouts differed between visual versus 
motor cortex and showed a gender difference in R192Q mice, when the experiments were performed 
in the absence of physiological control. All in all, our study demonstrates that parameters of CSD 
susceptibility may be masked or unmasked depending on the experimental paradigm used. Although 
controlling the physiological status of an animal seems the preferred experimental paradigm, it has the 
risk that certain characteristics of CSD susceptibility in mutant mice are missed, when they depend on 
differences in physiological status between R192Q and WT mice. 
A way to overcome the methodological issues related to CSD susceptibility measurements in 
anesthetized animals is to perform recordings of brain activity under freely behaving conditions. 
Therefore, in Chapter 3 we investigated mechanisms underlying CSD susceptibility in freely 
behaving FHM1 R192Q and WT mice. Long-term cortical DC-EEG recordings revealed an increase 
in cortical EEG gamma power in both the visual and motor cortex of R192Q compared with WT 
mice, which suggests that the mutant brain displays an overall enhanced cortical excitability. Notably, 
R192Q mice were found to display spontaneous CSD events, evidenced by characteristic changes in 
patterns of electrical activity, that were never observed in WT mice. Unfortunately, an insufficient 
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number of spontaneous CSD events has been recorded until now to demonstrate whether these events 
occur at a particular time of day, which may be expected considering reports from patients indicating 
a circadian component in the occurrence of their attacks. Parallel CSD frequency recordings carried 
out under anesthesia in the presence of physiological control, at least, did not reveal that the enhanced 
susceptibility of FHM1 R192Q mice for CSD was different between the start of the day and the 
start of the night. Our observations provide evidence that cortical hyperexcitability contributes to the 
enhanced susceptibility to experimentally induced and spontaneous CSD in FHM1 mice. 
Many migraine patients report stress as a prominent factor that brings about their migraine attacks. 
In Chapter 4 we investigated the link between stress and CSD susceptibility, as surrogate for a 
migraine attack. In FHM1 R192Q and WT mice two paradigms were tested: behavioral restraint 
stress and administration of stress hormone corticosterone. Whereas subjecting mice to 20 min or 
even 3 hr restraint stress did not change CSD susceptibility, the administration of a single injection of 
corticosterone increased CSD susceptibility in R192Q mice, but not WT mice. Our finding suggests 
that a sudden rise in stress hormone may lead to a migraine attack when this occurs in the context of a 
brain that is prone to display increased excitatory neurotransmission, like it is the case when specific 
genetic mutations are present. It remains an enigma why natural stress - such as the restraint stress 
paradigm used , in which corticosterone levels also rise, does not cause a change in CSD susceptibility. 
It may be that in response to natural stress a spatiotemporally more complex biological response with 
multiple modulators is needed before an effect on CSD susceptibility can be detected. Also, it may be 
that such a response takes longer than the 3 hr paradigm that was used in this experiment.  
In Chapters 5 and 6 we investigated effects of CSD on biomolecular profiles in brain using various 
mass spectrometry (MS) technologies. MS imaging (MSI) was combined with matrix-assisted laser 
desorption/ionisation (MALDI) for the analysis of brain sections to unravel molecular consequences 
of CSD in the brain of mice while maintaining spatial resolution of these compounds. 
Chapter 5 described the applicability of MALDI MSI in identifying molecular changes in the brains of 
WT mice that were subjected to CSD. CSD-related differences in metabolite and peptide composition 
were observed in the hemisphere in which 7 CSD events had been induced by topical application of 
KCl on the dura. No changes were observed in protein composition, which can be explained by the 
fact that changes in protein expression take longer than the duration of the experiment. Observed 
changes in metabolites and peptides were CSD-related as they were absent in sham controls, in whom 
KCl was replaced by NaCl, which does not induce CSD.
In Chapter 6 we used the applicability of MALDI MSI from Chapter 5 to investigate whether 
migraine-relevant molecular changes had occurred in the brains of FHM1 R192Q after experimentally 
induced CSD. CSD events were associated with various changes in the content of three molecular 
classes (i.e.,  metabolites, peptides and proteins); molecular changes were observed in cortex as well 
as subcortical areas. When in future research the identity of the molecules is revealed, these may 
pinpoint (novel) neurobiological pathways involved in migraine pathophysiology. At the moment, 
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the findings only demonstrate that CSD events in R192Q and WT mice are associated with different 
molecular profiles, shown as differences in m/z values.   
In Chapter 7, MS technology was combined with capillary electrophoresis (CE) to assess changes 
in plasma metabolite composition in FHM1 R192Q and WT mice following experimentally induced 
CSD. We could show that specific metabolite changes can be captured in peripheral body fluid. 
Compared with WT mice, CSD events induced in R192Q mice were associated with a lower level 
of lysine and a higher level of pipecolic acid, the by-product of lysine catabolism. The study holds 
the promise that metabolic changes that occur in the brains of migraine patients may be measured in 
plasma, which is accessible in clinical research. If proven correct, metabolic changes in plasma of 
migraine patients could serve as potential disease biomarkers. 
Chapter 8 provides a general discussion of the main findings in this thesis. 
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NEDERLANDSE SAMENVATTING 
Het onderzoek beschreven in dit proefschrift heeft als doel het identificeren en begrijpen van de 
mechanismen die ten grondslag liggen aan modulerende factoren en gevolgen van het fenomeen 
“cortical spreading depression” (CSD), het pathofysiologische substraat voor migraine aura dat 
optreedt in één derde van de migraine patiënten. Voor dit proefschrift werden experimentele studies 
naar CSD uitgevoerd in wild-type (WT) en transgene migraine muizen, die Ca
V
2.1 Ca2+ kanalen 
tot expressie brengen met een a1 subunit die de R192Q mutatie bevat. Deze R192Q mutatie is in 
het verleden geïdentificeerd bij patiënten met familiaire hemiplegische migraine type 1 (FHM1), 
en veroorzaakt “gain-of-function” effecten met betrekking tot neuronale Ca2+ influx, glutamaterge 
neurotransmissie, en gevoeligheid voor experimenteel geïnduceerde CSD. Met behulp van 
verschillende experimentele strategieën, beschreven in dit proefschrift, werd het FHM1 R192Q 
muismodel gebruikt om pathofysiologische mechanismen van de initiatie en modulatie van CSD te 
bestuderen, evenals de neurobiologische en moleculaire veranderingen die gepaard gaan met CSD.
In hoofdstuk 2 onderzochten we op welke manier de fysiologische factoren die in dieren kunnen 
variëren tijdens de operatie bij gebruik van verschillende experimentele methodologiёn, van invloed 
zijn op de resultaten van CSD experimenten, met name ten aanzien van de frequentie en drempel voor 
het opwekken van CSD. We hebben vastgesteld in welke mate de samenstelling van het gasmengsel 
voor de anesthesie en de keuze van de bewaking van fysiologie tijdens de anesthesie, door middel van 




, pH en bloeddruk, van invloed zijn op 
CSD parameters in FHM1 R192Q en WT dieren. Voor de fysiologische bewaking werden parameters 
gemeten in arterieel (femoralis) bloed. Het fysiologische controle paradigma verzekert dat variaties 
in fysiologische parameters worden aangepast via subtiele veranderingen in de ademhalingscondities 
van het dier, door aanpassingen in de mechanische ventilatie met behulp van tracheotomie. We 
toonden aan dat het fysiologische controle paradigma een geslachts-specifiek effect bloot legt ten 
aanzien van CSD gevoeligheid in de visuele cortex in R192Q muizen, en dat dit effect niet zichtbaar 
was wanneer de fysiologische parameters van de dieren niet werden gecontroleerd. Deze bevinding 
geeft aan dat CSD parameters gevoelig zijn voor veranderingen in pH, pCO
2
 of bloeddruk. We konden 
ook aantonen dat er verschillen zijn tussen de visuele en de motorische cortex in de CSD resultaten 
en dat er ook een geslachtverschil in R192Q muizen is wanneer de experimenten werden uitgevoerd 
zonder fysiologische controle. Al met al blijkt uit onze studie dat verschillen in CSD gevoeligheid 
aan het licht gebracht of verborgen kunnen worden, afhankelijk van het experimentele paradigma. 
Hoewel het controleren van de fysiologische toestand van een dier de voorkeur heeft, brengt het 
als risico mee dat bepaalde kenmerken van CSD gevoeligheid in mutante muizen worden gemist, 
wanneer deze kenmerken afhankelijk zijn van verschillen in fysiologische toestand tussen R192Q en 
WT muizen tijdens de operatie.
Een manier om de afhankelijkheid van de anesthesie bij CSD gevoeligheidsmetingen in dieren 
te overkomen is om de hersenactiviteit te meten in wakkere dieren. Daarom onderzochten we in 
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hoofdstuk 3 de mechanismen die ten grondslag liggen aan CSD gevoeligheid in wakkere FHM1 
R192Q en WT muizen. Langdurig corticale DC-EEG-opnames onthulden een toename in de 
intensiteit van EEG gamma-band activiteit in zowel de visuele als de motorische cortex van R192Q 
muizen ten opzichte van WT muizen, wat suggereert dat de FHM1 mutatie een versterkte corticale 
prikkelbaarheid veroorzaakt. Ook werden er spontane gevallen van CSD gevonden in R192Q muizen, 
gekenmerkt door veranderingen in de patronen van corticale elektrische activiteit, zulke aanvallen 
werden nooit waargenomen in WT muizen. Helaas zijn er tot nu toe nog onvoldoende spontane CSD 
gebeurtenissen gemeten om aan te tonen of deze gebeurtenissen bij voorkeur op een bepaalde tijd van 
de dag gebeuren, zoals verwacht wordt gezien verslagen van patiënten die wijzen op een circadiane 
component in het optreden van aanvallen. Uit CSD frequentie opnames in dieren onder anesthesie 
met fysiologische controle bleek dat de verhoogde CSD gevoeligheid van FHM1 R192Q muizen niet 
verschillend was tussen het begin van de dag en het begin van de nacht. Onze waarnemingen leveren 
bewijs dat corticale hyperexcitabiliteit bijdraagt  aan de verhoogde gevoeligheid voor experimenteel 
geïnduceerde en spontane CSD in FHM1 muizen.
Veel migraine patiënten melden stress als een prominente factor die leidt tot hun migraineaanvallen. 
In hoofdstuk 4 onderzochten we het verband tussen stress en CSD gevoeligheid, als surrogaat voor 
een migraineaanval. In FHM1 R192Q en WT muizen werden twee methoden gebruikt: ‘restraint 
stress’, wat inhoudt dat de muis opgesloten wordt in een kleine ruimte waar hij niet kan bewegen, 
of een injectie met het stress hormoon corticosteron. ‘Restraint stress’ gedurende 20 min of zelfs 
gedurende 3 uur veranderde de CSD gevoeligheid niet, terwijl de toediening van één enkele injectie 
van corticosteron de CSD gevoeligheid in R192Q muizen, maar niet in WT muizen, liet toenemen. 
Onze bevinding suggereert dat een plotselinge stijging van stress hormonen kan leiden tot een 
migraine aanval, wanneer dit gebeurd bij hersenen die gevoelig zijn voor verhoogde excitatoire 
neurotransmissie, bijvoorbeeld als er specifieke genetische mutaties aanwezig zijn. Het blijft een 
raadsel waarom natuurlijke stress - zoals bij de ‘restraint stress’ methode, waarbij corticosteron niveaus 
ook stijgen, niet een verandering in de CSD gevoeligheid veroorzaakt. Het kan zijn dat in reactie op 
natuurlijke stress een spatiotemporeel complexere biologische respons met meerdere modulatoren 
nodig is voordat er een effect op CSD gevoeligheid kan worden gedetecteerd. Ook kan het zijn dat 
een dergelijke reactie langer duurt dan het 3 uur stress paradigma dat werd gebruikt in dit experiment.
In de hoofdstukken 5 en 6 onderzochten we de effecten van CSD op biomoleculaire profielen in de 
hersenen met behulp van verschillende massaspectrometrie (MS) technologieën. MS imaging (MSI) 
werd gecombineerd met matrix-geassisteerde laser desorptie/ionisatie (MALDI) voor het analyseren 
van hersencoupes om de moleculaire gevolgen van CSD in de hersenen van muizen te ontrafelen met 
een hoge spatiële resolutie. 
Hoofdstuk 5 beschrijft de toepassing van MALDI MSI bij het identificeren van moleculaire 
veranderingen in de hersenen van WT muizen die werden onderworpen aan CSD. CSD-gerelateerde 
verschillen in metabolieten- en peptidensamenstelling werden waargenomen in de hersenhelft waarin 
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7 CSD voorvallen waren geïnduceerd door lokale toediening van KCl op de dura mater. Er werden 
geen veranderingen waargenomen in eiwitsamenstelling. Dit kan worden verklaard door het feit dat 
veranderingen in eiwitexpressie later zichtbaar zijn dan de duur van dit experiment. De gevonden 
veranderingen in metabolieten en peptiden waren gerelateerd aan de CSD, omdat zij afwezig waren 
in de controles waar KCl vervangen werd door NaCl, wat geen CSD induceert.
In hoofdstuk 6 hebben we de toepassing van MALDI MSI uit hoofdstuk 5 om te onderzoeken 
of migraine-gerelateerde moleculaire veranderingen in de hersenen van FHM1 R192Q optreden na 
experimenteel geïnduceerde CSD. CSD voorvallen leidden tot diverse veranderingen in de inhoud 
van drie moleculaire groepen (d.w.z. metabolieten, peptiden en proteïnen) in zowel de cortex als 
subcorticale gebieden. Zodra toekomstig onderzoek de identiteit van de moleculaire veranderingen 
onthult, kunnen deze veranderingen nieuwe neurobiologische routes tonen die betrokken zijn bij de 
pathofysiologie van migraine. Op dit moment tonen de gevonden bevindingen aan dat CSD voorvallen 
in R192Q en WT muizen gerelateerd zijn aan verschillende moleculaire profielen, weergegeven als 
verschillen in m/z waarden.
In hoofdstuk 7 werd de MS technologie gecombineerd met capillaire elektroforese  om zo de 
veranderingen in plasmametabolietcompositie in FHM1 R192Q en WT muizen na experimenteel 
geïnduceerde CSD te beoordelen. We konden specifieke veranderingen in metabolieten in perifere 
lichaamsvloeistof aantonen. In vergelijking met WT muizen werden in R192Q muizen geïnduceerde 
CSD voorvallen geassocieerd met een lager niveau van lysine en een hoger niveau van pipecolinezuur, 
een bijproduct van lysine katabolisme. De studie suggereert dat metabolische veranderingen 
die optreden in de hersenen van migrainepatiënten kunnen worden gemeten in plasma, wat deze 
veranderingen toegankelijk maakt voor onderzoekers. Als dit inderdaad zo is, kunnen metabolische 
veranderingen in plasma van migrainepatiënten dienen als potentiële biomarkers.
Hoofdstuk 8 geeft een algemene discussie van de belangrijkste bevindingen in dit proefschrift.
188
ACKNOWLEDGEMENTS
I can say it now at the end of this journey that indeed it has been a unique and wonderful journey. 
First, I would like to express my gratitude to my promotor Arn van den Maagdenberg. Arn, your 
dedication to science, hard-working spirit and attention to detail have made me both a better scientist 
and a better person. 
Next, I would like to thank my co-promotor and everyday supervisor Else Tolner. Thank you for your 
patience during the difficult moments of the project and your immense help with my thesis. 
My other promotor Michel Ferrari. Michel, I always left your office with an important message that 
I will always remember.
Curtis, thank you for everything you taught me and your support during the first steps in my thesis.
Zonder goede analist ben je nergens. Sandra, these words best summarize your contribution to my 
thesis. It was really a privilege to work and learn from you. 
Roselin and Else E, you were really my PhD "buddies". In addition, I would like to thank all the other 
members of van den Maagdenberg group for their help and support during the PhD years. 
To my roomies. Lianne, Mathijs and Sam and all the other group Frants members.
I could not forget also all the people from mass spectrometry unit. Ricardo, Isabelle, Benjamin, Liam 
and Oleg, thank you for the very fruitful collaboration that we had. 
Erilda dhe Brunilda nuk mund te harroj kurajon dhe mbështetjen që ju me dhatë ne momente shumë 
të vështira gjatë kohës të doktoraturës.
Të dashur prinder. Faleminderit për të gjitha sakrificat që keni bërë për të realizuar ëndërrat e mia. 
Gjithashtu dhe për mbështetjen dhe dashurinë që më keni dhënë. 
Sandri. Faleminderit që ke qëndruar gjithmonë prane meje. Je vëllai më i mirë në botë.
I dashur gjyshi, faleminderit per frymëzimin që më dhe për të studiuar dhe të jem i dobishëm per 
njerëzit. Shpresoj që të kem arritur atje ku ti do të doje për mua.
Φυσικά θα ήθελα να ευχαριστήσω και όλους τους φίλους μου που στάθηκαν και στέκονται 
δίπλα μου με τον ένα ή τον άλλο τρόπο. Ιδιαίτερα την Χρυσάνθη για την υπέροχη δουλειά 
της με το layout και το εξώφυλλο αυτού του βιβλίου.
Finally, I would like to thank my life companion and best friend Marta. Your love and support allows 
me to believe that everything is possible.
189
LIST OF PUBLICATIONS
Reinald Shyti, Boukje de Vries, Arn M.J.M. van den Maagdenberg. Migraine genes and the relation 
to gender. Headache 2011;51:880-90
Boyan Todorov, Lieke Kros, Reinald Shyti, Petra Plak, Elize D. Haasdijk, Robert S. Raike, Rune R. 
Frants, Ellen J. Hess, Freek E. Hoebeek, Chris I. De Zeeuw, Arn M. J. M. van den Maagdenberg. 
Purkinje cell-specific ablation of Ca
V
2.1 channels is sufficient to cause cerebellar ataxia in mice. 
Cerebellum 2012;11:246-58
Emrys Jones, Reinald Shyti, Rene van Zeijl, Sandra H.van Heiningen, Michel D. Ferrari, Andre 
Deelder, Else A. Tolner, Arn M.J.M. van den Maagdenberg, Liam A. McDonnell. Imaging mass 
spectrometry to visualize biomolecule distributions in mouse brain tissue following hemispheric 
cortical spreading depression. Journal of Proteomics 2012;75:5027-35
Rawi Ramautar, Reinald Shyti, Bart Schoenmaker, Lotte de Groote, Rico J. E. Derks, Michel D. 
Ferrari, Arn M. J. M. van den Maagdenberg, André M. Deelder, Oleg A. Mayboroda. Metabolic 
profiling of mouse cerebrospinal fluid by sheathless CE-MS. Analytical and Bioanalytical Chemistry 
2012;404:2895-900
Walid M. Abdelmoula, Ricardo J. Carreira, Reinald Shyti, Benjamin Balluff, René J. M. van Zeijl, 
Else A. Tolner, Boudewijn F.P. Lelieveldt, Arn M.J.M. van den Maagdenberg, Liam A. McDonnell, 
Jouke Dijkstra. Automatic Registration of Mass Spectrometry Imaging data sets to the Allen Brain 
Atlas. Analytical Chemistry 2014;86:3947-54
Reinald Shyti, Katharina Eikermann-Haerter, Sandra H. van Heiningen, Onno C. Meijer, Cenk 
Ayata, Joels M, Michel D. Ferrari, Arn M.J.M. van den Maagdenberg, Else A. Tolner. Stress hormone 
corticosterone enhances susceptibility to cortical spreading depression in familial hemiplegic migraine 
type-1 mutant mice. Experimental Neurology 2015;263:214-20
Reinald Shyti, Isabelle Kohler, Bart Schoemaker, Rico Derks, Michel D. Ferrari, Else A. Tolner, Oleg 
A. Mayboroda, Arn M.J.M. van den Maagdenberg. Plasma metabolic profiling after cortical spreading 
depression in a transgenic mouse model of hemiplegic migraine by capillary electrophoresis - mass 
spectrometry. Molecular Biosystems 2015;11:1462-71
Ricardo J. Carreira, Reinald Shyti, Walid Abdelmoula, Benjamin Balluff, Rene van Zeijl, Ludo 
Broos, Jouke Dijkstra, Michel D. Ferrari, Else A. Tolner, Liam A. McDonnell, Arn M.J.M. van den 
Maagdenberg. Large-Scale Mass Spectrometry Imaging Investigation of Consequences of Cortical 
190
Spreading Depression in a Transgenic Mouse Model of Migraine. Journal of the American Society for 
Mass Spectrometry 2015;26:853-61
CURRICULUM VITAE
Reinald Shyti was born on 24th September 1981, in Berat, Albania. In May 1992 he moved to 
Athens, Greece where in 2000 he graduated from the 3rd High School (3ο Λυκειο) of Argyroupolis, 
Athens. In 2001, Reinald started his studies at the American College of Greece where he graduated in 
2005 with a Bachelor’s degree in Psychology. 
In 2006, Reinald went on to complete his Master’s studies in Cognitive Neuroscience at the Radboud 
University Nijmegen in the Netherlands. During the 2nd year of his studies he conducted basic 
research at the Department of Cellular Animal Physiology, Donders Institute for Brain, Cognition 
and Behavior, Radboud University Nijmegen. Under the supervision of Prof. Dr. Tamas Kozicz and 
Prof. Dr. Eric Roubos.
In August 2008, Reinald started his graduate (PhD) studies at the Department of Human Genetics 
of Leiden University Medical Centre. Reinald investigated the causes and consequences of cortical 
spreading depression in migraine mouse models under the supervision of Prof. Arn van den 
Maagdenberg, Prof. Michel Ferrari and Dr. Else Tolner. The findings of this research project are 
presented in the current thesis. Since August 2015 Reinald is a postdoc researcher in the Department 
of Experimental Oncology of European Institute of Oncology, Milan, Italy. Reinald is investigating 
epigenetic mechanisms in induced pluripotent stem cells as a model for neurodevelopmental  disorders. 
191
